{"matching_results": 32465, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 1515, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 1062}, {"key": "negative", "matching_results": 443}, {"key": "neutral", "matching_results": 10}]}]}, {"key": "watchlistnews.com", "matching_results": 778, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 554}, {"key": "negative", "matching_results": 224}]}]}, {"key": "tickerreport.com", "matching_results": 768, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 632}, {"key": "negative", "matching_results": 134}, {"key": "neutral", "matching_results": 2}]}]}, {"key": "wkrb13.com", "matching_results": 752, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 572}, {"key": "negative", "matching_results": 180}]}]}, {"key": "zolmax.com", "matching_results": 716, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 532}, {"key": "negative", "matching_results": 184}]}]}, {"key": "dailypolitical.com", "matching_results": 674, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 540}, {"key": "negative", "matching_results": 134}]}]}, {"key": "freelancer.com.co", "matching_results": 643, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 593}, {"key": "negative", "matching_results": 50}]}]}, {"key": "thelincolnianonline.com", "matching_results": 577, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 391}, {"key": "negative", "matching_results": 185}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "marketscreener.com", "matching_results": 550, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 398}, {"key": "negative", "matching_results": 150}, {"key": "neutral", "matching_results": 2}]}]}, {"key": "theolympiareport.com", "matching_results": 542, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 378}, {"key": "negative", "matching_results": 163}, {"key": "neutral", "matching_results": 1}]}]}]}], "results": [{"id": "adlsFeLYD8q4s3A5eWEalZvuDT21Y2-LGWUqGBl3Vj4_o8hFTLzmpGGcOjNPyR89", "result_metadata": {"score": 37.134373}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "USD", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pharmaceuticals Healthcare", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$250", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Medicine", "relevance": 0.9477, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}], "categories": [{"score": 0.712453, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.534035, "label": "/health and fitness/drugs"}], "relations": [], "keywords": [{"text": "Pharmaceuticals Healthcare Deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.969915}, {"text": "Alliances Profile Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.837201}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.638609}, {"text": "USD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.263644}]}, "crawl_date": "2018-11-14T14:16:11Z", "url": "https://www.bioportfolio.com/news/article/3816130/Takeda-Pharmaceutical-Co-Ltd-4502-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-Report.html", "host": "bioportfolio.com", "text": "Advertisement Topics Track topics on Twitter Track topics that are important to you Printed From BioPortfolio.com Takeda Pharmaceutical Co Ltd 4502 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250 07:57 EST 14 Nov 2018 | BioPortfolio Report Blog Summary Takeda Pharmaceutical Company Ltd Takeda is", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-14T12:57:00Z", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Ltd Takeda", "relevance": 0.568075, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.413531, "label": "positive"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.277372, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.489186, "label": "positive"}, "text": "Venture Financing and Partnerships", "relevance": 0.199689, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pharmaceutical and Healthcare News", "relevance": 0.183012, "type": "PrintMedia"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.182671, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Osaka", "relevance": 0.181499, "type": "Location", "disambiguation": {"subtype": ["JapaneseDesignatedCity", "OlympicBiddingCity", "City"], "name": "Osaka", "dbpedia_resource": "http://dbpedia.org/resource/Osaka"}}, {"count": 2, "sentiment": {"score": 0.413531, "label": "positive"}, "text": "Pharmaceuticals Healthcare", "relevance": 0.172609, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.171236, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0.378807, "label": "positive"}, "text": "Twitter", "relevance": 0.171191, "type": "Company", "disambiguation": {"subtype": ["Website", "VentureFundedCompany"], "name": "Twitter", "dbpedia_resource": "http://dbpedia.org/resource/Twitter"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.155664, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "USD", "relevance": 0.15221, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Singapore", "relevance": 0.142431, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Singapore", "dbpedia_resource": "http://dbpedia.org/resource/Singapore"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Central America", "relevance": 0.140838, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Central America", "dbpedia_resource": "http://dbpedia.org/resource/Central_America"}}, {"count": 1, "sentiment": {"score": 0.448255, "label": "positive"}, "text": "Alliances Profile", "relevance": 0.139314, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.1368, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia", "relevance": 0.136181, "type": "Location", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.134536, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Switzerland", "relevance": 0.129637, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Switzerland", "dbpedia_resource": "http://dbpedia.org/resource/Switzerland"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Columbia", "relevance": 0.129274, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Germany", "relevance": 0.128967, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Country"], "name": "Germany", "dbpedia_resource": "http://dbpedia.org/resource/Germany"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "India", "relevance": 0.128937, "type": "Location", "disambiguation": {"subtype": ["HumanLanguage", "Region", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"count": 2, "sentiment": {"score": 0.330933, "label": "positive"}, "text": "China", "relevance": 0.128746, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.12817, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chuoku", "relevance": 0.126204, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Estonia", "relevance": 0.12558, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Indonesia", "relevance": 0.124865, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Country"], "name": "Indonesia", "dbpedia_resource": "http://dbpedia.org/resource/Indonesia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Austria", "relevance": 0.124787, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Country"], "name": "Austria", "dbpedia_resource": "http://dbpedia.org/resource/Austria"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Denmark", "relevance": 0.124615, "type": "Location", "disambiguation": {"subtype": ["Brand", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "Country"], "name": "Denmark", "dbpedia_resource": "http://dbpedia.org/resource/Denmark"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Italy", "relevance": 0.12347, "type": "Location", "disambiguation": {"subtype": ["HumanLanguage", "PoliticalDistrict", "Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Country"], "name": "Italy", "dbpedia_resource": "http://dbpedia.org/resource/Italy"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mexico", "relevance": 0.123405, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "FilmCinematographer", "Country"], "name": "Mexico", "dbpedia_resource": "http://dbpedia.org/resource/Mexico"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "US", "relevance": 0.122912, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Brazil", "relevance": 0.118537, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Argentina", "relevance": 0.118323, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Norway", "relevance": 0.111958, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Poland", "relevance": 0.111712, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Russia", "relevance": 0.111553, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Belgium", "relevance": 0.111425, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ireland", "relevance": 0.110863, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0.31307, "label": "positive"}, "text": "UK", "relevance": 0.108459, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "five year", "relevance": 0.108459, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$250 07", "relevance": 0.108459, "type": "Quantity"}], "sentiment": {"document": {"score": 0.80199, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Takeda Pharmaceutical Company Ltd Takeda", "keywords": [{"text": "Company Ltd Takeda"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd Takeda"}]}, "sentence": " Takeda Pharmaceutical Company Ltd Takeda is a researchbased global pharmaceutical company which focuses on the research and development, manufacture, marketing, commercialization and import and export of pharmaceutical drugs and consumer health care products.", "object": {"text": "a researchbased global pharmaceutical company which focuses on the research and development", "keywords": [{"text": "global pharmaceutical company"}, {"text": "research"}, {"text": "development"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": []}, "sentence": " The company manufactures and markets a wide range of products including photographic chemicals, inorganic chemicals, vitamin bulks, test reagents and clinical diagnostics.", "object": {"text": "a wide range of products including photographic chemicals, inorganic chemicals, vitamin bulks, test reagents and clinical diagnostics", "keywords": [{"text": "vitamin bulks"}, {"text": "test reagents"}, {"text": "clinical diagnostics"}, {"text": "inorganic chemicals"}]}, "action": {"verb": {"text": "manufacture", "tense": "present"}, "text": "manufactures and markets", "normalized": "manufacture and market"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": []}, "sentence": " The company manufactures and markets a wide range of products including photographic chemicals, inorganic chemicals, vitamin bulks, test reagents and clinical diagnostics.", "object": {"text": "a wide range of products including photographic chemicals, inorganic chemicals, vitamin bulks, test reagents and clinical diagnostics", "keywords": [{"text": "vitamin bulks"}, {"text": "test reagents"}, {"text": "clinical diagnostics"}, {"text": "inorganic chemicals"}]}, "action": {"verb": {"text": "market", "tense": "present"}, "text": "manufactures and markets", "normalized": "manufacture and market"}}, {"subject": {"text": "photographic chemicals, inorganic chemicals, vitamin bulks, test reagents and clinical diagnostics", "keywords": [{"text": "vitamin bulks"}, {"text": "test reagents"}, {"text": "clinical diagnostics"}, {"text": "inorganic chemicals"}]}, "sentence": " The company manufactures and markets a wide range of products including photographic chemicals, inorganic chemicals, vitamin bulks, test reagents and clinical diagnostics.", "object": {"text": "products", "keywords": [{"text": "products"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd Takeda"}]}, "sentence": " Takeda markets its drugs worldwide through its subsidiaries in North America, Europe and Asia.", "object": {"text": "its drugs worldwide", "keywords": [{"text": "drugs"}]}, "action": {"verb": {"text": "market", "tense": "present"}, "text": "markets", "normalized": "market"}}, {"subject": {"text": "It"}, "sentence": " It operates production facilities in Osaka and Hikari in Japan; Italy; Ireland; Germany; Austria; Denmark; Belgium; Norway; Poland; Russia; China; Indonesia; Mexico; Brazil; Argentina; Columbia; Estonia; and India.", "object": {"text": "production facilities in Osaka and Hikari", "keywords": [{"text": "Hikari"}, {"text": "Osaka"}, {"text": "production facilities"}], "entities": [{"type": "Location", "text": "Osaka", "disambiguation": {"subtype": ["JapaneseDesignatedCity", "OlympicBiddingCity", "CityTown", "City"], "name": "Osaka", "dbpedia_resource": "http://dbpedia.org/resource/Osaka"}}]}, "action": {"verb": {"text": "operate", "tense": "present"}, "text": "operates", "normalized": "operate"}}, {"subject": {"text": "It"}, "sentence": " It also operates research and development facilities at various locations in Japan and the US, China and the UK; and in Brazil, Germany, Switzerland, and Singapore.", "object": {"text": "research and development facilities", "keywords": [{"text": "development facilities"}, {"text": "research"}]}, "action": {"verb": {"text": "operate", "tense": "present"}, "text": "operates", "normalized": "operate"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd Takeda"}]}, "sentence": " Takeda is headquartered in Chuoku, Osaka, Japan.", "object": {"text": "headquartered"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd Takeda"}]}, "sentence": " Takeda is headquartered in Chuoku, Osaka, Japan.", "action": {"verb": {"text": "headquarter", "tense": "past"}, "text": "is headquartered", "normalized": "be headquarter"}}, {"subject": {"text": "Takeda Pharmaceutical Co Ltd 4502 Pharmaceuticals Healthcare Deals and Alliances Profile", "keywords": [{"text": "Pharmaceuticals Healthcare Deals"}, {"text": "Takeda Pharmaceutical"}, {"text": "Alliances Profile"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co Ltd"}, {"type": "Company", "text": "Pharmaceuticals Healthcare"}, {"type": "Company", "text": "Alliances Profile"}]}, "sentence": " Takeda Pharmaceutical Co Ltd 4502 Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings.", "object": {"text": "comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings", "keywords": [{"text": "Acquisitions MAs"}, {"text": "trend analysis"}, {"text": "comprehensive data"}, {"text": "financings"}], "entities": []}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.", "object": {"text": "detailed information", "keywords": [{"text": "information"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "by the company", "keywords": [{"text": "company"}], "entities": []}, "sentence": " The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.", "object": {"text": "Partnership transactions", "keywords": [{"text": "Partnership transactions"}]}, "action": {"verb": {"text": "record", "tense": "past"}, "text": "recorded", "normalized": "record"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions.", "object": {"text": "detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions", "keywords": [{"text": "comparative data"}, {"text": "deal types"}, {"text": "subsector"}, {"text": "deals"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "GlobalData", "keywords": [{"text": "GlobalData"}]}, "sentence": " GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research.", "object": {"text": "the data presented in this report", "keywords": [{"text": "data"}, {"text": "report"}]}, "action": {"verb": {"text": "derive", "tense": "past"}, "text": "derived", "normalized": "derive"}}, {"subject": {"text": "the data", "keywords": [{"text": "data"}]}, "sentence": " GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research.", "action": {"verb": {"text": "present", "tense": "past"}, "text": "presented", "normalized": "present"}}, {"subject": {"text": "proprietary inhouse Pharma eTrack", "keywords": [{"text": "inhouse Pharma eTrack"}]}, "sentence": " GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research.", "object": {"text": "database", "keywords": [{"text": "database"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deals", "normalized": "deal"}}, {"subject": {"text": "Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships", "keywords": [{"text": "Equity/Debt Offerings"}, {"text": "Private Equity"}, {"text": "Venture Financing"}, {"text": "Mergers"}], "entities": [{"type": "JobTitle", "text": "Venture Financing and Partnerships"}]}, "sentence": " Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.", "object": {"text": "the company's financial deals", "keywords": [{"text": "financial deals"}, {"text": "company"}], "entities": []}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Deals by Year Chart and table", "keywords": [{"text": "Deals"}, {"text": "Chart"}, {"text": "table"}]}, "sentence": " Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.", "object": {"text": "information encompassing the number of deals and value", "keywords": [{"text": "deals"}, {"text": "information"}, {"text": "number"}, {"text": "value"}]}, "action": {"verb": {"text": "display", "tense": "present"}, "text": "displaying", "normalized": "display"}}, {"subject": {"text": "by the company", "keywords": [{"text": "company"}], "entities": []}, "sentence": " Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.", "object": {"text": "value", "keywords": [{"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "Deals by Type Chart and table", "keywords": [{"text": "Deals"}, {"text": "Type Chart"}, {"text": "table"}]}, "sentence": " Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.", "object": {"text": "information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc", "keywords": [{"text": "Equity/Debt Offering"}, {"text": "Mergers"}, {"text": "Acquisitions"}, {"text": "deals"}], "entities": []}, "action": {"verb": {"text": "depict", "tense": "present"}, "text": "depicting", "normalized": "depict"}}, {"subject": {"text": "the number of deals and value", "keywords": [{"text": "deals"}, {"text": "number"}, {"text": "value"}]}, "sentence": " Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.", "object": {"text": "information", "keywords": [{"text": "information"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc", "keywords": [{"text": "Equity/Debt Offering"}, {"text": "Mergers"}, {"text": "Acquisitions"}, {"text": "company"}], "entities": []}, "sentence": " Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.", "object": {"text": "value", "keywords": [{"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America", "keywords": [{"text": "Asia Pacific"}, {"text": "Middle East"}, {"text": "North America"}, {"text": "Central America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Company", "text": "Asia Pacific"}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"type": "Location", "text": "Central America", "disambiguation": {"subtype": ["Region"], "name": "Central America", "dbpedia_resource": "http://dbpedia.org/resource/Central_America"}}]}, "sentence": " Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.", "object": {"text": "deals and value", "keywords": [{"text": "deals"}, {"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "Deals by Subsector Chart and table", "keywords": [{"text": "Subsector Chart"}, {"text": "Deals"}, {"text": "table"}]}, "sentence": " Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector.", "object": {"text": "information on the number of deals and value", "keywords": [{"text": "deals"}, {"text": "information"}, {"text": "number"}, {"text": "value"}]}, "action": {"verb": {"text": "show", "tense": "present"}, "text": "showing", "normalized": "show"}}, {"subject": {"text": "by the company", "keywords": [{"text": "company"}], "entities": []}, "sentence": " Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector.", "object": {"text": "deals and value", "keywords": [{"text": "deals"}, {"text": "value"}]}, "action": {"verb": {"text": "report", "tense": "past"}, "text": "reported", "normalized": "report"}}, {"subject": {"text": "Each such deal", "keywords": [{"text": "deal"}]}, "sentence": " Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "object": {"text": "a brief summary, deal type, deal rationale", "keywords": [{"text": "brief summary"}, {"text": "rationale"}, {"text": "type"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Each such deal", "keywords": [{"text": "deal"}]}, "sentence": " Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "object": {"text": "type, deal rationale", "keywords": [{"text": "rationale"}, {"text": "type"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "Each such deal", "keywords": [{"text": "deal"}]}, "sentence": " Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "object": {"text": "financials", "keywords": [{"text": "financials"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "the company's financial deals", "keywords": [{"text": "financial deals"}, {"text": "company"}], "entities": []}, "sentence": " Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements", "object": {"text": "you to understand the company's expansion/divestiture and fund requirements", "keywords": [{"text": "company"}, {"text": "requirements"}], "entities": []}, "action": {"verb": {"text": "enable", "tense": "present"}, "text": "enable", "normalized": "enable"}}, {"subject": {"text": "The profile", "keywords": [{"text": "profile"}]}, "sentence": " The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "object": {"text": "to analyze the company's financial deals by region", "keywords": [{"text": "financial deals"}, {"text": "company"}, {"text": "region"}], "entities": []}, "action": {"verb": {"text": "enable", "tense": "present"}, "text": "enables", "normalized": "enable"}}, {"subject": {"text": "you"}, "sentence": " The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "object": {"text": "the company's financial deals by region", "keywords": [{"text": "financial deals"}, {"text": "company"}, {"text": "region"}], "entities": []}, "action": {"verb": {"text": "analyze", "tense": "future"}, "text": "to analyze", "normalized": "to analyze"}}, {"subject": {"text": "The profile", "keywords": [{"text": "profile"}]}, "sentence": " The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.", "object": {"text": "deals", "keywords": [{"text": "deals"}]}, "action": {"verb": {"text": "present", "tense": "present"}, "text": "presents", "normalized": "present"}}, {"subject": {"text": "you"}, "sentence": " The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.", "object": {"text": "its corporate strategy", "keywords": [{"text": "corporate strategy"}]}, "action": {"verb": {"text": "understand", "tense": "present"}, "text": "understand", "normalized": "understand"}}, {"subject": {"text": "the company's recent financial deals", "keywords": [{"text": "recent financial deals"}, {"text": "company"}], "entities": []}, "sentence": " Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company", "object": {"text": "you to understand the key deals which have shaped the company", "keywords": [{"text": "key deals"}, {"text": "company"}], "entities": []}, "action": {"verb": {"text": "enable", "tense": "present"}, "text": "enable", "normalized": "enable"}}, {"subject": {"text": "the key deals", "keywords": [{"text": "key deals"}]}, "sentence": " Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company", "object": {"text": "shaped the company", "keywords": [{"text": "company"}], "entities": []}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios", "keywords": [{"text": "deal"}, {"text": "Target Company"}, {"text": "rationale"}, {"text": "financials"}], "entities": [{"type": "Company", "text": "pharmaceutical company"}]}, "sentence": " Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.", "object": {"text": "Detailed information on major recent deals", "keywords": [{"text": "major recent deals"}, {"text": "information"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "a summary of each deal, deal type,", "keywords": [{"text": "deal"}, {"text": "summary"}, {"text": "type"}]}, "sentence": " Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.", "object": {"text": "rationale", "keywords": [{"text": "rationale"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "each deal, deal type, deal rationale,", "keywords": [{"text": "deal"}, {"text": "rationale"}, {"text": "type"}]}, "sentence": " Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.", "object": {"text": "financials and Target Company's key financial metrics and ratios", "keywords": [{"text": "Target Company"}, {"text": "financials"}, {"text": "ratios"}, {"text": "metrics"}], "entities": [{"type": "Company", "text": "pharmaceutical company"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}], "entities": []}, "sentence": " Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.", "object": {"text": "potential customers and suppliers", "keywords": [{"text": "potential customers"}, {"text": "suppliers"}]}, "action": {"verb": {"text": "identify", "tense": "future"}, "text": "to identify", "normalized": "to identify"}}, {"subject": {"text": "The profile", "keywords": [{"text": "profile"}]}, "sentence": " The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.", "object": {"text": "the company's business structure, locations and subsidiaries, key executives and key competitors", "keywords": [{"text": "key competitors"}, {"text": "key executives"}, {"text": "business structure"}, {"text": "subsidiaries"}], "entities": []}, "action": {"verb": {"text": "analyze", "tense": "present"}, "text": "analyzes", "normalized": "analyze"}}, {"subject": {"text": "the major developments", "keywords": [{"text": "major developments"}]}, "sentence": " Stay uptodate on the major developments affecting the company", "object": {"text": "the company", "keywords": [{"text": "company"}], "entities": []}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affecting", "normalized": "affect"}}, {"subject": {"text": "Recent developments", "keywords": [{"text": "Recent developments"}]}, "sentence": " Recent developments concerning the company presented in the profile help you track important events.", "object": {"text": "the company presented", "keywords": [{"text": "company"}], "entities": []}, "action": {"verb": {"text": "concern", "tense": "present"}, "text": "concerning", "normalized": "concern"}}, {"subject": {"text": "you"}, "sentence": " Recent developments concerning the company presented in the profile help you track important events.", "object": {"text": "important events", "keywords": [{"text": "important events"}]}, "action": {"verb": {"text": "track", "tense": "present"}, "text": "track", "normalized": "track"}}, {"subject": {"text": "Key elements such as break up of deals into categories and information on detailed major deals", "keywords": [{"text": "detailed major deals"}, {"text": "Key elements"}, {"text": "categories"}, {"text": "information"}], "entities": []}, "sentence": " Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.", "object": {"text": "incorporated"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Key elements such as break up of deals into categories and information on detailed major deals", "keywords": [{"text": "detailed major deals"}, {"text": "Key elements"}, {"text": "categories"}, {"text": "information"}], "entities": []}, "sentence": " Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.", "object": {"text": "your academic or business research needs", "keywords": [{"text": "business research"}]}, "action": {"verb": {"text": "assist", "tense": "future"}, "text": "to assist", "normalized": "to assist"}}, {"subject": {"text": "Some sections", "keywords": [{"text": "sections"}]}, "sentence": " Note*: Some sections may be missing if data is unavailable for the company.", "object": {"text": "missing"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "data", "keywords": [{"text": "data"}]}, "sentence": " Note*: Some sections may be missing if data is unavailable for the company.", "object": {"text": "unavailable for the company", "keywords": [{"text": "company"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "is", "normalized": "be"}}], "concepts": [{"text": "Pharmacology", "relevance": 0.945442, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Venture capital", "relevance": 0.86572, "dbpedia_resource": "http://dbpedia.org/resource/Venture_capital"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.84105, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Mergers and acquisitions", "relevance": 0.837847, "dbpedia_resource": "http://dbpedia.org/resource/Mergers_and_acquisitions"}, {"text": "Finance", "relevance": 0.83561, "dbpedia_resource": "http://dbpedia.org/resource/Finance"}, {"text": "Pharmaceutical drug", "relevance": 0.826907, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Pharmacy", "relevance": 0.734795, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacy"}, {"text": "Companies based in Osaka Prefecture", "relevance": 0.709033, "dbpedia_resource": "http://dbpedia.org/resource/Companies_based_in_Osaka_Prefecture"}], "categories": [{"score": 0.646277, "label": "/finance/financial news"}, {"score": 0.451611, "label": "/business and industrial"}, {"score": 0.39926, "label": "/business and industrial/company"}], "relations": [{"type": "agentOf", "sentence": "Advertisement Topics Track topics on Twitter Track topics that are important to you Printed From BioPortfolio.com Takeda Pharmaceutical Co Ltd 4502 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250 07:57 EST 14 Nov 2018 | BioPortfolio Report Blog Summary Takeda Pharmaceutical Company Ltd Takeda is a researchbased global pharmaceutical company which focuses on the research and development, manufacture, marketing, commercialization and import and export of pharmaceutical drugs and consumer health care products.", "score": 0.535886, "arguments": [{"text": "BioPortfolio.com Takeda Pharmaceutical Co Ltd", "location": [97, 142], "entities": [{"type": "Organization", "text": "BioPortfolio.com Takeda Pharmaceutical Co Ltd"}]}, {"text": "Report", "location": [204, 210], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "locatedAt", "sentence": "It operates production facilities in Osaka and Hikari in Japan; Italy; Ireland; Germany; Austria; Denmark; Belgium; Norway; Poland; Russia; China; Indonesia; Mexico; Brazil; Argentina; Columbia; Estonia; and India.", "score": 0.58524, "arguments": [{"text": "Hikari", "location": [882, 888], "entities": [{"type": "Person", "text": "Hikari"}]}, {"text": "Japan", "location": [892, 897], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "It also operates research and development facilities at various locations in Japan and the US, China and the UK; and in Brazil, Germany, Switzerland, and Singapore.", "score": 0.620085, "arguments": [{"text": "facilities", "location": [1092, 1102], "entities": [{"type": "Facility", "text": "facilities"}]}, {"text": "locations", "location": [1114, 1123], "entities": [{"type": "Facility", "text": "locations"}]}]}, {"type": "locatedAt", "sentence": "It also operates research and development facilities at various locations in Japan and the US, China and the UK; and in Brazil, Germany, Switzerland, and Singapore.", "score": 0.846092, "arguments": [{"text": "locations", "location": [1114, 1123], "entities": [{"type": "Facility", "text": "locations"}]}, {"text": "Japan", "location": [1127, 1132], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "It also operates research and development facilities at various locations in Japan and the US, China and the UK; and in Brazil, Germany, Switzerland, and Singapore.", "score": 0.828139, "arguments": [{"text": "Brazil", "location": [1170, 1176], "entities": [{"type": "GeopoliticalEntity", "text": "Brazil"}]}, {"text": "Germany", "location": [1178, 1185], "entities": [{"type": "GeopoliticalEntity", "text": "Germany", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "It also operates research and development facilities at various locations in Japan and the US, China and the UK; and in Brazil, Germany, Switzerland, and Singapore.", "score": 0.553457, "arguments": [{"text": "Brazil", "location": [1170, 1176], "entities": [{"type": "GeopoliticalEntity", "text": "Brazil"}]}, {"text": "Singapore", "location": [1204, 1213], "entities": [{"type": "GeopoliticalEntity", "text": "Singapore", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "basedIn", "sentence": "Takeda is headquartered in Chuoku, Osaka, Japan.", "score": 0.857891, "arguments": [{"text": "Takeda", "location": [1215, 1221], "entities": [{"type": "Organization", "text": "BioPortfolio Report Blog\nSummary\nTakeda Pharmaceutical Company Ltd Takeda"}]}, {"text": "Chuoku", "location": [1242, 1248], "entities": [{"type": "GeopoliticalEntity", "text": "Chuoku"}]}]}, {"type": "locatedAt", "sentence": "Takeda is headquartered in Chuoku, Osaka, Japan.", "score": 0.972047, "arguments": [{"text": "Chuoku", "location": [1242, 1248], "entities": [{"type": "GeopoliticalEntity", "text": "Chuoku"}]}, {"text": "Osaka", "location": [1250, 1255], "entities": [{"type": "GeopoliticalEntity", "text": "Osaka"}]}]}, {"type": "locatedAt", "sentence": "Takeda is headquartered in Chuoku, Osaka, Japan.", "score": 0.541068, "arguments": [{"text": "Chuoku", "location": [1242, 1248], "entities": [{"type": "GeopoliticalEntity", "text": "Chuoku"}]}, {"text": "Japan", "location": [1257, 1262], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Takeda is headquartered in Chuoku, Osaka, Japan.", "score": 0.930548, "arguments": [{"text": "Osaka", "location": [1250, 1255], "entities": [{"type": "GeopoliticalEntity", "text": "Osaka"}]}, {"text": "Japan", "location": [1257, 1262], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Takeda Pharmaceutical Co Ltd 4502 Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings.", "score": 0.617414, "arguments": [{"text": "Mergers", "location": [1421, 1428], "entities": [{"type": "Organization", "text": "Mergers", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "company", "location": [1411, 1418], "entities": [{"type": "Organization", "text": "Target Company", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Advertisement Topics Track topics on Twitter Track topics that are important to you Printed From BioPortfolio.com Takeda Pharmaceutical Co Ltd 4502 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250 07:57 EST 14 Nov 2018 | BioPortfolio Report Blog Summary Takeda Pharmaceutical Company Ltd Takeda is a researchbased global pharmaceutical company which focuses on the research and development, manufacture, marketing, commercialization and import and export of pharmaceutical drugs and consumer health care products.", "score": 0.731488, "arguments": [{"text": "Pharmaceuticals Healthcare Deals", "location": [148, 180], "entities": [{"type": "Organization", "text": "Pharmaceuticals Healthcare Deals and Alliances Profile"}]}, {"text": "Report", "location": [204, 210], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "partOf", "sentence": "The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.", "score": 0.25222, "arguments": [{"text": "company", "location": [1652, 1659], "entities": [{"type": "Organization", "text": "Target Company", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Equity", "location": [1550, 1556], "entities": [{"type": "Organization", "text": "Private Equity", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.", "score": 0.590828, "arguments": [{"text": "Acquisitions", "location": [2050, 2062], "entities": [{"type": "Organization", "text": "Acquisitions MAs", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "company", "location": [2002, 2009], "entities": [{"type": "Organization", "text": "Target Company", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.", "score": 0.441085, "arguments": [{"text": "Equity", "location": [2064, 2070], "entities": [{"type": "Organization", "text": "Private Equity", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "company", "location": [2002, 2009], "entities": [{"type": "Organization", "text": "Target Company", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.", "score": 0.648284, "arguments": [{"text": "Debt Offerings", "location": [2071, 2085], "entities": [{"type": "Organization", "text": "Debt Offerings", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "company", "location": [2002, 2009], "entities": [{"type": "Organization", "text": "Target Company", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.", "score": 0.618132, "arguments": [{"text": "Venture Financing", "location": [2103, 2120], "entities": [{"type": "Organization", "text": "Venture Financing", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "company", "location": [2002, 2009], "entities": [{"type": "Organization", "text": "Target Company", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.", "score": 0.564807, "arguments": [{"text": "Type Chart", "location": [2301, 2311], "entities": [{"type": "Organization", "text": "Type Chart"}]}, {"text": "Deals", "location": [2292, 2297], "entities": [{"type": "Organization", "text": "Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "partOf", "sentence": "Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.", "score": 0.576002, "arguments": [{"text": "Deals", "location": [2476, 2481], "entities": [{"type": "Organization", "text": "Pharmaceuticals Healthcare Deals and Alliances Profile"}]}, {"text": "Region Chart", "location": [2485, 2497], "entities": [{"type": "Organization", "text": "Region Chart"}]}]}, {"type": "locatedAt", "sentence": "Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.", "score": 0.706156, "arguments": [{"text": "Asia", "location": [2637, 2641], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [2642, 2649], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "partOf", "sentence": "Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector.", "score": 0.656702, "arguments": [{"text": "Subsector Chart", "location": [2718, 2733], "entities": [{"type": "Organization", "text": "Subsector Chart"}]}, {"text": "Deals", "location": [2709, 2714], "entities": [{"type": "Organization", "text": "Pharmaceuticals Healthcare Deals and Alliances Profile"}]}]}, {"type": "partOf", "sentence": "Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios.", "score": 0.910852, "arguments": [{"text": "companies", "location": [3017, 3026], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Company", "location": [2994, 3001], "entities": [{"type": "Organization", "text": "BioPortfolio Report Blog\nSummary\nTakeda Pharmaceutical Company Ltd Takeda"}]}]}, {"type": "managerOf", "sentence": "Advertisement Topics Track topics on Twitter Track topics that are important to you Printed From BioPortfolio.com Takeda Pharmaceutical Co Ltd 4502 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250 07:57 EST 14 Nov 2018 | BioPortfolio Report Blog Summary Takeda Pharmaceutical Company Ltd Takeda is a researchbased global pharmaceutical company which focuses on the research and development, manufacture, marketing, commercialization and import and export of pharmaceutical drugs and consumer health care products.", "score": 0.273768, "arguments": [{"text": "Nov", "location": [264, 267], "entities": [{"type": "Person", "text": "Nov"}]}, {"text": "BioPortfolio Report Blog\nSummary\nTakeda Pharmaceutical Company Ltd Takeda", "location": [275, 348], "entities": [{"type": "Organization", "text": "BioPortfolio Report Blog\nSummary\nTakeda Pharmaceutical Company Ltd Takeda"}]}]}, {"type": "employedBy", "sentence": "Key Employees A list of the key executives of the company.", "score": 0.50864, "arguments": [{"text": "executives", "location": [3163, 3173], "entities": [{"type": "Person", "text": "executives"}]}, {"text": "company", "location": [3181, 3188], "entities": [{"type": "Organization", "text": "Target Company", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company.", "score": 0.803355, "arguments": [{"text": "subsidiaries", "location": [3286, 3298], "entities": [{"type": "Organization", "text": "Subsidiaries"}]}, {"text": "company", "location": [3306, 3313], "entities": [{"type": "Organization", "text": "Target Company", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Key Competitors A list of the key competitors of the company.", "score": 0.84577, "arguments": [{"text": "competitors", "location": [3349, 3360], "entities": [{"type": "Organization", "text": "competitors", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "company", "location": [3368, 3375], "entities": [{"type": "Organization", "text": "Target Company", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "score": 0.350071, "arguments": [{"text": "you", "location": [3528, 3531], "entities": [{"type": "Person", "text": "yourself"}]}, {"text": "company", "location": [3550, 3557], "entities": [{"type": "Organization", "text": "Target Company", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.", "score": 0.799113, "arguments": [{"text": "you", "location": [3624, 3627], "entities": [{"type": "Person", "text": "yourself"}]}, {"text": "analyze", "location": [3631, 3638], "entities": [{"type": "EventCommunication", "text": "analyze"}]}]}, {"type": "agentOf", "sentence": "Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.", "score": 0.953283, "arguments": [{"text": "company", "location": [4088, 4095], "entities": [{"type": "Organization", "text": "Target Company", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Detailed", "location": [4096, 4104], "entities": [{"type": "EventCommunication", "text": "detailed"}]}]}, {"type": "partOf", "sentence": "The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.", "score": 0.496537, "arguments": [{"text": "competitors", "location": [4495, 4506], "entities": [{"type": "Organization", "text": "competitors", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "subsidiaries", "location": [4458, 4470], "entities": [{"type": "Organization", "text": "Subsidiaries"}]}]}, {"type": "partOf", "sentence": "Takeda markets its drugs worldwide through its subsidiaries in North America, Europe and Asia.", "score": 0.798877, "arguments": [{"text": "subsidiaries", "location": [787, 799], "entities": [{"type": "Organization", "text": "Subsidiaries"}]}, {"text": "its", "location": [783, 786], "entities": [{"type": "Organization", "text": "BioPortfolio Report Blog\nSummary\nTakeda Pharmaceutical Company Ltd Takeda"}]}]}, {"type": "locatedAt", "sentence": "Takeda markets its drugs worldwide through its subsidiaries in North America, Europe and Asia.", "score": 0.611004, "arguments": [{"text": "subsidiaries", "location": [787, 799], "entities": [{"type": "Organization", "text": "Subsidiaries"}]}, {"text": "North America", "location": [803, 816], "entities": [{"type": "GeopoliticalEntity", "text": "North America", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Takeda markets its drugs worldwide through its subsidiaries in North America, Europe and Asia.", "score": 0.626811, "arguments": [{"text": "subsidiaries", "location": [787, 799], "entities": [{"type": "Organization", "text": "Subsidiaries"}]}, {"text": "Europe", "location": [818, 824], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Takeda markets its drugs worldwide through its subsidiaries in North America, Europe and Asia.", "score": 0.607293, "arguments": [{"text": "subsidiaries", "location": [787, 799], "entities": [{"type": "Organization", "text": "Subsidiaries"}]}, {"text": "Asia", "location": [829, 833], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "It operates production facilities in Osaka and Hikari in Japan; Italy; Ireland; Germany; Austria; Denmark; Belgium; Norway; Poland; Russia; China; Indonesia; Mexico; Brazil; Argentina; Columbia; Estonia; and India.", "score": 0.968488, "arguments": [{"text": "facilities", "location": [858, 868], "entities": [{"type": "Facility", "text": "facilities"}]}, {"text": "Osaka", "location": [872, 877], "entities": [{"type": "GeopoliticalEntity", "text": "Osaka"}]}]}, {"type": "locatedAt", "sentence": "It operates production facilities in Osaka and Hikari in Japan; Italy; Ireland; Germany; Austria; Denmark; Belgium; Norway; Poland; Russia; China; Indonesia; Mexico; Brazil; Argentina; Columbia; Estonia; and India.", "score": 0.658305, "arguments": [{"text": "facilities", "location": [858, 868], "entities": [{"type": "Facility", "text": "facilities"}]}, {"text": "Japan", "location": [892, 897], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}], "keywords": [{"text": "deals", "sentiment": {"score": 0.438298, "label": "positive"}, "relevance": 0.985631}, {"text": "financial deals", "sentiment": {"score": 0.572001, "label": "positive"}, "relevance": 0.984686}, {"text": "company", "sentiment": {"score": -0.022198, "label": "negative"}, "relevance": 0.943744}, {"text": "Pharmaceuticals Healthcare Deals", "sentiment": {"score": 0.413531, "label": "positive"}, "relevance": 0.890502}, {"text": "Major Deals Information", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.668708}, {"text": "Financial Deals Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.663548}, {"text": "major financial deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.658647}, {"text": "eTrack deals database", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.65836}, {"text": "detailed major deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.632667}, {"text": "recent financial deals", "sentiment": {"score": 0.466963, "label": "positive"}, "relevance": 0.629763}, {"text": "major recent deals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.621346}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.614341}, {"text": "key deals", "sentiment": {"score": 0.466963, "label": "positive"}, "relevance": 0.549928}, {"text": "global pharmaceutical company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.537462}, {"text": "BioPortfolio.com Takeda Pharmaceutical", "sentiment": {"score": 0.378807, "label": "positive"}, "relevance": 0.529536}, {"text": "detailed information", "sentiment": {"score": 0.677039, "label": "positive"}, "relevance": 0.513103}, {"text": "key competitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.489481}, {"text": "business segments", "sentiment": {"score": -0.352689, "label": "negative"}, "relevance": 0.460441}, {"text": "target company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.453011}, {"text": "key financial metrics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.451543}, {"text": "Alliances Profile", "sentiment": {"score": 0.413531, "label": "positive"}, "relevance": 0.447156}, {"text": "Twitter Track topics", "sentiment": {"score": 0.378807, "label": "positive"}, "relevance": 0.441483}, {"text": "consumer health care", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.438064}, {"text": "North America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.429583}, {"text": "Private Equity", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.425847}, {"text": "Venture Financing", "sentiment": {"score": 0.489186, "label": "positive"}, "relevance": 0.425282}, {"text": "detailed comparative data", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.424136}, {"text": "Equity/Debt Offerings", "sentiment": {"score": 0.343645, "label": "positive"}, "relevance": 0.422381}, {"text": "Gain key insights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.420375}, {"text": "Access elaborate information", "sentiment": {"score": 0.466963, "label": "positive"}, "relevance": 0.418479}, {"text": "key executives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.416246}, {"text": "major public companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.414091}, {"text": "core business segments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.411557}, {"text": "business research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.384647}, {"text": "deal types", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.366382}, {"text": "Subsector Chart", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.349748}, {"text": "BioPortfolio Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.346161}, {"text": "Key Employees", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.341961}, {"text": "key centers", "sentiment": {"score": 0.539694, "label": "positive"}, "relevance": 0.341167}, {"text": "Report Updated", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.338526}, {"text": "Key elements", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.338011}, {"text": "Advertisement Topics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.334263}, {"text": "pharmaceutical drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.332946}, {"text": "wide range", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.329265}, {"text": "photographic chemicals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.327802}, {"text": "Acquisitions MAs", "sentiment": {"score": 0.448255, "label": "positive"}, "relevance": 0.325715}, {"text": "vitamin bulks", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.325208}, {"text": "test reagents", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.324992}, {"text": "inorganic chemicals", "sentiment": {"score": -0.331437, "label": "negative"}, "relevance": 0.324343}, {"text": "clinical diagnostics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.324323}]}, "extracted_metadata": {"sha1": "dec8a4f1dd99659b93cc34c7be61627ee0594437", "filename": "1542204971231.zip-7720686cb13726edce9549242c2f3265.xml", "file_type": "json"}, "title": "Takeda Pharmaceutical Co Ltd 4502 Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 09112018 Prices from USD $250", "forum_title": "BioPortfolio Rising Global Prevalence Migraine Headaches Drive Migraine Drugs News"}, {"id": "qCv6eGg1CYTyz26bD1_0Ry-i1qbXf-kVmqUBFzUzu8i-BYAy4Oy-I8XhWz4DMrlH", "result_metadata": {"score": 34.258522}, "author": "Healthcare Intelligence Markets", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MedImmune", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "MedImmune", "dbpedia_resource": "http://dbpedia.org/resource/MedImmune"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China National Biotec", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GSK", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GSK", "relevance": 0.33, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Crucell", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Crucell", "dbpedia_resource": "http://dbpedia.org/resource/Crucell"}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Biotechnology companies", "relevance": 0.955275, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology_companies"}, {"text": "Influenza vaccine", "relevance": 0.839919, "dbpedia_resource": "http://dbpedia.org/resource/Influenza_vaccine"}, {"text": "InnoMed PredTox", "relevance": 0.482547, "dbpedia_resource": "http://dbpedia.org/resource/InnoMed_PredTox"}], "categories": [{"score": 0.625386, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.470818, "label": "/health and fitness/disease/cold and flu"}, {"score": 0.402367, "label": "/health and fitness/drugs"}], "relations": [{"type": "locatedAt", "sentence": "Complete Analysis of Global Human Vaccines Market by Forecast 2022: Top Manufactures Covered Like GSK, Sanofi, Merck, Pfizer, Novartis (GSK), CSL, MedImmune, J&J Crucell), China National Biotec", "score": 0.982352, "arguments": [{"text": "GSK", "location": [98, 101], "entities": [{"type": "GeopoliticalEntity", "text": "GSK"}]}, {"text": "Sanofi", "location": [103, 109], "entities": [{"type": "GeopoliticalEntity", "text": "Sanofi"}]}]}], "keywords": [{"text": "Covered Like GSK", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.945168}, {"text": "Global Human Vaccines", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.898561}, {"text": "China National Biotec", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.875638}, {"text": "Complete Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.571647}, {"text": "J&J Crucell", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.538446}, {"text": "Sanofi", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.495124}, {"text": "MedImmune", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.485098}, {"text": "CSL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.463097}, {"text": "Pfizer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.455758}, {"text": "Novartis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.452824}, {"text": "Merck", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.427866}, {"text": "Forecast", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.416762}, {"text": "Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.334321}]}, "crawl_date": "2018-11-13T17:48:45Z", "url": "https://www.openpr.com/news/1366890/Complete-Analysis-of-Global-Human-Vaccines-Market-by-Forecast-2022-Top-Manufactures-Covered-Like-GSK-Sanofi-Merck-Pfizer-Novartis-GSK-CSL-MedImmune-J-J-Crucell-China-National-Biotec.html", "host": "openpr.com", "text": "., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Mymetics, Novartis AG, Pfizer, Inc., Sanofi, Shenzhen Kangtai Biological Products Co., Ltd., Takeda Pharmaceutical Company Limited etc.", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-13T17:45:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "IT industries", "relevance": 0.249087, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.235116, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca", "relevance": 0.222772, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Inc.", "relevance": 0.208592, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson", "relevance": 0.206167, "type": "Company", "disambiguation": {"subtype": ["AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ltd.", "relevance": 0.201835, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis AG", "relevance": 0.199866, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shenzhen Kangtai Biological Products Co.", "relevance": 0.19746, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.195453, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CSL Limited", "relevance": 0.194405, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.238151, "label": "negative"}, "text": "Merck & Co.", "relevance": 0.193157, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bharat Biotech", "relevance": 0.183218, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.464662, "label": "positive"}, "text": "Bavarian Nordic", "relevance": 0.182444, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer, Inc.", "relevance": 0.177421, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mymetics", "relevance": 0.17566, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "360-degree", "relevance": 0.17566, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "five-years", "relevance": 0.17566, "type": "Quantity"}], "sentiment": {"document": {"score": 0.706546, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Healthcare Intelligence Markets Vaccination", "keywords": [{"text": "Intelligence Markets Vaccination"}]}, "sentence": "Press release from: Healthcare Intelligence Markets Vaccination plays an important role in maintaining the sustainable health of people in countries.", "object": {"text": "an important role", "keywords": [{"text": "important role"}]}, "action": {"verb": {"text": "play", "tense": "present"}, "text": "plays", "normalized": "play"}}, {"subject": {"text": "Healthcare Intelligence Markets Vaccination", "keywords": [{"text": "Intelligence Markets Vaccination"}]}, "sentence": "Press release from: Healthcare Intelligence Markets Vaccination plays an important role in maintaining the sustainable health of people in countries.", "object": {"text": "the sustainable health of people in countries", "keywords": [{"text": "sustainable health"}, {"text": "people"}, {"text": "countries"}]}, "action": {"verb": {"text": "maintain", "tense": "present"}, "text": "maintaining", "normalized": "maintain"}}, {"subject": {"text": "they"}, "sentence": " Therefore they are engaged in various local disease prevention strategies.", "object": {"text": "engaged in various local disease prevention strategies", "keywords": [{"text": "various local disease"}, {"text": "prevention strategies"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "they"}, "sentence": " Therefore they are engaged in various local disease prevention strategies.", "object": {"text": "in various local disease prevention strategies", "keywords": [{"text": "various local disease"}, {"text": "prevention strategies"}]}, "action": {"verb": {"text": "engage", "tense": "past"}, "text": "are engaged", "normalized": "be engage"}}, {"subject": {"text": "immunizations", "keywords": [{"text": "immunizations"}]}, "sentence": " The incidence of viral and bacterial infections has increased, and demand for immunizations has increased in the last few years.", "object": {"text": "increased"}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Vaccinations", "keywords": [{"text": "Vaccinations"}]}, "sentence": " Vaccinations are administered to people of essentially different ages, strengthening the immune system throughout the lifetime and providing protection against a wide variety of infectious diseases.", "object": {"text": "to people", "keywords": [{"text": "people"}]}, "action": {"verb": {"text": "administer", "tense": "past"}, "text": "are administered", "normalized": "be administer"}}, {"subject": {"text": "the immune system", "entities": []}, "sentence": " Vaccinations are administered to people of essentially different ages, strengthening the immune system throughout the lifetime and providing protection against a wide variety of infectious diseases.", "action": {"verb": {"text": "strengthen", "tense": "present"}, "text": "strengthening", "normalized": "strengthen"}}, {"subject": {"text": "Vaccinations", "keywords": [{"text": "Vaccinations"}]}, "sentence": " Vaccinations are administered to people of essentially different ages, strengthening the immune system throughout the lifetime and providing protection against a wide variety of infectious diseases.", "object": {"text": "protection", "keywords": [{"text": "protection"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "providing", "normalized": "provide"}}, {"subject": {"text": "This report", "keywords": [{"text": "report"}]}, "sentence": " This report presents a 360-degree overview of the competitive scenario of the Global Human Vaccines market.", "object": {"text": "a 360-degree overview of the competitive scenario of the Global Human Vaccines market", "keywords": [{"text": "Global Human Vaccines"}, {"text": "360-degree overview"}, {"text": "competitive scenario"}, {"text": "market"}], "entities": [{"type": "Quantity", "text": "360-degree"}]}, "action": {"verb": {"text": "present", "tense": "present"}, "text": "presents", "normalized": "present"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report also presents a thorough qualitative and quantitative data affecting to the projected impact of these factors on market\u2019s future growth prospects.", "object": {"text": "a thorough qualitative and quantitative data affecting to the projected impact of these factors on market\u2019s future growth prospects", "keywords": [{"text": "future growth prospects"}, {"text": "quantitative data"}, {"text": "factors"}, {"text": "impact"}]}, "action": {"verb": {"text": "present", "tense": "present"}, "text": "presents", "normalized": "present"}}, {"subject": {"text": "for sample copy", "keywords": [{"text": "sample copy"}]}, "sentence": " Ask for sample copy at www.healthcareintelligencemarkets.com/request_sample.php?...", "action": {"verb": {"text": "Ask", "tense": "present"}, "text": "Ask", "normalized": "Ask"}}, {"subject": {"text": "Top manufactures", "keywords": [{"text": "manufactures"}], "entities": [{"type": "Company", "text": "AstraZeneca", "disambiguation": {"subtype": ["Company"], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}]}, "sentence": " Top manufactures are covered in this report: AstraZeneca, Bavarian Nordic, Bharat Biotech, CSL Limited, Emergent BioSolutions, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Mymetics, Novartis AG, Pfizer, Inc., Sanofi, Shenzhen Kangtai Biological Products Co., Ltd., Takeda Pharmaceutical Company Limited etc.", "object": {"text": "covered in this report", "keywords": [{"text": "report"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Top manufactures", "keywords": [{"text": "manufactures"}], "entities": [{"type": "Company", "text": "AstraZeneca", "disambiguation": {"subtype": ["Company"], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}]}, "sentence": " Top manufactures are covered in this report: AstraZeneca, Bavarian Nordic, Bharat Biotech, CSL Limited, Emergent BioSolutions, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Mymetics, Novartis AG, Pfizer, Inc., Sanofi, Shenzhen Kangtai Biological Products Co., Ltd., Takeda Pharmaceutical Company Limited etc.", "object": {"text": "in this report: AstraZeneca, Bavarian Nordic, Bharat Biotech, CSL Limited, Emergent BioSolutions, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Mymetics, Novartis AG, Pfizer, Inc., Sanofi, Shenzhen Kangtai Biological Products Co., Ltd., Takeda Pharmaceutical Company Limited etc", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "Shenzhen Kangtai Biological"}, {"text": "Emergent BioSolutions"}, {"text": "Bharat Biotech"}], "entities": [{"type": "Company", "text": "AstraZeneca", "disambiguation": {"subtype": ["Company"], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"type": "Company", "text": "Bavarian Nordic"}, {"type": "Company", "text": "Bharat Biotech"}, {"type": "Company", "text": "CSL Limited"}, {"type": "Company", "text": "Inc."}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Johnson & Johnson", "disambiguation": {"subtype": ["Organization", "AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"type": "Company", "text": "Merck & Co.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "Inc."}, {"type": "Company", "text": "Mymetics"}, {"type": "Company", "text": "Novartis AG", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Pfizer, Inc."}, {"type": "Company", "text": "Shenzhen Kangtai Biological Products Co."}, {"type": "Location", "text": "Ltd.", "disambiguation": {"subtype": ["Country"]}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "cover", "tense": "past"}, "text": "are covered", "normalized": "be cover"}}, {"subject": {"text": "The research on the global Human Vaccines market", "keywords": [{"text": "global Human Vaccines"}, {"text": "market"}, {"text": "research"}], "entities": []}, "sentence": " The research on the global Human Vaccines market will be useful to investors, regularity authorities, and policy makers, state the analysts.", "object": {"text": "useful to investors, regularity authorities, and policy makers", "keywords": [{"text": "regularity authorities"}, {"text": "policy makers"}, {"text": "investors"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "will be", "normalized": "will be"}}, {"subject": {"text": "Key companies", "keywords": [{"text": "Key companies"}]}, "sentence": " Key companies operating in the global Human Vaccines market is profiled by considering factors such as capacity production, products/services, applications, cost, gross, and revenue.", "action": {"verb": {"text": "operate", "tense": "present"}, "text": "operating", "normalized": "operate"}}, {"subject": {"text": "Key companies operating in the global Human Vaccines market", "keywords": [{"text": "global Human Vaccines"}, {"text": "Key companies"}], "entities": []}, "sentence": " Key companies operating in the global Human Vaccines market is profiled by considering factors such as capacity production, products/services, applications, cost, gross, and revenue.", "object": {"text": "profiled by considering factors such as capacity production, products/services, applications, cost, gross, and revenue", "keywords": [{"text": "capacity production"}, {"text": "products/services"}, {"text": "revenue"}, {"text": "factors"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by considering factors such as capacity production, products/services, applications, cost, gross, and revenue", "keywords": [{"text": "capacity production"}, {"text": "products/services"}, {"text": "revenue"}, {"text": "factors"}]}, "sentence": " Key companies operating in the global Human Vaccines market is profiled by considering factors such as capacity production, products/services, applications, cost, gross, and revenue.", "object": {"text": "Key companies operating in the global Human Vaccines market", "keywords": [{"text": "global Human Vaccines"}, {"text": "Key companies"}], "entities": []}, "action": {"verb": {"text": "profile", "tense": "past"}, "text": "is profiled", "normalized": "be profile"}}, {"subject": {"text": "Key companies operating in the global Human Vaccines market", "keywords": [{"text": "global Human Vaccines"}, {"text": "Key companies"}], "entities": []}, "sentence": " Key companies operating in the global Human Vaccines market is profiled by considering factors such as capacity production, products/services, applications, cost, gross, and revenue.", "object": {"text": "factors such as capacity production, products/services, applications, cost, gross, and revenue", "keywords": [{"text": "capacity production"}, {"text": "products/services"}, {"text": "revenue"}, {"text": "factors"}]}, "action": {"verb": {"text": "consider", "tense": "present"}, "text": "considering", "normalized": "consider"}}, {"subject": {"text": "the global market for Human Vaccines", "keywords": [{"text": "Human Vaccines"}, {"text": "global market"}], "entities": []}, "sentence": " According to the research report, the global market for Human Vaccines is witnessing a continual rise in its valuation with the advancement in technologies, which is impacting the consumer behavior and, accordingly, their purchasing patterns to a great extent.", "object": {"text": "witnessing a continual rise in its valuation with the advancement in technologies, which is impacting the consumer behavior and, accordingly, their purchasing patterns to a great extent", "keywords": [{"text": "continual rise"}, {"text": "great extent"}, {"text": "consumer behavior"}, {"text": "purchasing patterns"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the global market for Human Vaccines", "keywords": [{"text": "Human Vaccines"}, {"text": "global market"}], "entities": []}, "sentence": " According to the research report, the global market for Human Vaccines is witnessing a continual rise in its valuation with the advancement in technologies, which is impacting the consumer behavior and, accordingly, their purchasing patterns to a great extent.", "object": {"text": "a continual rise in its valuation with the advancement in technologies, which is impacting the consumer behavior and, accordingly, their purchasing patterns to a great extent", "keywords": [{"text": "continual rise"}, {"text": "great extent"}, {"text": "consumer behavior"}, {"text": "purchasing patterns"}]}, "action": {"verb": {"text": "witness", "tense": "present"}, "text": "is witnessing", "normalized": "be witness"}}, {"subject": {"text": "the rising penetration of internet and the surge in mobile surfing", "keywords": [{"text": "mobile surfing"}, {"text": "surge"}, {"text": "penetration"}, {"text": "internet"}]}, "sentence": " In addition to this, the rising penetration of internet and the surge in mobile surfing are anticipated to boost the demand for Human Vaccines across the world, states the research report.", "object": {"text": "anticipated"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "the rising penetration of internet and the surge in mobile surfing", "keywords": [{"text": "mobile surfing"}, {"text": "surge"}, {"text": "penetration"}, {"text": "internet"}]}, "sentence": " In addition to this, the rising penetration of internet and the surge in mobile surfing are anticipated to boost the demand for Human Vaccines across the world, states the research report.", "object": {"text": "the demand for Human Vaccines", "keywords": [{"text": "Human Vaccines"}, {"text": "demand"}]}, "action": {"verb": {"text": "boost", "tense": "future"}, "text": "are anticipated to boost", "normalized": "be anticipate to boost"}}, {"subject": {"text": "The organization", "keywords": [{"text": "organization"}]}, "sentence": " The organization\u2019s vivacious and significant procedures will secure the latest and renewed updates on the organization\u2019s outline and besides this data and reports of the anticipated products and services in the market.", "object": {"text": "vivacious and significant procedures", "keywords": [{"text": "significant procedures"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "The organization\u2019s vivacious and significant procedures", "keywords": [{"text": "significant procedures"}, {"text": "organization"}]}, "sentence": " The organization\u2019s vivacious and significant procedures will secure the latest and renewed updates on the organization\u2019s outline and besides this data and reports of the anticipated products and services in the market.", "object": {"text": "updates", "keywords": [{"text": "updates"}]}, "action": {"verb": {"text": "renew", "tense": "future"}, "text": "renewed", "normalized": "renew"}}, {"subject": {"text": "outline", "keywords": [{"text": "outline"}]}, "sentence": " The organization\u2019s vivacious and significant procedures will secure the latest and renewed updates on the organization\u2019s outline and besides this data and reports of the anticipated products and services in the market.", "object": {"text": "the organization", "keywords": [{"text": "organization"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "the information gathering", "keywords": [{"text": "information gathering"}]}, "sentence": " The methodology of the global Human Vaccines market is that the information gathering will confirm a crisp and inventive method of market analysis to help its customers and arise the development of their business.", "object": {"text": "a crisp and inventive method of market analysis to help its customers and arise the development of their business", "keywords": [{"text": "inventive method"}, {"text": "market analysis"}, {"text": "crisp"}, {"text": "customers"}]}, "action": {"verb": {"text": "confirm", "tense": "future"}, "text": "will confirm", "normalized": "will confirm"}}, {"subject": {"text": "The broad collection of research services", "keywords": [{"text": "broad collection"}, {"text": "research services"}]}, "sentence": " The broad collection of research services will ensure a match with each organization as a business need.", "object": {"text": "a match with each organization", "keywords": [{"text": "match"}, {"text": "organization"}]}, "action": {"verb": {"text": "ensure", "tense": "future"}, "text": "will ensure", "normalized": "will ensure"}}, {"subject": {"text": "The prime objective of this research report", "keywords": [{"text": "prime objective"}, {"text": "research report"}]}, "sentence": " The prime objective of this research report is to provide a deep insight into the global market for Human Vaccines to the key market participants and assist them in making rewarding strategies to gain an edge over competitors.", "object": {"text": "a deep insight", "keywords": [{"text": "deep insight"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "is to provide", "normalized": "be to provide"}}, {"subject": {"text": "them"}, "sentence": " The prime objective of this research report is to provide a deep insight into the global market for Human Vaccines to the key market participants and assist them in making rewarding strategies to gain an edge over competitors.", "object": {"text": "in making rewarding strategies to gain an edge over competitors", "keywords": [{"text": "rewarding strategies"}, {"text": "competitors"}, {"text": "edge"}]}, "action": {"verb": {"text": "assist", "tense": "present"}, "text": "assist", "normalized": "assist"}}, {"subject": {"text": "them"}, "sentence": " The prime objective of this research report is to provide a deep insight into the global market for Human Vaccines to the key market participants and assist them in making rewarding strategies to gain an edge over competitors.", "object": {"text": "rewarding strategies", "keywords": [{"text": "rewarding strategies"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "we"}, "sentence": " Being a B2B firm, we help businesses to meet the challenges of an ever evolving market with unbridled confidence.", "object": {"text": "businesses to meet the challenges of an ever evolving market with unbridled confidence", "keywords": [{"text": "unbridled confidence"}, {"text": "challenges"}, {"text": "businesses"}, {"text": "market"}], "entities": []}, "action": {"verb": {"text": "help", "tense": "present"}, "text": "help", "normalized": "help"}}, {"subject": {"text": "market", "keywords": [{"text": "market"}]}, "sentence": " Being a B2B firm, we help businesses to meet the challenges of an ever evolving market with unbridled confidence.", "action": {"verb": {"text": "evolve", "tense": "present"}, "text": "evolving", "normalized": "evolve"}}, {"subject": {"text": "We"}, "sentence": " We craft customized and syndicated market research reports that help market players to build game changing strategies.", "object": {"text": "customized and syndicated market research reports", "keywords": [{"text": "market research reports"}]}, "action": {"verb": {"text": "craft", "tense": "present"}, "text": "craft", "normalized": "craft"}}, {"subject": {"text": "We craft customized and syndicated market research", "keywords": [{"text": "market research"}]}, "sentence": " We craft customized and syndicated market research reports that help market players to build game changing strategies.", "object": {"text": "that help market players to build game changing strategies", "keywords": [{"text": "market players"}, {"text": "game"}, {"text": "strategies"}]}, "action": {"verb": {"text": "report", "tense": "present"}, "text": "reports", "normalized": "report"}}, {"subject": {"text": "we"}, "sentence": " Besides, we also provide upcoming trends & future market prospects in our reports pertaining to Drug development, Clinical & healthcare IT industries.", "object": {"text": "upcoming trends & future market prospects in our reports pertaining to Drug development, Clinical & healthcare IT industries", "keywords": [{"text": "future market prospects"}, {"text": "Drug development"}, {"text": "trends"}, {"text": "reports"}], "entities": [{"type": "Company", "text": "IT industries"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provide", "normalized": "provide"}}, {"subject": {"text": "we"}, "sentence": " Besides, we also provide upcoming trends & future market prospects in our reports pertaining to Drug development, Clinical & healthcare IT industries.", "object": {"text": "trends", "keywords": [{"text": "trends"}]}, "action": {"verb": {"text": "upcoming", "tense": "present"}, "text": "upcoming", "normalized": "upcoming"}}, {"subject": {"text": "IT", "entities": [{"type": "Company", "text": "IT industries"}]}, "sentence": " Besides, we also provide upcoming trends & future market prospects in our reports pertaining to Drug development, Clinical & healthcare IT industries.", "object": {"text": "Clinical & healthcare", "keywords": [{"text": "Clinical"}, {"text": "healthcare"}]}, "action": {"verb": {"text": "industries", "tense": "present"}, "text": "industries", "normalized": "industries"}}, {"subject": {"text": "Our intelligence", "keywords": [{"text": "intelligence"}]}, "sentence": " Our intelligence enables our clients to take decisions with which in turn proves a game-changer for them.", "object": {"text": "our clients to take decisions with which in turn proves a game-changer for them", "keywords": [{"text": "decisions"}, {"text": "turn"}, {"text": "clients"}, {"text": "game-changer"}]}, "action": {"verb": {"text": "enable", "tense": "present"}, "text": "enables", "normalized": "enable"}}, {"subject": {"text": "We"}, "sentence": " We constantly strive to serve our clients better by directly allowing them sessions with our research analysts so the report is at par with their expectations.", "object": {"text": "to serve our clients better by directly allowing them sessions with our research analysts so the report is at par with their expectations", "keywords": [{"text": "research analysts"}, {"text": "expectations"}, {"text": "par"}, {"text": "clients"}]}, "action": {"verb": {"text": "strive", "tense": "present"}, "text": "strive", "normalized": "strive"}}], "concepts": [{"text": "Marketing", "relevance": 0.955141, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "Immune system", "relevance": 0.600504, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Economics", "relevance": 0.58882, "dbpedia_resource": "http://dbpedia.org/resource/Economics"}, {"text": "Bankruptcy in the United States", "relevance": 0.586739, "dbpedia_resource": "http://dbpedia.org/resource/Bankruptcy_in_the_United_States"}, {"text": "Competition", "relevance": 0.532574, "dbpedia_resource": "http://dbpedia.org/resource/Competition"}, {"text": "Vaccination", "relevance": 0.496216, "dbpedia_resource": "http://dbpedia.org/resource/Vaccination"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.481806, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "United States bankruptcy law", "relevance": 0.48016, "dbpedia_resource": "http://dbpedia.org/resource/United_States_bankruptcy_law"}, {"text": "Competitor analysis", "relevance": 0.446486, "dbpedia_resource": "http://dbpedia.org/resource/Competitor_analysis"}, {"text": "Abbas Kiarostami", "relevance": 0.437475, "dbpedia_resource": "http://dbpedia.org/resource/Abbas_Kiarostami"}, {"text": "The Key", "relevance": 0.424105, "dbpedia_resource": "http://dbpedia.org/resource/The_Key_(novel)"}, {"text": "Influenza vaccine", "relevance": 0.398123, "dbpedia_resource": "http://dbpedia.org/resource/Influenza_vaccine"}, {"text": "Economics terminology", "relevance": 0.393429, "dbpedia_resource": "http://dbpedia.org/resource/Economics_terminology"}, {"text": "Emergent BioSolutions", "relevance": 0.38885, "dbpedia_resource": "http://dbpedia.org/resource/Emergent_BioSolutions"}], "categories": [{"score": 0.596859, "label": "/business and industrial/business operations/management/business process"}, {"score": 0.513816, "label": "/finance/financial news"}, {"score": 0.389914, "label": "/finance/investing"}], "relations": [{"type": "residesIn", "sentence": "Press release from: Healthcare Intelligence Markets Vaccination plays an important role in maintaining the sustainable health of people in countries.", "score": 0.715219, "arguments": [{"text": "people", "location": [129, 135], "entities": [{"type": "Person", "text": "people"}]}, {"text": "countries", "location": [139, 148], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Table of Contents Global Human Vaccines Market Research Report Chapter 1 Global Human Vaccines Market Overview Chapter 2 Global Economic Impact on Industry Chapter 3 Global Market Competition by Manufacturers Chapter 4 Global Production, Revenue (Value) by Region Chapter 5 Global Supply (Production), Consumption, Export Chapter 6 Production, Revenue (Value), Price Trend by Type Chapter 7 Market Analysis by Application Chapter 8 Manufacturing Cost Analysis Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers Chapter 10 Marketing Strategy Analysis, Distributors/Traders Chapter 11 Market Effect Factors Analysis Chapter 12 Market Forecast About us: HealthCare Intelligence Markets Reports provides market intelligence & consulting services to a global clientele spread over 145 countries.", "score": 0.516911, "arguments": [{"text": "Marketing Strategy Analysis", "location": [4268, 4295], "entities": [{"type": "Organization", "text": "Marketing Strategy Analysis", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Sourcing Strategy and Downstream Buyers Chapter", "location": [4217, 4264], "entities": [{"type": "Organization", "text": "Sourcing Strategy and Downstream Buyers Chapter"}]}]}, {"type": "employedBy", "sentence": "Our intelligence enables our clients to take decisions with which in turn proves a game-changer for them.", "score": 0.699581, "arguments": [{"text": "clients", "location": [4950, 4957], "entities": [{"type": "Person", "text": "clients"}]}, {"text": "our", "location": [4946, 4949], "entities": [{"type": "Organization", "text": "B2B"}]}]}, {"type": "employedBy", "sentence": "We constantly strive to serve our clients better by directly allowing them sessions with our research analysts so the report is at par with their expectations.", "score": 0.720447, "arguments": [{"text": "clients", "location": [5061, 5068], "entities": [{"type": "Person", "text": "clients"}]}, {"text": "our", "location": [5057, 5060], "entities": [{"type": "Organization", "text": "B2B"}]}]}, {"type": "participantIn", "sentence": "We constantly strive to serve our clients better by directly allowing them sessions with our research analysts so the report is at par with their expectations.", "score": 0.914205, "arguments": [{"text": "them", "location": [5097, 5101], "entities": [{"type": "Person", "text": "their"}]}, {"text": "sessions", "location": [5102, 5110], "entities": [{"type": "EventMeeting", "text": "sessions"}]}]}, {"type": "participantIn", "sentence": "We constantly strive to serve our clients better by directly allowing them sessions with our research analysts so the report is at par with their expectations.", "score": 0.900195, "arguments": [{"text": "analysts", "location": [5129, 5137], "entities": [{"type": "Person", "text": "analysts"}]}, {"text": "sessions", "location": [5102, 5110], "entities": [{"type": "EventMeeting", "text": "sessions"}]}]}, {"type": "hasAttribute", "sentence": "Therefore they are engaged in various local disease prevention strategies.", "score": 0.910296, "arguments": [{"text": "they", "location": [160, 164], "entities": [{"type": "Person", "text": "people"}]}, {"text": "disease", "location": [194, 201], "entities": [{"type": "HealthCondition", "text": "infections"}]}]}, {"type": "hasAttribute", "sentence": "Vaccinations are administered to people of essentially different ages, strengthening the immune system throughout the lifetime and providing protection against a wide variety of infectious diseases.", "score": 0.62848, "arguments": [{"text": "people", "location": [387, 393], "entities": [{"type": "Person", "text": "people"}]}, {"text": "diseases", "location": [543, 551], "entities": [{"type": "HealthCondition", "text": "infections"}]}]}, {"type": "employedBy", "sentence": "... Top manufactures are covered in this report: AstraZeneca, Bavarian Nordic, Bharat Biotech, CSL Limited, Emergent BioSolutions, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Mymetics, Novartis AG, Pfizer, Inc., Sanofi, Shenzhen Kangtai Biological Products Co., Ltd., Takeda Pharmaceutical Company Limited etc. The research on the global Human Vaccines market will be useful to investors, regularity authorities, and policy makers, state the analysts.", "score": 0.743808, "arguments": [{"text": "analysts", "location": [1465, 1473], "entities": [{"type": "Person", "text": "analysts"}]}, {"text": "state", "location": [1455, 1460], "entities": [{"type": "GeopoliticalEntity", "text": "Independent research institutions"}]}]}, {"type": "agentOf", "sentence": "Independent research institutions, commercial entities, and non-profit organization in this sector can also benefit from the report.", "score": 0.774013, "arguments": [{"text": "organization", "location": [1546, 1558], "entities": [{"type": "Organization", "text": "Global Human Vaccines Market Research Report Chapter 1 Global Human Vaccines Market Overview Chapter 2 Global Economic Impact on Industry Chapter 3 Global Market Competition"}]}, {"text": "report", "location": [1600, 1606], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "locatedAt", "sentence": "In addition to this, the rising penetration of internet and the surge in mobile surfing are anticipated to boost the demand for Human Vaccines across the world, states the research report.", "score": 0.55145, "arguments": [{"text": "Human Vaccines", "location": [2903, 2917], "entities": [{"type": "Organization", "text": "Global Human Vaccines Market Research Report Chapter 1 Global Human Vaccines Market Overview Chapter 2 Global Economic Impact on Industry Chapter 3 Global Market Competition"}]}, {"text": "world", "location": [2929, 2934], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "employedBy", "sentence": "The methodology of the global Human Vaccines market is that the information gathering will confirm a crisp and inventive method of market analysis to help its customers and arise the development of their business.", "score": 0.483682, "arguments": [{"text": "customers", "location": [3342, 3351], "entities": [{"type": "Person", "text": "customers"}]}, {"text": "its", "location": [3338, 3341], "entities": [{"type": "Organization", "text": "Global Human Vaccines Market Research Report Chapter 1 Global Human Vaccines Market Overview Chapter 2 Global Economic Impact on Industry Chapter 3 Global Market Competition"}]}]}, {"type": "partOf", "sentence": "Table of Contents Global Human Vaccines Market Research Report Chapter 1 Global Human Vaccines Market Overview Chapter 2 Global Economic Impact on Industry Chapter 3 Global Market Competition by Manufacturers Chapter 4 Global Production, Revenue (Value) by Region Chapter 5 Global Supply (Production), Consumption, Export Chapter 6 Production, Revenue (Value), Price Trend by Type Chapter 7 Market Analysis by Application Chapter 8 Manufacturing Cost Analysis Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers Chapter 10 Marketing Strategy Analysis, Distributors/Traders Chapter 11 Market Effect Factors Analysis Chapter 12 Market Forecast About us: HealthCare Intelligence Markets Reports provides market intelligence & consulting services to a global clientele spread over 145 countries.", "score": 0.647763, "arguments": [{"text": "Manufacturers Chapter 4 Global Production", "location": [3924, 3965], "entities": [{"type": "Organization", "text": "Manufacturers Chapter 4 Global Production"}]}, {"text": "Global Human Vaccines Market Research Report Chapter 1 Global Human Vaccines Market Overview Chapter 2 Global Economic Impact on Industry Chapter 3 Global Market Competition", "location": [3747, 3920], "entities": [{"type": "Organization", "text": "Global Human Vaccines Market Research Report Chapter 1 Global Human Vaccines Market Overview Chapter 2 Global Economic Impact on Industry Chapter 3 Global Market Competition"}]}]}, {"type": "employedBy", "sentence": "Table of Contents Global Human Vaccines Market Research Report Chapter 1 Global Human Vaccines Market Overview Chapter 2 Global Economic Impact on Industry Chapter 3 Global Market Competition by Manufacturers Chapter 4 Global Production, Revenue (Value) by Region Chapter 5 Global Supply (Production), Consumption, Export Chapter 6 Production, Revenue (Value), Price Trend by Type Chapter 7 Market Analysis by Application Chapter 8 Manufacturing Cost Analysis Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers Chapter 10 Marketing Strategy Analysis, Distributors/Traders Chapter 11 Market Effect Factors Analysis Chapter 12 Market Forecast About us: HealthCare Intelligence Markets Reports provides market intelligence & consulting services to a global clientele spread over 145 countries.", "score": 0.724653, "arguments": [{"text": "Price Trend", "location": [4090, 4101], "entities": [{"type": "Person", "text": "Price Trend"}]}, {"text": "Type Chapter 7 Market Analysis", "location": [4105, 4135], "entities": [{"type": "Organization", "text": "Type Chapter 7 Market Analysis"}]}]}], "keywords": [{"text": "human vaccines market", "sentiment": {"score": 0.843696, "label": "positive"}, "relevance": 0.916457}, {"text": "global human vaccines", "sentiment": {"score": 0.843696, "label": "positive"}, "relevance": 0.915653}, {"text": "market research report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.603319}, {"text": "global market", "sentiment": {"score": 0.150072, "label": "positive"}, "relevance": 0.573593}, {"text": "healthcare intelligence markets", "sentiment": {"score": 0.531515, "label": "positive"}, "relevance": 0.569043}, {"text": "Vaccines Market Research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.568468}, {"text": "Vaccines Market Overview", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.554441}, {"text": "Global Market Competition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536261}, {"text": "key market participants", "sentiment": {"score": 0.879167, "label": "positive"}, "relevance": 0.517587}, {"text": "market analysis", "sentiment": {"score": 0.843696, "label": "positive"}, "relevance": 0.515127}, {"text": "help market players", "sentiment": {"score": 0.555621, "label": "positive"}, "relevance": 0.513918}, {"text": "Market Effect Factors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513724}, {"text": "future market prospects", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512447}, {"text": "Contents Global Human", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.511261}, {"text": "Independent research institutions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.500468}, {"text": "Intelligence Markets Vaccination", "sentiment": {"score": 0.531515, "label": "positive"}, "relevance": 0.499612}, {"text": "Global Economic Impact", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.498889}, {"text": "disease prevention strategies", "sentiment": {"score": -0.474477, "label": "negative"}, "relevance": 0.497433}, {"text": "pin point analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.492825}, {"text": "Downstream Buyers Chapter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.492001}, {"text": "essentially different ages", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.48971}, {"text": "future growth prospects", "sentiment": {"score": 0.833965, "label": "positive"}, "relevance": 0.489215}, {"text": "Manufacturing Cost Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.488356}, {"text": "Marketing Strategy Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.48817}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.4873}, {"text": "key product segments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.487205}, {"text": "Biological Products Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.487023}, {"text": "Highlighted key points", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.486499}, {"text": "market growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.485937}, {"text": "market segments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.484965}, {"text": "Intelligence Markets Reports", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.484425}, {"text": "market intelligence", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.482257}, {"text": "Market Forecast", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.481743}, {"text": "game changing strategies", "sentiment": {"score": 0.555621, "label": "positive"}, "relevance": 0.478482}, {"text": "Report Chapter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.477505}, {"text": "Analysis Chapter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.469878}, {"text": "report further projects", "sentiment": {"score": -0.528996, "label": "negative"}, "relevance": 0.467808}, {"text": "Global Production", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.466434}, {"text": "Global Supply", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.462681}, {"text": "global clientele", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.461237}, {"text": "Industry Chapter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.459749}, {"text": "Manufacturers Chapter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.45969}, {"text": "Region Chapter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.459599}, {"text": "research services", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.459514}, {"text": "Export Chapter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.459507}, {"text": "Type Chapter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.459399}, {"text": "Application Chapter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.459349}, {"text": "Distributors/Traders Chapter", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.459166}, {"text": "research analysts", "sentiment": {"score": 0.88704, "label": "positive"}, "relevance": 0.457007}, {"text": "pin-point analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.457}]}, "extracted_metadata": {"sha1": "fcac0b4bb02bd0fa5aa8b81a244b93aa18b05aa1", "filename": "1542131325044.zip-99fbaa1bfabbe622fde9f976a5d12237.xml", "file_type": "json"}, "external_links": ["https://www.healthcareintelligencemarkets.com/request_sample.php?id=3656", "https://www.healthcareintelligencemarkets.com/ask_for_discount.php?id=3656"], "title": "Complete Analysis of Global Human Vaccines Market by Forecast 2022: Top Manufactures Covered Like GSK, Sanofi, Merck, Pfizer, Novartis (GSK), CSL, MedImmune, J&J Crucell), China National Biotec", "forum_title": "openPR.com - Newsfeed"}, {"id": "EVIDCaBAfJKzuTOvpeKYVxzH4FzDnTkR8ACFNpaSFefy7C_WzyVFK1R4lxO0W782", "result_metadata": {"score": 32.651722}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.328886, "label": "positive"}, "text": "Barclays", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.725716, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.952352}, {"text": "Barclays", "sentiment": {"score": 0.328886, "label": "positive"}, "relevance": 0.829402}, {"text": "AMENDMENT", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.691455}, {"text": "MarketScreener", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.387318}]}, "crawl_date": "2018-11-14T14:36:48Z", "url": "https://www.marketscreener.com/BARCLAYS-9583556/news/Barclays-Form-8-3-TAKEDA-PHARMACEUTICAL-CO-LTD-AMENDMENT-27605560/", "host": "marketscreener.com", "text": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC. are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-14T00:00:00Z", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.765956, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.668844, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.621501, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.538735, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Class of Product Nature", "relevance": 0.521117, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.516667, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.470205, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.428807, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.41254, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,255,100 1.29%", "relevance": 0.41254, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.41254, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.41254, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,287,764 1.44%", "relevance": 0.41254, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,845,486 1.49%", "relevance": 0.41254, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,497,625 1.57%", "relevance": 0.41254, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,654,850 4.25%", "relevance": 0.41254, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,694,325 4.24%", "relevance": 0.41254, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.41254, "type": "Quantity"}], "sentiment": {"document": {"score": 0.620223, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "33,654,850 4.25% 33,694,325 4.24% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "33,654,850 4.25"}, {"type": "Quantity", "text": "33,694,325 4.24"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,287,764 1.44% 12,497,625 1.57% (2) Cash-settled derivatives: 11,845,486 1.49% 10,255,100 1.29% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 33,654,850 4.25% 33,694,325 4.24% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors' and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors' and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 14 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "disclosure requirements"}, {"text": "relation"}, {"text": "consultation"}, {"text": "Code"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "disclosure requirements"}, {"text": "relation"}, {"text": "consultation"}, {"text": "Code"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "Barclays plc", "keywords": [{"text": "Barclays plc"}], "entities": [{"type": "Company", "text": "BARCLAYS PLC", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}]}, "sentence": " Barclays plc published this content on 14 November 2018 and is solely responsible for the information contained herein.", "object": {"text": "this content", "keywords": [{"text": "content"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "by Public", "keywords": [{"text": "Public"}]}, "sentence": " Distributed by Public, unedited and unaltered, on 14 November 2018 14:08:15 UTC", "object": {"text": "15 UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "Distributed", "tense": "past"}, "text": "Distributed", "normalized": "Distributed"}}], "concepts": [{"text": "Option", "relevance": 0.970889, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.735422, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.685542, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.607718, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.499687, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.407264, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Options", "relevance": 0.393603, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Moneyness", "relevance": 0.376189, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "1973", "relevance": 0.366915, "dbpedia_resource": "http://dbpedia.org/resource/1973"}, {"text": "1969", "relevance": 0.357176, "dbpedia_resource": "http://dbpedia.org/resource/1969"}, {"text": "1984", "relevance": 0.355177, "dbpedia_resource": "http://dbpedia.org/resource/1984"}, {"text": "Security", "relevance": 0.34269, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "United States dollar", "relevance": 0.330986, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}, {"text": "1967", "relevance": 0.324119, "dbpedia_resource": "http://dbpedia.org/resource/1967"}, {"text": "Contract", "relevance": 0.321518, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Bond", "relevance": 0.319522, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "1982", "relevance": 0.315256, "dbpedia_resource": "http://dbpedia.org/resource/1982"}, {"text": "December", "relevance": 0.315209, "dbpedia_resource": "http://dbpedia.org/resource/December"}, {"text": "1971", "relevance": 0.314335, "dbpedia_resource": "http://dbpedia.org/resource/1971"}, {"text": "1940", "relevance": 0.314159, "dbpedia_resource": "http://dbpedia.org/resource/1940"}], "categories": [{"score": 0.573647, "label": "/real estate/buying and selling homes"}, {"score": 0.481775, "label": "/finance/financial news"}, {"score": 0.444279, "label": "/finance/investing"}], "relations": [{"type": "hasAttribute", "sentence": "sale Number of Price per unit security securities ADR Purchase 3,892 19.7795 USD ADR Purchase 6,370 19.8575 USD ADR Purchase 13,817 19.7356 USD ADR Purchase 251,700 19.7899 USD ADR Purchase 382,720 19.7857 USD ADR Sale 6,370 19.8575 USD ADR Sale 10,000 19.8017 USD ADR Sale 13,817 19.7356 USD ADR Sale 144,912 19.7795 USD ADR Sale 241,700 19.7894 USD ADR Sale 243,646 19.7893 USD Ordinary NPV Purchase 100 4,515.5000 JPY Ordinary NPV Purchase 400 4,550.5500 JPY Ordinary NPV Purchase 500 4,514.8000 JPY Ordinary NPV Purchase 600 4,518.5000 JPY Ordinary NPV Purchase 700 4,542.6714 JPY Ordinary NPV Purchase 800 4,564.2500 JPY Ordinary NPV Purchase 1,300 4,515.7692 JPY Ordinary NPV Purchase 1,800 4,569.1666 JPY Ordinary NPV Purchase 1,900 4,545.8421 JPY Ordinary NPV Purchase 2,300 4,509.5652 JPY Ordinary NPV Purchase 2,400 4,535.7916 JPY Ordinary NPV Purchase 2,900 4,501.6552 JPY Ordinary NPV Purchase 3,700 4,548.1027 JPY Ordinary NPV Purchase 4,000 4,571.9000 JPY Ordinary NPV Purchase 4,100", "score": 0.658918, "arguments": [{"text": "USD ADR Sale", "location": [2783, 2795], "entities": [{"type": "Organization", "text": "USD ADR Sale"}]}, {"text": "10,000 19.8017 USD", "location": [2796, 2814], "entities": [{"type": "Money", "text": "10,000 19.8017 USD", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "timeOf", "sentence": "View source version on businesswire.com: https://www.businesswire.com/news/home/20181114005532/en/ BARCLAYS PLC Source: BARCLAYS PLC Attachments Original document Permalink Disclaimer Barclays plc published this content on 14 November 2018 and is solely responsible for the information contained herein.", "score": 0.742985, "arguments": [{"text": "November 2018", "location": [10350, 10363], "entities": [{"type": "Date", "text": "November 2018"}]}, {"text": "published", "location": [10321, 10330], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "hasAttribute", "sentence": "sale Number of Price per unit security securities ADR Purchase 3,892 19.7795 USD ADR Purchase 6,370 19.8575 USD ADR Purchase 13,817 19.7356 USD ADR Purchase 251,700 19.7899 USD ADR Purchase 382,720 19.7857 USD ADR Sale 6,370 19.8575 USD ADR Sale 10,000 19.8017 USD ADR Sale 13,817 19.7356 USD ADR Sale 144,912 19.7795 USD ADR Sale 241,700 19.7894 USD ADR Sale 243,646 19.7893 USD Ordinary NPV Purchase 100 4,515.5000 JPY Ordinary NPV Purchase 400 4,550.5500 JPY Ordinary NPV Purchase 500 4,514.8000 JPY Ordinary NPV Purchase 600 4,518.5000 JPY Ordinary NPV Purchase 700 4,542.6714 JPY Ordinary NPV Purchase 800 4,564.2500 JPY Ordinary NPV Purchase 1,300 4,515.7692 JPY Ordinary NPV Purchase 1,800 4,569.1666 JPY Ordinary NPV Purchase 1,900 4,545.8421 JPY Ordinary NPV Purchase 2,300 4,509.5652 JPY Ordinary NPV Purchase 2,400 4,535.7916 JPY Ordinary NPV Purchase 2,900 4,501.6552 JPY Ordinary NPV Purchase 3,700 4,548.1027 JPY Ordinary NPV Purchase 4,000 4,571.9000 JPY Ordinary NPV Purchase 4,100", "score": 0.693357, "arguments": [{"text": "ADR Sale", "location": [2815, 2823], "entities": [{"type": "Organization", "text": "ADR Sale"}]}, {"text": "10,000 19.8017 USD", "location": [2796, 2814], "entities": [{"type": "Money", "text": "10,000 19.8017 USD", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "employedBy", "sentence": "JPY Ordinary NPV Sale 7,000 4,515.9571 JPY Ordinary NPV Sale 11,300 4,557.5575 JPY Ordinary NPV Sale 27,300 4,548.9890 JPY Ordinary NPV Sale 41,300 4,559.0000 JPY Ordinary NPV Sale 41,400 4,540.0458 JPY Ordinary NPV Sale 44,800 4,519.2366 JPY Ordinary NPV Sale 46,300 4,541.5550 JPY Ordinary NPV Sale 60,000 4,533.8600 JPY Ordinary NPV Sale 154,300 4,525.8476 JPY Ordinary NPV Sale 344,000 4,531.1872 JPY Ordinary NPV Sale 370,000 4,531.8018 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV CFD Long 38,600 4,559.0000 JPY Ordinary NPV SWAP Long 38,600 4,559.0000 JPY Ordinary NPV SWAP Short 900 4,546.3111 JPY Ordinary NPV CFD Short 15,500 4,500.4500 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling,", "score": 0.500498, "arguments": [{"text": "Cash", "location": [5036, 5040], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Product Nature", "location": [5082, 5096], "entities": [{"type": "Organization", "text": "Product Nature", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [6398, 6404], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [6415, 6422], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 14 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [7324, 7330], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [7338, 7342], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the 'Code') 1.", "score": 0.846433, "arguments": [{"text": "Rule 8", "location": [7770, 7776], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [7784, 7797], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [7405, 7429], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [7397, 7402], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [9916, 9940], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [9908, 9913], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [7564, 7569], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [7583, 7610], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [10075, 10080], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [10094, 10121], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC.", "score": 0.419441, "arguments": [{"text": "person", "location": [7846, 7852], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [7878, 7890], "entities": [{"type": "Organization", "text": "BARCLAYS PLC\nAttachments\nOriginal", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "View source version on businesswire.com: https://www.businesswire.com/news/home/20181114005532/en/ BARCLAYS PLC Source: BARCLAYS PLC Attachments Original document Permalink Disclaimer Barclays plc published this content on 14 November 2018 and is solely responsible for the information contained herein.", "score": 0.979718, "arguments": [{"text": "Permalink Disclaimer\nBarclays plc", "location": [10287, 10320], "entities": [{"type": "Organization", "text": "BARCLAYS PLC\nAttachments\nOriginal", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "published", "location": [10321, 10330], "entities": [{"type": "EventCommunication", "text": "published"}]}]}], "keywords": [{"text": "JPY Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.991341}, {"text": "Ordinary NPV Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.760399}, {"text": "Ordinary NPV Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.717771}, {"text": "Ordinary NPV Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.427393}, {"text": "USD Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.426827}, {"text": "Ordinary NPV CFD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.424527}, {"text": "Ordinary NPV SWAP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.424148}, {"text": "securities Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.420276}, {"text": "relevant securities", "sentiment": {"score": 0.229926, "label": "positive"}, "relevance": 0.40947}, {"text": "NPV Call Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.379215}, {"text": "NPV Put Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.363947}, {"text": "NPV CFD Short", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351595}, {"text": "NPV SWAP Long", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351328}, {"text": "NPV SWAP Short", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351279}, {"text": "USD ADR Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.342566}, {"text": "Options Written", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.336927}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.319188}, {"text": "USD ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.30353}, {"text": "supplemental form", "sentiment": {"score": 0.425721, "label": "positive"}, "relevance": 0.277728}, {"text": "open positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.271469}, {"text": "Product description e.g.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.264224}, {"text": "relevant security Product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.263229}, {"text": "security Product description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.262662}, {"text": "Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.260513}, {"text": "short positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.259641}, {"text": "Options Purchased", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.259624}, {"text": "unit security securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.259099}, {"text": "class", "sentiment": {"score": -0.251285, "label": "negative"}, "relevance": 0.258223}, {"text": "disclosure", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.255839}, {"text": "securities ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.249726}, {"text": "person", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.24082}, {"text": "details", "sentiment": {"score": 0.0877268, "label": "positive"}, "relevance": 0.240576}, {"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.240312}, {"text": "Barclays PLC.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.239912}, {"text": "new securities", "sentiment": {"score": 0.582177, "label": "positive"}, "relevance": 0.239882}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.239015}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.2389}, {"text": "number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.238745}, {"text": "relevant Purchase/sale Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.238383}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.23802}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.237411}, {"text": "monetary amounts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.237034}, {"text": "agreements", "sentiment": {"score": 0.0334629, "label": "positive"}, "relevance": 0.236921}, {"text": "relevant description reference", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.236742}, {"text": "Short Positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.236301}, {"text": "relevant security Nature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.236073}, {"text": "disclosure requirements", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235973}, {"text": "stock-settled derivative positions", "sentiment": {"score": -0.27481, "label": "negative"}, "relevance": 0.235736}, {"text": "PUBLIC OPENING POSITION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235617}, {"text": "securities Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235596}]}, "extracted_metadata": {"sha1": "a773edfc1ce6b277acd98cb52e81f9d33703701f", "filename": "1542206208958.zip-946d872307adcbfa72618e373242574a.xml", "file_type": "json"}, "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.thetakeoverpanel.org.uk&esheet=51899639&newsitemid=20181114005532&lan=en-US&anchor=www.thetakeoverpanel.org.uk&index=2&md5=7c6eca308ebc23310302f5d2b533582f", "https://www.businesswire.com/news/home/20181114005532/en/", "http://www.publicnow.com/view/E323994657E6BB187BB4EAEC03D6BC142A6AB80B", "http://otp.investis.com/clients/uk/barclays1/rns/regulatory-story.aspx?cid=68&newsid=1207452", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.thetakeoverpanel.org.uk&esheet=51899639&newsitemid=20181114005532&lan=en-US&anchor=www.thetakeoverpanel.org.uk&index=1&md5=e3afdbb90a0c36ae77bd5dfd5bc08756"], "title": "Barclays : Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD AMENDMENT | MarketScreener", "forum_title": "Stock market news - Company News  - MarketScreener.com"}, {"id": "UNMLJV-LlIdhUVFoLdzj29T1w9FNSnMySqlG6cRGxGMT-g5oJwuQg1wX14MCMoEB", "result_metadata": {"score": 32.553593}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0.328886, "label": "positive"}, "text": "Barclays", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.725716, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.910547}, {"text": "Barclays", "sentiment": {"score": 0.328886, "label": "positive"}, "relevance": 0.775237}, {"text": "AMENDMENT", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.644713}]}, "crawl_date": "2018-11-14T14:58:57Z", "url": "http://www.4-traders.com/BARCLAYS-9583556/news/Barclays-Form-8-3-TAKEDA-PHARMACEUTICAL-CO-LTD-AMENDMENT-27605560/", "host": "4-traders.com", "text": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC. are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-14T00:00:00+01:00", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.765956, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.668844, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.621501, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.538735, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Class of Product Nature", "relevance": 0.521117, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.516667, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.470205, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.428807, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.41254, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,255,100 1.29%", "relevance": 0.41254, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.41254, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.41254, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,287,764 1.44%", "relevance": 0.41254, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,845,486 1.49%", "relevance": 0.41254, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,497,625 1.57%", "relevance": 0.41254, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,654,850 4.25%", "relevance": 0.41254, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,694,325 4.24%", "relevance": 0.41254, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.41254, "type": "Quantity"}], "sentiment": {"document": {"score": 0.620223, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "33,654,850 4.25% 33,694,325 4.24% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "33,654,850 4.25"}, {"type": "Quantity", "text": "33,694,325 4.24"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,287,764 1.44% 12,497,625 1.57% (2) Cash-settled derivatives: 11,845,486 1.49% 10,255,100 1.29% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 33,654,850 4.25% 33,694,325 4.24% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors' and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors' and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 14 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "disclosure requirements"}, {"text": "relation"}, {"text": "consultation"}, {"text": "Code"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "disclosure requirements"}, {"text": "relation"}, {"text": "consultation"}, {"text": "Code"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "Barclays plc", "keywords": [{"text": "Barclays plc"}], "entities": [{"type": "Company", "text": "BARCLAYS PLC", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}]}, "sentence": " Barclays plc published this content on 14 November 2018 and is solely responsible for the information contained herein.", "object": {"text": "this content", "keywords": [{"text": "content"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "by Public", "keywords": [{"text": "Public"}]}, "sentence": " Distributed by Public, unedited and unaltered, on 14 November 2018 14:08:15 UTC", "object": {"text": "15 UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "Distributed", "tense": "past"}, "text": "Distributed", "normalized": "Distributed"}}], "concepts": [{"text": "Option", "relevance": 0.970889, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.735422, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.685542, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.607718, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.499687, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.407264, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Options", "relevance": 0.393603, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Moneyness", "relevance": 0.376189, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "1973", "relevance": 0.366915, "dbpedia_resource": "http://dbpedia.org/resource/1973"}, {"text": "1969", "relevance": 0.357176, "dbpedia_resource": "http://dbpedia.org/resource/1969"}, {"text": "1984", "relevance": 0.355177, "dbpedia_resource": "http://dbpedia.org/resource/1984"}, {"text": "Security", "relevance": 0.34269, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "United States dollar", "relevance": 0.330986, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}, {"text": "1967", "relevance": 0.324119, "dbpedia_resource": "http://dbpedia.org/resource/1967"}, {"text": "Contract", "relevance": 0.321518, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Bond", "relevance": 0.319522, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "1982", "relevance": 0.315256, "dbpedia_resource": "http://dbpedia.org/resource/1982"}, {"text": "December", "relevance": 0.315209, "dbpedia_resource": "http://dbpedia.org/resource/December"}, {"text": "1971", "relevance": 0.314335, "dbpedia_resource": "http://dbpedia.org/resource/1971"}, {"text": "1940", "relevance": 0.314159, "dbpedia_resource": "http://dbpedia.org/resource/1940"}], "categories": [{"score": 0.573647, "label": "/real estate/buying and selling homes"}, {"score": 0.481775, "label": "/finance/financial news"}, {"score": 0.444279, "label": "/finance/investing"}], "relations": [{"type": "hasAttribute", "sentence": "sale Number of Price per unit security securities ADR Purchase 3,892 19.7795 USD ADR Purchase 6,370 19.8575 USD ADR Purchase 13,817 19.7356 USD ADR Purchase 251,700 19.7899 USD ADR Purchase 382,720 19.7857 USD ADR Sale 6,370 19.8575 USD ADR Sale 10,000 19.8017 USD ADR Sale 13,817 19.7356 USD ADR Sale 144,912 19.7795 USD ADR Sale 241,700 19.7894 USD ADR Sale 243,646 19.7893 USD Ordinary NPV Purchase 100 4,515.5000 JPY Ordinary NPV Purchase 400 4,550.5500 JPY Ordinary NPV Purchase 500 4,514.8000 JPY Ordinary NPV Purchase 600 4,518.5000 JPY Ordinary NPV Purchase 700 4,542.6714 JPY Ordinary NPV Purchase 800 4,564.2500 JPY Ordinary NPV Purchase 1,300 4,515.7692 JPY Ordinary NPV Purchase 1,800 4,569.1666 JPY Ordinary NPV Purchase 1,900 4,545.8421 JPY Ordinary NPV Purchase 2,300 4,509.5652 JPY Ordinary NPV Purchase 2,400 4,535.7916 JPY Ordinary NPV Purchase 2,900 4,501.6552 JPY Ordinary NPV Purchase 3,700 4,548.1027 JPY Ordinary NPV Purchase 4,000 4,571.9000 JPY Ordinary NPV Purchase 4,100", "score": 0.658918, "arguments": [{"text": "USD ADR Sale", "location": [2783, 2795], "entities": [{"type": "Organization", "text": "USD ADR Sale"}]}, {"text": "10,000 19.8017 USD", "location": [2796, 2814], "entities": [{"type": "Money", "text": "10,000 19.8017 USD", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "timeOf", "sentence": "View source version on businesswire.com: https://www.businesswire.com/news/home/20181114005532/en/ BARCLAYS PLC Source: BARCLAYS PLC Attachments Original document Permalink Disclaimer Barclays plc published this content on 14 November 2018 and is solely responsible for the information contained herein.", "score": 0.742985, "arguments": [{"text": "November 2018", "location": [10350, 10363], "entities": [{"type": "Date", "text": "November 2018"}]}, {"text": "published", "location": [10321, 10330], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "hasAttribute", "sentence": "sale Number of Price per unit security securities ADR Purchase 3,892 19.7795 USD ADR Purchase 6,370 19.8575 USD ADR Purchase 13,817 19.7356 USD ADR Purchase 251,700 19.7899 USD ADR Purchase 382,720 19.7857 USD ADR Sale 6,370 19.8575 USD ADR Sale 10,000 19.8017 USD ADR Sale 13,817 19.7356 USD ADR Sale 144,912 19.7795 USD ADR Sale 241,700 19.7894 USD ADR Sale 243,646 19.7893 USD Ordinary NPV Purchase 100 4,515.5000 JPY Ordinary NPV Purchase 400 4,550.5500 JPY Ordinary NPV Purchase 500 4,514.8000 JPY Ordinary NPV Purchase 600 4,518.5000 JPY Ordinary NPV Purchase 700 4,542.6714 JPY Ordinary NPV Purchase 800 4,564.2500 JPY Ordinary NPV Purchase 1,300 4,515.7692 JPY Ordinary NPV Purchase 1,800 4,569.1666 JPY Ordinary NPV Purchase 1,900 4,545.8421 JPY Ordinary NPV Purchase 2,300 4,509.5652 JPY Ordinary NPV Purchase 2,400 4,535.7916 JPY Ordinary NPV Purchase 2,900 4,501.6552 JPY Ordinary NPV Purchase 3,700 4,548.1027 JPY Ordinary NPV Purchase 4,000 4,571.9000 JPY Ordinary NPV Purchase 4,100", "score": 0.693357, "arguments": [{"text": "ADR Sale", "location": [2815, 2823], "entities": [{"type": "Organization", "text": "ADR Sale"}]}, {"text": "10,000 19.8017 USD", "location": [2796, 2814], "entities": [{"type": "Money", "text": "10,000 19.8017 USD", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "employedBy", "sentence": "JPY Ordinary NPV Sale 7,000 4,515.9571 JPY Ordinary NPV Sale 11,300 4,557.5575 JPY Ordinary NPV Sale 27,300 4,548.9890 JPY Ordinary NPV Sale 41,300 4,559.0000 JPY Ordinary NPV Sale 41,400 4,540.0458 JPY Ordinary NPV Sale 44,800 4,519.2366 JPY Ordinary NPV Sale 46,300 4,541.5550 JPY Ordinary NPV Sale 60,000 4,533.8600 JPY Ordinary NPV Sale 154,300 4,525.8476 JPY Ordinary NPV Sale 344,000 4,531.1872 JPY Ordinary NPV Sale 370,000 4,531.8018 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV CFD Long 38,600 4,559.0000 JPY Ordinary NPV SWAP Long 38,600 4,559.0000 JPY Ordinary NPV SWAP Short 900 4,546.3111 JPY Ordinary NPV CFD Short 15,500 4,500.4500 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling,", "score": 0.500498, "arguments": [{"text": "Cash", "location": [5036, 5040], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Product Nature", "location": [5082, 5096], "entities": [{"type": "Organization", "text": "Product Nature", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [6398, 6404], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [6415, 6422], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 14 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [7324, 7330], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [7338, 7342], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the 'Code') 1.", "score": 0.846433, "arguments": [{"text": "Rule 8", "location": [7770, 7776], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [7784, 7797], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [7405, 7429], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [7397, 7402], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [9916, 9940], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [9908, 9913], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [7564, 7569], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [7583, 7610], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [10075, 10080], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [10094, 10121], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC.", "score": 0.419441, "arguments": [{"text": "person", "location": [7846, 7852], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [7878, 7890], "entities": [{"type": "Organization", "text": "BARCLAYS PLC\nAttachments\nOriginal", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "View source version on businesswire.com: https://www.businesswire.com/news/home/20181114005532/en/ BARCLAYS PLC Source: BARCLAYS PLC Attachments Original document Permalink Disclaimer Barclays plc published this content on 14 November 2018 and is solely responsible for the information contained herein.", "score": 0.979718, "arguments": [{"text": "Permalink Disclaimer\nBarclays plc", "location": [10287, 10320], "entities": [{"type": "Organization", "text": "BARCLAYS PLC\nAttachments\nOriginal", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "published", "location": [10321, 10330], "entities": [{"type": "EventCommunication", "text": "published"}]}]}], "keywords": [{"text": "JPY Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.991341}, {"text": "Ordinary NPV Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.760399}, {"text": "Ordinary NPV Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.717771}, {"text": "Ordinary NPV Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.427393}, {"text": "USD Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.426827}, {"text": "Ordinary NPV CFD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.424527}, {"text": "Ordinary NPV SWAP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.424148}, {"text": "securities Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.420276}, {"text": "relevant securities", "sentiment": {"score": 0.229926, "label": "positive"}, "relevance": 0.40947}, {"text": "NPV Call Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.379215}, {"text": "NPV Put Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.363947}, {"text": "NPV CFD Short", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351595}, {"text": "NPV SWAP Long", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351328}, {"text": "NPV SWAP Short", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.351279}, {"text": "USD ADR Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.342566}, {"text": "Options Written", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.336927}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.319188}, {"text": "USD ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.30353}, {"text": "supplemental form", "sentiment": {"score": 0.425721, "label": "positive"}, "relevance": 0.277728}, {"text": "open positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.271469}, {"text": "Product description e.g.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.264224}, {"text": "relevant security Product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.263229}, {"text": "security Product description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.262662}, {"text": "Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.260513}, {"text": "short positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.259641}, {"text": "Options Purchased", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.259624}, {"text": "unit security securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.259099}, {"text": "class", "sentiment": {"score": -0.251285, "label": "negative"}, "relevance": 0.258223}, {"text": "disclosure", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.255839}, {"text": "securities ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.249726}, {"text": "person", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.24082}, {"text": "details", "sentiment": {"score": 0.0877267, "label": "positive"}, "relevance": 0.240576}, {"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.240312}, {"text": "Barclays PLC.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.239912}, {"text": "new securities", "sentiment": {"score": 0.582177, "label": "positive"}, "relevance": 0.239882}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.239015}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.2389}, {"text": "number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.238745}, {"text": "relevant Purchase/sale Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.238383}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.23802}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.237411}, {"text": "monetary amounts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.237034}, {"text": "agreements", "sentiment": {"score": 0.0334629, "label": "positive"}, "relevance": 0.236921}, {"text": "relevant description reference", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.236742}, {"text": "Short Positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.236301}, {"text": "relevant security Nature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.236073}, {"text": "disclosure requirements", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235973}, {"text": "stock-settled derivative positions", "sentiment": {"score": -0.27481, "label": "negative"}, "relevance": 0.235736}, {"text": "PUBLIC OPENING POSITION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235617}, {"text": "securities Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235596}]}, "extracted_metadata": {"sha1": "8e2bcc20aa0afbceeefa5747c82d1a5a6bc81ef1", "filename": "1542207537031.zip-712622f5c575d56e37b99d598ceae11b.xml", "file_type": "json"}, "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.thetakeoverpanel.org.uk&esheet=51899639&newsitemid=20181114005532&lan=en-US&anchor=www.thetakeoverpanel.org.uk&index=2&md5=7c6eca308ebc23310302f5d2b533582f", "https://www.businesswire.com/news/home/20181114005532/en/", "http://www.publicnow.com/view/E323994657E6BB187BB4EAEC03D6BC142A6AB80B", "http://otp.investis.com/clients/uk/barclays1/rns/regulatory-story.aspx?cid=68&newsid=1207452", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.thetakeoverpanel.org.uk&esheet=51899639&newsitemid=20181114005532&lan=en-US&anchor=www.thetakeoverpanel.org.uk&index=1&md5=e3afdbb90a0c36ae77bd5dfd5bc08756"], "title": "Barclays : Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD AMENDMENT", "forum_title": "F100 Stock Quote | FTSE 100 Index Stock Price () | Autre: F100 | MarketScreener"}, {"id": "GgbK3UwWvQgG80aAMNH7KwGo3MZHI53yhbUqxae19CFuF1mYzhVgn8-KiCi0SVxg", "result_metadata": {"score": 32.28451}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Barclays", "relevance": 0.972986, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "United Kingdom", "relevance": 0.700474, "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.5607, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.6964, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.412502, "label": "/law, govt and politics/government"}], "relations": [], "keywords": [{"text": "BARCLAYS PLC UK", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.901143}, {"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.587635}, {"text": "Regulatory Announcement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.506342}, {"text": "AMENDMENT", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.304243}]}, "crawl_date": "2018-11-14T14:34:42Z", "url": "https://www.businesswire.com/news/home/20181114005532/en/BARCLAYS-PLC-UK-Regulatory-Announcement-Form-8.3", "host": "businesswire.com", "text": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC. are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "main_image_url": "http://www.businesswire.com/images/bwlogo_square.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-14T13:53:00-06:00", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.743617, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.710536, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.576572, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Class of Product Nature", "relevance": 0.571248, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS", "relevance": 0.551161, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.542871, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Contacts BARCLAYS PLC", "relevance": 0.526098, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.51274, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.469644, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.452904, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,255,100 1.29%", "relevance": 0.452904, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.452904, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.452904, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,287,764 1.44%", "relevance": 0.452904, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,845,486 1.49%", "relevance": 0.452904, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,497,625 1.57%", "relevance": 0.452904, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,654,850 4.25%", "relevance": 0.452904, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,694,325 4.24%", "relevance": 0.452904, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.452904, "type": "Quantity"}], "sentiment": {"document": {"score": 0.64979, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "33,654,850 4.25% 33,694,325 4.24% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "33,654,850 4.25"}, {"type": "Quantity", "text": "33,694,325 4.24"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,287,764 1.44% 12,497,625 1.57% (2) Cash-settled derivatives: 11,845,486 1.49% 10,255,100 1.29% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 33,654,850 4.25% 33,694,325 4.24% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 14 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Receipt", "keywords": [{"text": "Receipt"}]}, "sentence": " Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 659322 Time of Receipt (offset from UTC): 20181114T133833+0000 Contacts BARCLAYS PLC", "object": {"text": "from UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}], "concepts": [{"text": "Option", "relevance": 0.975089, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.737686, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.69229, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.615705, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.503494, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.409329, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Options", "relevance": 0.400601, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Moneyness", "relevance": 0.377708, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Security", "relevance": 0.345954, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "United States dollar", "relevance": 0.331445, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}, {"text": "Contract", "relevance": 0.326979, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Bond", "relevance": 0.322727, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "December", "relevance": 0.316259, "dbpedia_resource": "http://dbpedia.org/resource/December"}, {"text": "Unit type", "relevance": 0.300942, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Barclays", "relevance": 0.293975, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}], "categories": [{"score": 0.57896, "label": "/real estate/buying and selling homes"}, {"score": 0.472389, "label": "/finance/financial news"}, {"score": 0.448199, "label": "/finance/investing"}], "relations": [{"type": "basedIn", "sentence": "LONDON- FORM 8.3 Amendment to Purchase PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \"Code\") 1.", "score": 0.629662, "arguments": [{"text": "Amendment", "location": [17, 26], "entities": [{"type": "Organization", "text": "Amendment"}]}, {"text": "LONDON", "location": [0, 6], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "basedIn", "sentence": "Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 659322 Time of Receipt (offset from UTC): 20181114T133833+0000 Contacts BARCLAYS PLC", "score": 0.488667, "arguments": [{"text": "UTC", "location": [10203, 10206], "entities": [{"type": "Organization", "text": "UTC"}]}, {"text": "Receipt", "location": [10182, 10189], "entities": [{"type": "GeopoliticalEntity", "text": "Receipt"}]}]}, {"type": "hasAttribute", "sentence": "sale Number of Price per unit security securities ADR Purchase 3,892 19.7795 USD ADR Purchase 6,370 19.8575 USD ADR Purchase 13,817 19.7356 USD ADR Purchase 251,700 19.7899 USD ADR Purchase 382,720 19.7857 USD ADR Sale 6,370 19.8575 USD ADR Sale 10,000 19.8017 USD ADR Sale 13,817 19.7356 USD ADR Sale 144,912 19.7795 USD ADR Sale 241,700 19.7894 USD ADR Sale 243,646 19.7893 USD Ordinary NPV Purchase 100 4,515.5000 JPY Ordinary NPV Purchase 400 4,550.5500 JPY Ordinary NPV Purchase 500 4,514.8000 JPY Ordinary NPV Purchase 600 4,518.5000 JPY Ordinary NPV Purchase 700 4,542.6714 JPY Ordinary NPV Purchase 800 4,564.2500 JPY Ordinary NPV Purchase 1,300 4,515.7692 JPY Ordinary NPV Purchase 1,800 4,569.1666 JPY Ordinary NPV Purchase 1,900 4,545.8421 JPY Ordinary NPV Purchase 2,300 4,509.5652 JPY Ordinary NPV Purchase 2,400 4,535.7916 JPY Ordinary NPV Purchase 2,900 4,501.6552 JPY Ordinary NPV Purchase 3,700 4,548.1027 JPY Ordinary NPV Purchase 4,000 4,571.9000 JPY Ordinary NPV Purchase 4,100", "score": 0.658918, "arguments": [{"text": "USD ADR Sale", "location": [2765, 2777], "entities": [{"type": "Organization", "text": "USD ADR Sale"}]}, {"text": "10,000 19.8017 USD", "location": [2778, 2796], "entities": [{"type": "Money", "text": "10,000 19.8017 USD", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "sale Number of Price per unit security securities ADR Purchase 3,892 19.7795 USD ADR Purchase 6,370 19.8575 USD ADR Purchase 13,817 19.7356 USD ADR Purchase 251,700 19.7899 USD ADR Purchase 382,720 19.7857 USD ADR Sale 6,370 19.8575 USD ADR Sale 10,000 19.8017 USD ADR Sale 13,817 19.7356 USD ADR Sale 144,912 19.7795 USD ADR Sale 241,700 19.7894 USD ADR Sale 243,646 19.7893 USD Ordinary NPV Purchase 100 4,515.5000 JPY Ordinary NPV Purchase 400 4,550.5500 JPY Ordinary NPV Purchase 500 4,514.8000 JPY Ordinary NPV Purchase 600 4,518.5000 JPY Ordinary NPV Purchase 700 4,542.6714 JPY Ordinary NPV Purchase 800 4,564.2500 JPY Ordinary NPV Purchase 1,300 4,515.7692 JPY Ordinary NPV Purchase 1,800 4,569.1666 JPY Ordinary NPV Purchase 1,900 4,545.8421 JPY Ordinary NPV Purchase 2,300 4,509.5652 JPY Ordinary NPV Purchase 2,400 4,535.7916 JPY Ordinary NPV Purchase 2,900 4,501.6552 JPY Ordinary NPV Purchase 3,700 4,548.1027 JPY Ordinary NPV Purchase 4,000 4,571.9000 JPY Ordinary NPV Purchase 4,100", "score": 0.693357, "arguments": [{"text": "ADR Sale", "location": [2797, 2805], "entities": [{"type": "Organization", "text": "ADR Sale"}]}, {"text": "10,000 19.8017 USD", "location": [2778, 2796], "entities": [{"type": "Money", "text": "10,000 19.8017 USD", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "employedBy", "sentence": "JPY Ordinary NPV Sale 7,000 4,515.9571 JPY Ordinary NPV Sale 11,300 4,557.5575 JPY Ordinary NPV Sale 27,300 4,548.9890 JPY Ordinary NPV Sale 41,300 4,559.0000 JPY Ordinary NPV Sale 41,400 4,540.0458 JPY Ordinary NPV Sale 44,800 4,519.2366 JPY Ordinary NPV Sale 46,300 4,541.5550 JPY Ordinary NPV Sale 60,000 4,533.8600 JPY Ordinary NPV Sale 154,300 4,525.8476 JPY Ordinary NPV Sale 344,000 4,531.1872 JPY Ordinary NPV Sale 370,000 4,531.8018 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV CFD Long 38,600 4,559.0000 JPY Ordinary NPV SWAP Long 38,600 4,559.0000 JPY Ordinary NPV SWAP Short 900 4,546.3111 JPY Ordinary NPV CFD Short 15,500 4,500.4500 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling,", "score": 0.500498, "arguments": [{"text": "Cash", "location": [5018, 5022], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Product Nature", "location": [5064, 5078], "entities": [{"type": "Organization", "text": "Product Nature", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [6380, 6386], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [6397, 6404], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 14 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [7306, 7312], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [7320, 7324], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the \"Code\") 1.", "score": 0.522588, "arguments": [{"text": "Rule 8", "location": [7752, 7758], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [7766, 7779], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [7387, 7411], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [7379, 7384], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [9898, 9922], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [9890, 9895], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [7546, 7551], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [7565, 7592], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [10057, 10062], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [10076, 10103], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC.", "score": 0.419441, "arguments": [{"text": "person", "location": [7828, 7834], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [7860, 7872], "entities": [{"type": "Organization", "text": "BARCLAYS PLC Category Code", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "JPY Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.99422}, {"text": "Ordinary NPV Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.762944}, {"text": "Ordinary NPV Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.720303}, {"text": "Ordinary NPV Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.431619}, {"text": "USD Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.430643}, {"text": "Ordinary NPV CFD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.427818}, {"text": "Ordinary NPV SWAP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.427433}, {"text": "relevant securities", "sentiment": {"score": 0.229926, "label": "positive"}, "relevance": 0.424669}, {"text": "securities Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.423869}, {"text": "NPV Call Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.379494}, {"text": "NPV Put Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.364369}, {"text": "NPV CFD Short", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.353969}, {"text": "NPV SWAP Short", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.35365}, {"text": "NPV SWAP Long", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.353497}, {"text": "USD ADR Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.342988}, {"text": "Options Written", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.335815}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.329249}, {"text": "USD ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.303976}, {"text": "supplemental form", "sentiment": {"score": 0.425721, "label": "positive"}, "relevance": 0.27191}, {"text": "open positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.266183}, {"text": "short positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.265677}, {"text": "Product description e.g.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.264266}, {"text": "relevant security Product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.263339}, {"text": "security Product description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.262725}, {"text": "class", "sentiment": {"score": -0.251285, "label": "negative"}, "relevance": 0.262598}, {"text": "Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.261723}, {"text": "unit security securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.259405}, {"text": "Options Purchased", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.259233}, {"text": "securities ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.250244}, {"text": "number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.246256}, {"text": "person", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.240748}, {"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.240332}, {"text": "new securities", "sentiment": {"score": 0.582177, "label": "positive"}, "relevance": 0.24012}, {"text": "Barclays PLC.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.239674}, {"text": "Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.239608}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.239476}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.239116}, {"text": "relevant Purchase/sale Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.2388}, {"text": "disclosure", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.238764}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.238179}, {"text": "details", "sentiment": {"score": 0.0877268, "label": "positive"}, "relevance": 0.237941}, {"text": "monetary amounts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.23786}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.237487}, {"text": "Short Positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.237054}, {"text": "relevant description reference", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.23688}, {"text": "relevant security Nature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.236174}, {"text": "PUBLIC OPENING POSITION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.236098}, {"text": "stock-settled derivative positions", "sentiment": {"score": -0.27481, "label": "negative"}, "relevance": 0.236054}, {"text": "securities Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235809}, {"text": "cash-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235252}]}, "extracted_metadata": {"sha1": "addb7894836ea24ebc354b1f8233b2816185695c", "filename": "1542206082765.zip-5f5075a17b7566bd38b7e9d418b5e32d.xml", "file_type": "json"}, "title": "BARCLAYS PLC UK Regulatory Announcement: Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD AMENDMENT", "forum_title": "All News | Business Wire"}, {"id": "Xho54gAqg37fIwenfhqPVbcQkUpjGFnaEMT8GkjgavkaoKEEnNHiEH_2L5DxKNHb", "result_metadata": {"score": 32.11127}, "author": "Bloomberg News", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$7 Billion", "relevance": 0.01, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.569941, "label": "/finance/investing"}, {"score": 0.569941, "label": "/finance/investing/beginning investing"}, {"score": 0.362803, "label": "/finance/financial news"}], "relations": [], "keywords": [{"text": "Biotech Roivant Climbs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.949351}, {"text": "Valuation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.376404}]}, "crawl_date": "2018-11-13T15:40:46Z", "url": "https://www.bnn.ca/softbank-backed-biotech-roivant-climbs-to-7-billion-valuation-1.1167221", "host": "bnn.ca", "text": "The company licensed the drug from Takeda Pharmaceutical Co.", "main_image_url": "https://www.bnnbloomberg.ca/img/tsn/logos/tsn-logo.png", "country": "CA", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-13T00:00:00-06:00", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roivant", "relevance": 0.769959, "type": "Person"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vivek Ramaswamy", "relevance": 0.656566, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "NovaQuest Capital Management", "relevance": 0.551685, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vision Fund", "relevance": 0.496132, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roivant", "relevance": 0.439324, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.392333, "label": "positive"}, "text": "Roivant Sciences Ltd.", "relevance": 0.416837, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co. Ltd.", "relevance": 0.407124, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.389532, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SoftBank", "relevance": 0.382932, "type": "Company", "disambiguation": {"subtype": [], "name": "SoftBank", "dbpedia_resource": "http://dbpedia.org/resource/SoftBank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bloomberg", "relevance": 0.360579, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Matt Bullard", "relevance": 0.357607, "type": "Person", "disambiguation": {"subtype": ["BasketballPlayer"], "name": "Matt Bullard", "dbpedia_resource": "http://dbpedia.org/resource/Matt_Bullard"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Moderna Therapeutics Inc.", "relevance": 0.356729, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.747543, "label": "negative"}, "text": "Axovant Sciences Ltd.", "relevance": 0.348338, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "NovaQuest", "relevance": 0.347143, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "RTW Investments", "relevance": 0.337742, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia", "relevance": 0.336754, "type": "Location", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"count": 1, "sentiment": {"score": -0.747543, "label": "negative"}, "text": "Alzheimer", "relevance": 0.333493, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "OrganizationSector"], "name": "Alzheimer's disease", "dbpedia_resource": "http://dbpedia.org/resource/Alzheimer's_disease"}}, {"count": 1, "sentiment": {"score": -0.364089, "label": "negative"}, "text": "FDA", "relevance": 0.331456, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Drew Armstrong", "relevance": 0.327712, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.S.", "relevance": 0.321786, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Raleigh", "relevance": 0.320946, "type": "Location", "disambiguation": {"subtype": ["PlaceWithNeighborhoods", "City"], "name": "Raleigh, North Carolina", "dbpedia_resource": "http://dbpedia.org/resource/Raleigh,_North_Carolina"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Rebecca Spalding", "relevance": 0.320452, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "analyst", "relevance": 0.320422, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Myovant", "relevance": 0.318073, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "reporter", "relevance": 0.314886, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Timothy Annett", "relevance": 0.313756, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Axovant", "relevance": 0.313747, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Boston", "relevance": 0.295617, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "partner", "relevance": 0.29427, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Relugolix", "relevance": 0.286948, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mark Schoifet", "relevance": 0.281806, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "darmstrong17@bloomberg.net", "relevance": 0.281806, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "rspalding@bloomberg.net", "relevance": 0.281806, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$1.1 billion", "relevance": 0.281806, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$100 million", "relevance": 0.281806, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$2.9 billion", "relevance": 0.281806, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$200 million", "relevance": 0.281806, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$7 billion", "relevance": 0.281806, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33-year", "relevance": 0.281806, "type": "Quantity"}], "sentiment": {"document": {"score": 0.312051, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Roivant Sciences Ltd.", "keywords": [{"text": "Roivant Sciences"}], "entities": [{"type": "Company", "text": "Roivant Sciences Ltd."}]}, "sentence": "(Bloomberg) -- Roivant Sciences Ltd. raised $200 million in a new funding round that makes it one of the most highly valued private firms in the history of the biotechnology industry at $7 billion, according to the company.", "object": {"text": "$200 million in a new funding round", "keywords": [{"text": "new funding"}], "entities": [{"type": "Quantity", "text": "$200 million"}]}, "action": {"verb": {"text": "raise", "tense": "past"}, "text": "raised", "normalized": "raise"}}, {"subject": {"text": "a new funding round", "keywords": [{"text": "new funding"}]}, "sentence": "(Bloomberg) -- Roivant Sciences Ltd. raised $200 million in a new funding round that makes it one of the most highly valued private firms in the history of the biotechnology industry at $7 billion, according to the company.", "object": {"text": "it"}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "makes", "normalized": "make"}}, {"subject": {"text": "private firms", "keywords": [{"text": "private firms"}]}, "sentence": "(Bloomberg) -- Roivant Sciences Ltd. raised $200 million in a new funding round that makes it one of the most highly valued private firms in the history of the biotechnology industry at $7 billion, according to the company.", "object": {"text": "in the history of the biotechnology industry at $7 billion", "keywords": [{"text": "biotechnology industry"}, {"text": "history"}], "entities": [{"type": "Quantity", "text": "$7 billion"}]}, "action": {"verb": {"text": "value", "tense": "past"}, "text": "valued", "normalized": "value"}}, {"subject": {"text": "a new funding round that makes it one of the most highly valued private firms in the history of the biotechnology industry at $7 billion", "keywords": [{"text": "new funding"}, {"text": "biotechnology industry"}, {"text": "private firms"}, {"text": "history"}], "entities": [{"type": "Quantity", "text": "$7 billion"}]}, "sentence": "(Bloomberg) -- Roivant Sciences Ltd. raised $200 million in a new funding round that makes it one of the most highly valued private firms in the history of the biotechnology industry at $7 billion, according to the company.", "object": {"text": "to the company", "keywords": [{"text": "company"}]}, "action": {"verb": {"text": "accord", "tense": "present"}, "text": "according", "normalized": "accord"}}, {"subject": {"text": "SoftBank\u2019s Vision Fund", "keywords": [{"text": "Vision Fund"}, {"text": "SoftBank"}], "entities": [{"type": "Company", "text": "SoftBank", "disambiguation": {"subtype": ["Company"], "name": "SoftBank", "dbpedia_resource": "http://dbpedia.org/resource/SoftBank"}}, {"type": "Organization", "text": "Vision Fund"}]}, "sentence": " Previous backers including SoftBank\u2019s Vision Fund took part in the new financing, as did new investors NovaQuest Capital Management and RTW Investments, Roivant said in a statement on Tuesday.", "object": {"text": "Previous backers", "keywords": [{"text": "Previous backers"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Previous backers including SoftBank\u2019s Vision Fund", "keywords": [{"text": "Previous backers"}, {"text": "SoftBank\u2019s Vision"}, {"text": "Fund"}], "entities": [{"type": "Company", "text": "SoftBank", "disambiguation": {"subtype": ["Company"], "name": "SoftBank", "dbpedia_resource": "http://dbpedia.org/resource/SoftBank"}}, {"type": "Organization", "text": "Vision Fund"}]}, "sentence": " Previous backers including SoftBank\u2019s Vision Fund took part in the new financing, as did new investors NovaQuest Capital Management and RTW Investments, Roivant said in a statement on Tuesday.", "object": {"text": "part"}, "action": {"verb": {"text": "take", "tense": "past"}, "text": "took", "normalized": "take"}}, {"subject": {"text": "Previous backers including SoftBank\u2019s Vision Fund", "keywords": [{"text": "Previous backers"}, {"text": "SoftBank\u2019s Vision"}, {"text": "Fund"}], "entities": [{"type": "Company", "text": "SoftBank", "disambiguation": {"subtype": ["Company"], "name": "SoftBank", "dbpedia_resource": "http://dbpedia.org/resource/SoftBank"}}, {"type": "Organization", "text": "Vision Fund"}]}, "sentence": " Previous backers including SoftBank\u2019s Vision Fund took part in the new financing, as did new investors NovaQuest Capital Management and RTW Investments, Roivant said in a statement on Tuesday.", "object": {"text": "new investors NovaQuest Capital Management and RTW Investments", "keywords": [{"text": "NovaQuest Capital Management"}, {"text": "new investors"}, {"text": "Investments"}], "entities": [{"type": "Company", "text": "NovaQuest Capital Management"}, {"type": "Company", "text": "RTW Investments"}]}, "action": {"verb": {"text": "do", "tense": "past"}, "text": "did", "normalized": "do"}}, {"subject": {"text": "Roivant", "keywords": [{"text": "Roivant"}], "entities": [{"type": "Person", "text": "Roivant"}]}, "sentence": " Previous backers including SoftBank\u2019s Vision Fund took part in the new financing, as did new investors NovaQuest Capital Management and RTW Investments, Roivant said in a statement on Tuesday.", "object": {"text": "Previous backers including SoftBank\u2019s Vision Fund took part in the new financing, as did new investors NovaQuest Capital Management and RTW Investments", "keywords": [{"text": "RTW Investments"}, {"text": "NovaQuest Capital Management"}, {"text": "Previous backers"}, {"text": "new investors"}], "entities": [{"type": "Company", "text": "SoftBank", "disambiguation": {"subtype": ["Company"], "name": "SoftBank", "dbpedia_resource": "http://dbpedia.org/resource/SoftBank"}}, {"type": "Organization", "text": "Vision Fund"}, {"type": "Company", "text": "NovaQuest Capital Management"}, {"type": "Company", "text": "RTW Investments"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}]}, "sentence": " In August 2017, the company raised $1.1 billion from the Vision Fund, which has placed a series of splashy bets on Internet and other startups but backed few other biotech ventures.", "object": {"text": "$1.1 billion", "entities": [{"type": "Quantity", "text": "$1.1 billion"}]}, "action": {"verb": {"text": "raise", "tense": "past"}, "text": "raised", "normalized": "raise"}}, {"subject": {"text": "the Vision Fund", "keywords": [{"text": "Vision Fund"}], "entities": [{"type": "Organization", "text": "Vision Fund"}]}, "sentence": " In August 2017, the company raised $1.1 billion from the Vision Fund, which has placed a series of splashy bets on Internet and other startups but backed few other biotech ventures.", "object": {"text": "placed a series of splashy bets on Internet and other startups", "keywords": [{"text": "splashy bets"}, {"text": "startups"}, {"text": "series"}, {"text": "Internet"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "the Vision Fund", "keywords": [{"text": "Vision Fund"}], "entities": [{"type": "Organization", "text": "Vision Fund"}]}, "sentence": " In August 2017, the company raised $1.1 billion from the Vision Fund, which has placed a series of splashy bets on Internet and other startups but backed few other biotech ventures.", "object": {"text": "a series of splashy bets on Internet and other startups", "keywords": [{"text": "splashy bets"}, {"text": "startups"}, {"text": "series"}, {"text": "Internet"}]}, "action": {"verb": {"text": "place", "tense": "past"}, "text": "has placed", "normalized": "have place"}}, {"subject": {"text": "Roivant", "keywords": [{"text": "Roivant"}], "entities": [{"type": "Person", "text": "Roivant"}]}, "sentence": " Roivant is run by 33-year-old Vivek Ramaswamy, who began his career as a hedge-fund analyst before founding the company.", "object": {"text": "run by 33-year-old Vivek Ramaswamy, who began his career as a hedge-fund analyst before founding the company", "keywords": [{"text": "33-year-old Vivek Ramaswamy"}, {"text": "hedge-fund analyst"}], "entities": [{"type": "Person", "text": "Vivek Ramaswamy"}, {"type": "JobTitle", "text": "analyst"}, {"type": "Quantity", "text": "33-year"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by 33-year-old Vivek Ramaswamy, who began his career as a hedge-fund analyst before founding the company", "keywords": [{"text": "33-year-old Vivek Ramaswamy"}, {"text": "hedge-fund analyst"}, {"text": "career"}, {"text": "company"}], "entities": [{"type": "Person", "text": "Vivek Ramaswamy"}, {"type": "JobTitle", "text": "analyst"}, {"type": "Quantity", "text": "33-year"}]}, "sentence": " Roivant is run by 33-year-old Vivek Ramaswamy, who began his career as a hedge-fund analyst before founding the company.", "object": {"text": "Roivant", "keywords": [{"text": "Roivant"}], "entities": [{"type": "Person", "text": "Roivant"}]}, "action": {"verb": {"text": "run", "tense": "past"}, "text": "is run", "normalized": "be run"}}, {"subject": {"text": "33-year-old Vivek Ramaswamy", "keywords": [{"text": "33-year-old Vivek Ramaswamy"}], "entities": [{"type": "Person", "text": "Vivek Ramaswamy"}, {"type": "Quantity", "text": "33-year"}]}, "sentence": " Roivant is run by 33-year-old Vivek Ramaswamy, who began his career as a hedge-fund analyst before founding the company.", "object": {"text": "his career", "keywords": [{"text": "career"}]}, "action": {"verb": {"text": "begin", "tense": "past"}, "text": "began", "normalized": "begin"}}, {"subject": {"text": "It"}, "sentence": " It has a unique structure predicated on Ramaswamy\u2019s belief that pharmaceutical research is more costly than it needs to be and that executives\u2019 incentives are misaligned.", "object": {"text": "a unique structure predicated on Ramaswamy\u2019s belief that pharmaceutical research is more costly than it needs to be and that executives\u2019 incentives are misaligned", "keywords": [{"text": "Ramaswamy\u2019s belief"}, {"text": "unique structure"}, {"text": "pharmaceutical research"}, {"text": "incentives"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The financing", "keywords": [{"text": "financing"}]}, "sentence": " The financing is the latest private biotechnology funding round to top $100 million, which was once rare for the industry but has become routine.", "object": {"text": "the latest private biotechnology funding round", "keywords": [{"text": "private biotechnology funding"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "top $100 million", "entities": [{"type": "Quantity", "text": "$100 million"}]}, "sentence": " The financing is the latest private biotechnology funding round to top $100 million, which was once rare for the industry but has become routine.", "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "top $100 million", "entities": [{"type": "Quantity", "text": "$100 million"}]}, "sentence": " The financing is the latest private biotechnology funding round to top $100 million, which was once rare for the industry but has become routine.", "object": {"text": "routine"}, "action": {"verb": {"text": "become", "tense": "past"}, "text": "has become", "normalized": "have become"}}, {"subject": {"text": "private valuations", "keywords": [{"text": "private valuations"}]}, "sentence": " Record amounts of private capital have flowed into the sector, leading to private valuations that dwarfed historic norms.", "object": {"text": "historic norms", "keywords": [{"text": "historic norms"}]}, "action": {"verb": {"text": "dwarf", "tense": "past"}, "text": "dwarfed", "normalized": "dwarf"}}, {"subject": {"text": "Forty-nine biotechnology companies", "keywords": [{"text": "Forty-nine biotechnology companies"}], "entities": []}, "sentence": " Forty-nine biotechnology companies have gone public on U.S. exchanges this year, close to the all-time record set in 2014 when 53 companies conducted IPOs, including a Roivant subsidiary.", "object": {"text": "gone public on U.S. exchanges", "keywords": [{"text": "U.S. exchanges"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Forty-nine biotechnology companies", "keywords": [{"text": "Forty-nine biotechnology companies"}], "entities": []}, "sentence": " Forty-nine biotechnology companies have gone public on U.S. exchanges this year, close to the all-time record set in 2014 when 53 companies conducted IPOs, including a Roivant subsidiary.", "object": {"text": "public", "keywords": [{"text": "public"}]}, "action": {"verb": {"text": "go", "tense": "past"}, "text": "have gone", "normalized": "have go"}}, {"subject": {"text": "the all-time record", "keywords": [{"text": "all-time record"}]}, "sentence": " Forty-nine biotechnology companies have gone public on U.S. exchanges this year, close to the all-time record set in 2014 when 53 companies conducted IPOs, including a Roivant subsidiary.", "action": {"verb": {"text": "set", "tense": "past"}, "text": "set", "normalized": "set"}}, {"subject": {"text": "53 companies", "keywords": [{"text": "companies"}]}, "sentence": " Forty-nine biotechnology companies have gone public on U.S. exchanges this year, close to the all-time record set in 2014 when 53 companies conducted IPOs, including a Roivant subsidiary.", "object": {"text": "IPOs", "keywords": [{"text": "IPOs"}]}, "action": {"verb": {"text": "conduct", "tense": "past"}, "text": "conducted", "normalized": "conduct"}}, {"subject": {"text": "a Roivant subsidiary", "keywords": [{"text": "Roivant subsidiary"}], "entities": [{"type": "Company", "text": "Roivant"}]}, "sentence": " Forty-nine biotechnology companies have gone public on U.S. exchanges this year, close to the all-time record set in 2014 when 53 companies conducted IPOs, including a Roivant subsidiary.", "object": {"text": "53 companies conducted IPOs", "keywords": [{"text": "IPOs"}, {"text": "companies"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "startup", "keywords": [{"text": "startup"}]}, "sentence": " Last week, closely watched startup Moderna Therapeutics Inc., which boasts a similar valuation to Roivant\u2019s new price tag, said it plans to go public soon.", "action": {"verb": {"text": "watch", "tense": "past"}, "text": "watched", "normalized": "watch"}}, {"subject": {"text": "Moderna Therapeutics Inc., which boasts a similar valuation to Roivant\u2019s new price tag,", "keywords": [{"text": "Moderna Therapeutics Inc."}, {"text": "new price tag"}, {"text": "similar valuation"}, {"text": "Roivant"}], "entities": [{"type": "Company", "text": "Moderna Therapeutics Inc."}, {"type": "Company", "text": "Roivant"}]}, "sentence": " Last week, closely watched startup Moderna Therapeutics Inc., which boasts a similar valuation to Roivant\u2019s new price tag, said it plans to go public soon.", "object": {"text": "it plans to go public soon"}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "it"}, "sentence": " Last week, closely watched startup Moderna Therapeutics Inc., which boasts a similar valuation to Roivant\u2019s new price tag, said it plans to go public soon.", "action": {"verb": {"text": "go", "tense": "future"}, "text": "plans to go", "normalized": "plan to go"}}, {"subject": {"text": "Roivant", "keywords": [{"text": "Roivant"}], "entities": [{"type": "Person", "text": "Roivant"}]}, "sentence": " Roivant acts as a parent company for 14 offshoot firms known by their suffix, \u201c-vant.\u201d Each smaller firm had a different area of expertise and the drug-focused units have their own proprietary research pipeline.", "object": {"text": "as a parent company", "keywords": [{"text": "parent company"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acts", "normalized": "act"}}, {"subject": {"text": "by their suffix", "keywords": [{"text": "suffix"}]}, "sentence": " Roivant acts as a parent company for 14 offshoot firms known by their suffix, \u201c-vant.\u201d Each smaller firm had a different area of expertise and the drug-focused units have their own proprietary research pipeline.", "object": {"text": "14 offshoot firms", "keywords": [{"text": "offshoot firms"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "known", "normalized": "know"}}, {"subject": {"text": "Each smaller firm", "keywords": [{"text": "smaller firm"}]}, "sentence": " Roivant acts as a parent company for 14 offshoot firms known by their suffix, \u201c-vant.\u201d Each smaller firm had a different area of expertise and the drug-focused units have their own proprietary research pipeline.", "object": {"text": "a different area of expertise and the drug-focused units", "keywords": [{"text": "different area"}, {"text": "drug-focused units"}, {"text": "expertise"}]}, "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "Each smaller firm had a different area of expertise and the drug-focused units", "keywords": [{"text": "smaller firm"}, {"text": "different area"}, {"text": "drug-focused units"}, {"text": "expertise"}]}, "sentence": " Roivant acts as a parent company for 14 offshoot firms known by their suffix, \u201c-vant.\u201d Each smaller firm had a different area of expertise and the drug-focused units have their own proprietary research pipeline.", "object": {"text": "their own proprietary research pipeline", "keywords": [{"text": "proprietary research pipeline"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "The companies", "keywords": [{"text": "companies"}], "entities": []}, "sentence": " The companies often study compounds that larger pharmaceutical players have overlooked or retreated from.", "object": {"text": "compounds", "keywords": [{"text": "compounds"}]}, "action": {"verb": {"text": "study", "tense": "present"}, "text": "study", "normalized": "study"}}, {"subject": {"text": "larger pharmaceutical players", "keywords": [{"text": "larger pharmaceutical players"}]}, "sentence": " The companies often study compounds that larger pharmaceutical players have overlooked or retreated from.", "object": {"text": "overlooked"}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "larger pharmaceutical players", "keywords": [{"text": "larger pharmaceutical players"}]}, "sentence": " The companies often study compounds that larger pharmaceutical players have overlooked or retreated from.", "object": {"text": "The companies often study compounds", "keywords": [{"text": "compounds"}, {"text": "companies"}], "entities": []}, "action": {"verb": {"text": "retreat", "tense": "past"}, "text": "have overlooked or retreated", "normalized": "have overlook or retreat"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}]}, "sentence": " The company believes that approach can streamline drug research by aligning management teams\u2019 incentives with individual research programs.", "object": {"text": "that approach can streamline drug research by aligning management teams\u2019 incentives with individual research programs", "keywords": [{"text": "individual research programs"}, {"text": "management teams"}, {"text": "drug research"}, {"text": "incentives"}]}, "action": {"verb": {"text": "believe", "tense": "present"}, "text": "believes", "normalized": "believe"}}, {"subject": {"text": "That angle", "keywords": [{"text": "angle"}]}, "sentence": " That angle attracted new investor NovaQuest Capital Management.", "object": {"text": "new investor NovaQuest Capital Management", "keywords": [{"text": "new investor NovaQuest"}, {"text": "Capital Management"}], "entities": [{"type": "Company", "text": "NovaQuest Capital Management"}]}, "action": {"verb": {"text": "attract", "tense": "past"}, "text": "attracted", "normalized": "attract"}}, {"subject": {"text": "NovaQuest", "keywords": [{"text": "NovaQuest"}], "entities": [{"type": "Company", "text": "NovaQuest"}]}, "sentence": " NovaQuest, which typically backs late-stage pharmaceutical research programs, also says that drug executives don\u2019t have adequate incentives to ensure that the research programs they oversee will succeed.", "object": {"text": "late-stage pharmaceutical research programs", "keywords": [{"text": "late-stage pharmaceutical research"}, {"text": "programs"}]}, "action": {"verb": {"text": "back", "tense": "present"}, "text": "backs", "normalized": "back"}}, {"subject": {"text": "NovaQuest, which typically backs late-stage pharmaceutical research programs,", "keywords": [{"text": "late-stage pharmaceutical research"}, {"text": "NovaQuest"}, {"text": "programs"}], "entities": [{"type": "Company", "text": "NovaQuest"}]}, "sentence": " NovaQuest, which typically backs late-stage pharmaceutical research programs, also says that drug executives don\u2019t have adequate incentives to ensure that the research programs they oversee will succeed.", "object": {"text": "that drug executives don\u2019t have adequate incentives to ensure that the research programs they oversee will succeed", "keywords": [{"text": "adequate incentives"}, {"text": "drug executives"}, {"text": "research programs"}]}, "action": {"verb": {"text": "say", "tense": "present"}, "text": "says", "normalized": "say"}}, {"subject": {"text": "drug executives", "keywords": [{"text": "drug executives"}]}, "sentence": " NovaQuest, which typically backs late-stage pharmaceutical research programs, also says that drug executives don\u2019t have adequate incentives to ensure that the research programs they oversee will succeed.", "object": {"text": "n\u2019t have adequate incentives to ensure that the research programs they oversee will succeed", "keywords": [{"text": "adequate incentives"}, {"text": "research programs"}]}, "action": {"verb": {"text": "do", "tense": "present"}, "text": "do", "normalized": "do"}}, {"subject": {"text": "drug executives", "keywords": [{"text": "drug executives"}]}, "sentence": " NovaQuest, which typically backs late-stage pharmaceutical research programs, also says that drug executives don\u2019t have adequate incentives to ensure that the research programs they oversee will succeed.", "object": {"text": "that the research programs they oversee will succeed", "keywords": [{"text": "research programs"}]}, "action": {"verb": {"text": "ensure", "tense": "future"}, "text": "to ensure", "normalized": "to ensure"}}, {"subject": {"text": "they"}, "sentence": " NovaQuest, which typically backs late-stage pharmaceutical research programs, also says that drug executives don\u2019t have adequate incentives to ensure that the research programs they oversee will succeed.", "object": {"text": "the research programs", "keywords": [{"text": "research programs"}]}, "action": {"verb": {"text": "oversee", "tense": "present"}, "text": "oversee", "normalized": "oversee"}}, {"subject": {"text": "they"}, "sentence": " NovaQuest, which typically backs late-stage pharmaceutical research programs, also says that drug executives don\u2019t have adequate incentives to ensure that the research programs they oversee will succeed.", "object": {"text": "the research programs", "keywords": [{"text": "research programs"}]}, "action": {"verb": {"text": "succeed", "tense": "future"}, "text": "will succeed", "normalized": "will succeed"}}, {"subject": {"text": "you"}, "sentence": " If \u201ca program fails, you move on to the next product, but if you succeed, you may get a few more stock options\u201d said Matt Bullard, partner at the Raleigh, North Carolina-based firm.", "object": {"text": "a few more stock options", "keywords": [{"text": "stock options"}]}, "action": {"verb": {"text": "get", "tense": "future"}, "text": "may get", "normalized": "may get"}}, {"subject": {"text": "Matt Bullard, partner at the Raleigh, North Carolina-based firm", "keywords": [{"text": "Matt Bullard"}, {"text": "North Carolina-based firm"}, {"text": "Raleigh"}, {"text": "partner"}], "entities": [{"type": "Person", "text": "Matt Bullard", "disambiguation": {"subtype": ["BasketballPlayer"], "name": "Matt Bullard", "dbpedia_resource": "http://dbpedia.org/resource/Matt_Bullard"}}, {"type": "JobTitle", "text": "partner"}, {"type": "Location", "text": "Raleigh", "disambiguation": {"subtype": ["PlaceWithNeighborhoods", "CityTown", "City"], "name": "Raleigh, North Carolina", "dbpedia_resource": "http://dbpedia.org/resource/Raleigh,_North_Carolina"}}]}, "sentence": " If \u201ca program fails, you move on to the next product, but if you succeed, you may get a few more stock options\u201d said Matt Bullard, partner at the Raleigh, North Carolina-based firm.", "object": {"text": "If \u201ca program fails, you move on to the next product, but if you succeed, you may get a few more stock options", "keywords": [{"text": "stock options"}, {"text": "program"}, {"text": "product"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "they"}, "sentence": " \u201cAt the vants, they\u2019ve really incentivized those management teams for the success of their individual program.\u201d", "object": {"text": "really incentivized those management teams for the success of their individual program", "keywords": [{"text": "management teams"}, {"text": "individual program"}, {"text": "success"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "they"}, "sentence": " \u201cAt the vants, they\u2019ve really incentivized those management teams for the success of their individual program.\u201d", "object": {"text": "those management teams", "keywords": [{"text": "management teams"}]}, "action": {"verb": {"text": "incentivized", "tense": "past"}, "text": "ve really incentivized", "normalized": "ve really incentivized"}}, {"subject": {"text": "Late-stage clinical trials", "keywords": [{"text": "Late-stage clinical trials"}]}, "sentence": " Late-stage clinical trials are more costly to run than earlier research, but are generally seen as more likely to succeed because the drug candidates have been vetted by earlier studies.", "object": {"text": "more costly"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Late-stage clinical trials", "keywords": [{"text": "Late-stage clinical trials"}]}, "sentence": " Late-stage clinical trials are more costly to run than earlier research, but are generally seen as more likely to succeed because the drug candidates have been vetted by earlier studies.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Late-stage clinical trials", "keywords": [{"text": "Late-stage clinical trials"}]}, "sentence": " Late-stage clinical trials are more costly to run than earlier research, but are generally seen as more likely to succeed because the drug candidates have been vetted by earlier studies.", "object": {"text": "more"}, "action": {"verb": {"text": "succeed", "tense": "future"}, "text": "to succeed", "normalized": "to succeed"}}, {"subject": {"text": "the drug candidates", "keywords": [{"text": "drug candidates"}]}, "sentence": " Late-stage clinical trials are more costly to run than earlier research, but are generally seen as more likely to succeed because the drug candidates have been vetted by earlier studies.", "object": {"text": "been vetted by earlier studies", "keywords": [{"text": "earlier studies"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}], "concepts": [{"text": "Initial public offering", "relevance": 0.952122, "dbpedia_resource": "http://dbpedia.org/resource/Initial_public_offering"}, {"text": "Drug", "relevance": 0.642388, "dbpedia_resource": "http://dbpedia.org/resource/Drug"}, {"text": "Pharmacology", "relevance": 0.578527, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Google", "relevance": 0.570791, "dbpedia_resource": "http://dbpedia.org/resource/Google"}, {"text": "Capital", "relevance": 0.547824, "dbpedia_resource": "http://dbpedia.org/resource/Capital_(economics)"}, {"text": "Pharmaceutical drug", "relevance": 0.531937, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Finance", "relevance": 0.530143, "dbpedia_resource": "http://dbpedia.org/resource/Finance"}, {"text": "Company", "relevance": 0.521346, "dbpedia_resource": "http://dbpedia.org/resource/Company"}, {"text": "Venture capital", "relevance": 0.488445, "dbpedia_resource": "http://dbpedia.org/resource/Venture_capital"}, {"text": "Names of large numbers", "relevance": 0.482564, "dbpedia_resource": "http://dbpedia.org/resource/Names_of_large_numbers"}], "categories": [{"score": 0.572633, "label": "/finance/investing"}, {"score": 0.572633, "label": "/finance/investing/beginning investing"}, {"score": 0.357735, "label": "/finance/financial news"}], "relations": [{"type": "hasAttribute", "sentence": "(Bloomberg) -- Roivant Sciences Ltd. raised $200 million in a new funding round that makes it one of the most highly valued private firms in the history of the biotechnology industry at $7 billion, according to the company.", "score": 0.69459, "arguments": [{"text": "Roivant Sciences Ltd.", "location": [15, 36], "entities": [{"type": "Organization", "text": "Roivant unit Axovant Sciences Ltd."}]}, {"text": "$200 million", "location": [44, 56], "entities": [{"type": "Money", "text": "$200 million", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "agentOf", "sentence": "Last week, closely watched startup Moderna Therapeutics Inc., which boasts a similar valuation to Roivant's new price tag, said it plans to go public soon.", "score": 0.950812, "arguments": [{"text": "Moderna Therapeutics Inc.", "location": [1465, 1490], "entities": [{"type": "Organization", "text": "Moderna Therapeutics Inc."}]}, {"text": "said", "location": [1553, 1557], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "NovaQuest, which typically backs late-stage pharmaceutical research programs, also says that drug executives don't have adequate incentives to ensure that the research programs they oversee will succeed.", "score": 0.601979, "arguments": [{"text": "NovaQuest", "location": [2108, 2117], "entities": [{"type": "Organization", "text": "NovaQuest Capital Management", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "says", "location": [2191, 2195], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "NovaQuest, which typically backs late-stage pharmaceutical research programs, also says that drug executives don't have adequate incentives to ensure that the research programs they oversee will succeed.", "score": 0.716569, "arguments": [{"text": "which", "location": [2119, 2124], "entities": [{"type": "Organization", "text": "NovaQuest Capital Management", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "says", "location": [2191, 2195], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "affectedBy", "sentence": "NovaQuest, which typically backs late-stage pharmaceutical research programs, also says that drug executives don't have adequate incentives to ensure that the research programs they oversee will succeed.", "score": 0.587623, "arguments": [{"text": "executives", "location": [2206, 2216], "entities": [{"type": "Person", "text": "executives"}]}, {"text": "says", "location": [2191, 2195], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "If \"a program fails, you move on to the next product, but if you succeed, you may get a few more stock options\" said Matt Bullard, partner at the Raleigh, North Carolina-based firm.", "score": 0.721557, "arguments": [{"text": "Matt Bullard", "location": [2429, 2441], "entities": [{"type": "Person", "text": "Matt Bullard"}]}, {"text": "said", "location": [2424, 2428], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "residesIn", "sentence": "If \"a program fails, you move on to the next product, but if you succeed, you may get a few more stock options\" said Matt Bullard, partner at the Raleigh, North Carolina-based firm.", "score": 0.359128, "arguments": [{"text": "partner", "location": [2443, 2450], "entities": [{"type": "Person", "text": "Matt Bullard"}]}, {"text": "Raleigh", "location": [2458, 2465], "entities": [{"type": "GeopoliticalEntity", "text": "Raleigh"}]}]}, {"type": "employedBy", "sentence": "If \"a program fails, you move on to the next product, but if you succeed, you may get a few more stock options\" said Matt Bullard, partner at the Raleigh, North Carolina-based firm.", "score": 0.445621, "arguments": [{"text": "partner", "location": [2443, 2450], "entities": [{"type": "Person", "text": "Matt Bullard"}]}, {"text": "firm", "location": [2488, 2492], "entities": [{"type": "Organization", "text": "firms", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "If \"a program fails, you move on to the next product, but if you succeed, you may get a few more stock options\" said Matt Bullard, partner at the Raleigh, North Carolina-based firm.", "score": 0.946232, "arguments": [{"text": "Raleigh", "location": [2458, 2465], "entities": [{"type": "GeopoliticalEntity", "text": "Raleigh"}]}, {"text": "North Carolina-based", "location": [2467, 2487], "entities": [{"type": "GeopoliticalEntity", "text": "North Carolina-based"}]}]}, {"type": "basedIn", "sentence": "If \"a program fails, you move on to the next product, but if you succeed, you may get a few more stock options\" said Matt Bullard, partner at the Raleigh, North Carolina-based firm.", "score": 0.935506, "arguments": [{"text": "firm", "location": [2488, 2492], "entities": [{"type": "Organization", "text": "firms", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Raleigh", "location": [2458, 2465], "entities": [{"type": "GeopoliticalEntity", "text": "Raleigh"}]}]}, {"type": "basedIn", "sentence": "If \"a program fails, you move on to the next product, but if you succeed, you may get a few more stock options\" said Matt Bullard, partner at the Raleigh, North Carolina-based firm.", "score": 0.971762, "arguments": [{"text": "firm", "location": [2488, 2492], "entities": [{"type": "Organization", "text": "firms", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "North Carolina-based", "location": [2467, 2487], "entities": [{"type": "GeopoliticalEntity", "text": "North Carolina-based"}]}]}, {"type": "agentOf", "sentence": "\" Earlier Setback Late-stage clinical trials are more costly to run than earlier research, but are generally seen as more likely to succeed because the drug candidates have been vetted by earlier studies.", "score": 0.677532, "arguments": [{"text": "candidates", "location": [2761, 2771], "entities": [{"type": "Person", "text": "candidates"}]}, {"text": "vetted", "location": [2782, 2788], "entities": [{"type": "EventViolence", "text": "vetted"}]}]}, {"type": "partOf", "sentence": "Previous backers including SoftBank's Vision Fund took part in the new financing, as did new investors NovaQuest Capital Management and RTW Investments, Roivant said in a statement on Tuesday.", "score": 0.78662, "arguments": [{"text": "Vision Fund", "location": [262, 273], "entities": [{"type": "Organization", "text": "Vision Fund", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "SoftBank", "location": [251, 259], "entities": [{"type": "Organization", "text": "SoftBank", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "affectedBy", "sentence": "Last year, shares of Roivant unit Axovant Sciences Ltd. cratered after its experimental Alzheimer's disease drug failed in a late-stage trial.", "score": 0.515925, "arguments": [{"text": "its", "location": [2943, 2946], "entities": [{"type": "Organization", "text": "Roivant unit Axovant Sciences Ltd."}]}, {"text": "trial", "location": [3008, 3013], "entities": [{"type": "EventLegal", "text": "trial"}]}]}, {"type": "educatedAt", "sentence": "Prior to that, Ramaswamy had been hailed as a pharmaceutical wunderkind after taking Axovant public when he was only 29.", "score": 0.302454, "arguments": [{"text": "Ramaswamy", "location": [3030, 3039], "entities": [{"type": "Person", "text": "Vivek Ramaswamy"}]}, {"text": "Axovant public", "location": [3100, 3114], "entities": [{"type": "Organization", "text": "Axovant public"}]}]}, {"type": "hasAttribute", "sentence": "Prior to that, Ramaswamy had been hailed as a pharmaceutical wunderkind after taking Axovant public when he was only 29.", "score": 0.954287, "arguments": [{"text": "he", "location": [3120, 3122], "entities": [{"type": "Person", "text": "Vivek Ramaswamy"}]}, {"text": "29", "location": [3132, 3134], "entities": [{"type": "Age", "text": "29"}]}]}, {"type": "hasAttribute", "sentence": "The company reached a market value of as much as $2.9 billion before the trial failure, after which Ramaswamy was written off by some critics.", "score": 0.738942, "arguments": [{"text": "company", "location": [3140, 3147], "entities": [{"type": "Organization", "text": "Roivant unit Axovant Sciences Ltd."}]}, {"text": "$2.9 billion", "location": [3185, 3197], "entities": [{"type": "Money", "text": "$2.9 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "affectedBy", "sentence": "The company reached a market value of as much as $2.9 billion before the trial failure, after which Ramaswamy was written off by some critics.", "score": 0.494755, "arguments": [{"text": "Ramaswamy", "location": [3236, 3245], "entities": [{"type": "Person", "text": "Vivek Ramaswamy"}]}, {"text": "trial", "location": [3209, 3214], "entities": [{"type": "EventLegal", "text": "trial"}]}]}, {"type": "timeOf", "sentence": "Earlier this year, it said it planned to file for FDA approval for one of its drugs that treats an ultrarare childhood disease.", "score": 0.844622, "arguments": [{"text": "Earlier this year", "location": [3335, 3352], "entities": [{"type": "Date", "text": "Earlier this year"}]}, {"text": "said", "location": [3357, 3361], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "partOf", "sentence": "It has a number of candidates in late-stage study at companies across its portfolio, including Relugolix, a drug for endometriosis and uterine fibroids.", "score": 0.571026, "arguments": [{"text": "companies", "location": [3516, 3525], "entities": [{"type": "Organization", "text": "biotechnology companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "its", "location": [3533, 3536], "entities": [{"type": "Organization", "text": "its", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "It has a number of candidates in late-stage study at companies across its portfolio, including Relugolix, a drug for endometriosis and uterine fibroids.", "score": 0.566086, "arguments": [{"text": "Relugolix", "location": [3558, 3567], "entities": [{"type": "Person", "text": "Relugolix"}]}, {"text": "companies", "location": [3516, 3525], "entities": [{"type": "Organization", "text": "biotechnology companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "It has a number of candidates in late-stage study at companies across its portfolio, including Relugolix, a drug for endometriosis and uterine fibroids.", "score": 0.428605, "arguments": [{"text": "Relugolix", "location": [3558, 3567], "entities": [{"type": "Person", "text": "Relugolix"}]}, {"text": "its", "location": [3533, 3536], "entities": [{"type": "Organization", "text": "its", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "The company licensed the drug from Takeda Pharmaceutical Co. Ltd., which has reported positive final-stage studies already in Japan.", "score": 0.906139, "arguments": [{"text": "which", "location": [3683, 3688], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co. Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "reported", "location": [3693, 3701], "entities": [{"type": "EventCommunication", "text": "reported"}]}]}, {"type": "employedBy", "sentence": "Previous backers including SoftBank's Vision Fund took part in the new financing, as did new investors NovaQuest Capital Management and RTW Investments, Roivant said in a statement on Tuesday.", "score": 0.487308, "arguments": [{"text": "investors", "location": [317, 326], "entities": [{"type": "Person", "text": "investors"}]}, {"text": "NovaQuest Capital Management", "location": [327, 355], "entities": [{"type": "Organization", "text": "NovaQuest Capital Management", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "To contact the reporter on this story: Rebecca Spalding in Boston at rspalding@bloomberg.net To contact the editors Drew Armstrong at darmstrong17@bloomberg.net, Timothy Annett, Mark Schoifet", "score": 0.401691, "arguments": [{"text": "Rebecca Spalding", "location": [3866, 3882], "entities": [{"type": "Person", "text": "Rebecca Spalding"}]}, {"text": "Boston", "location": [3886, 3892], "entities": [{"type": "GeopoliticalEntity", "text": "Boston"}]}]}, {"type": "locatedAt", "sentence": "To contact the reporter on this story: Rebecca Spalding in Boston at rspalding@bloomberg.net To contact the editors Drew Armstrong at darmstrong17@bloomberg.net, Timothy Annett, Mark Schoifet", "score": 0.418201, "arguments": [{"text": "editors", "location": [3935, 3942], "entities": [{"type": "Person", "text": "editors"}]}, {"text": "Boston", "location": [3886, 3892], "entities": [{"type": "GeopoliticalEntity", "text": "Boston"}]}]}, {"type": "partOfMany", "sentence": "To contact the reporter on this story: Rebecca Spalding in Boston at rspalding@bloomberg.net To contact the editors Drew Armstrong at darmstrong17@bloomberg.net, Timothy Annett, Mark Schoifet", "score": 0.961194, "arguments": [{"text": "Drew Armstrong", "location": [3943, 3957], "entities": [{"type": "Person", "text": "Drew Armstrong"}]}, {"text": "editors", "location": [3935, 3942], "entities": [{"type": "Person", "text": "editors"}]}]}, {"type": "partOfMany", "sentence": "To contact the reporter on this story: Rebecca Spalding in Boston at rspalding@bloomberg.net To contact the editors Drew Armstrong at darmstrong17@bloomberg.net, Timothy Annett, Mark Schoifet", "score": 0.735221, "arguments": [{"text": "Timothy Annett", "location": [3989, 4003], "entities": [{"type": "Person", "text": "Timothy Annett"}]}, {"text": "editors", "location": [3935, 3942], "entities": [{"type": "Person", "text": "editors"}]}]}, {"type": "partOfMany", "sentence": "To contact the reporter on this story: Rebecca Spalding in Boston at rspalding@bloomberg.net To contact the editors Drew Armstrong at darmstrong17@bloomberg.net, Timothy Annett, Mark Schoifet", "score": 0.562866, "arguments": [{"text": "Mark Schoifet", "location": [4005, 4018], "entities": [{"type": "Person", "text": "Mark Schoifet"}]}, {"text": "editors", "location": [3935, 3942], "entities": [{"type": "Person", "text": "editors"}]}]}, {"type": "hasAttribute", "sentence": "To contact the reporter on this story: Rebecca Spalding in Boston at rspalding@bloomberg.net To contact the editors Drew Armstrong at darmstrong17@bloomberg.net, Timothy Annett, Mark Schoifet", "score": 0.98133, "arguments": [{"text": "Drew Armstrong", "location": [3943, 3957], "entities": [{"type": "Person", "text": "Drew Armstrong"}]}, {"text": "darmstrong17@bloomberg.net", "location": [3961, 3987], "entities": [{"type": "Age", "text": "darmstrong17@bloomberg.net"}]}]}, {"type": "agentOf", "sentence": "Previous backers including SoftBank's Vision Fund took part in the new financing, as did new investors NovaQuest Capital Management and RTW Investments, Roivant said in a statement on Tuesday.", "score": 0.936028, "arguments": [{"text": "Roivant", "location": [377, 384], "entities": [{"type": "Organization", "text": "Roivant unit Axovant Sciences Ltd."}]}, {"text": "said", "location": [385, 389], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "timeOf", "sentence": "Previous backers including SoftBank's Vision Fund took part in the new financing, as did new investors NovaQuest Capital Management and RTW Investments, Roivant said in a statement on Tuesday.", "score": 0.982818, "arguments": [{"text": "Tuesday", "location": [408, 415], "entities": [{"type": "Date", "text": "Tuesday"}]}, {"text": "said", "location": [385, 389], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "hasAttribute", "sentence": "In August 2017, the company raised $1.1 billion from the Vision Fund, which has placed a series of splashy bets on Internet and other startups but backed few other biotech ventures.", "score": 0.8263, "arguments": [{"text": "company", "location": [437, 444], "entities": [{"type": "Organization", "text": "Roivant unit Axovant Sciences Ltd."}]}, {"text": "$1.1 billion", "location": [452, 464], "entities": [{"type": "Money", "text": "$1.1 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "In August 2017, the company raised $1.1 billion from the Vision Fund, which has placed a series of splashy bets on Internet and other startups but backed few other biotech ventures.", "score": 0.580866, "arguments": [{"text": "Vision Fund", "location": [474, 485], "entities": [{"type": "Organization", "text": "Vision Fund", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "$1.1 billion", "location": [452, 464], "entities": [{"type": "Money", "text": "$1.1 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "Roivant is run by 33-year-old Vivek Ramaswamy, who began his career as a hedge-fund analyst before founding the company.", "score": 0.979968, "arguments": [{"text": "Vivek Ramaswamy", "location": [629, 644], "entities": [{"type": "Person", "text": "Vivek Ramaswamy"}]}, {"text": "33-year-old", "location": [617, 628], "entities": [{"type": "Age", "text": "33-year-old"}]}]}, {"type": "employedBy", "sentence": "Roivant is run by 33-year-old Vivek Ramaswamy, who began his career as a hedge-fund analyst before founding the company.", "score": 0.562841, "arguments": [{"text": "analyst", "location": [683, 690], "entities": [{"type": "Person", "text": "Vivek Ramaswamy"}]}, {"text": "company", "location": [711, 718], "entities": [{"type": "Organization", "text": "Roivant unit Axovant Sciences Ltd."}]}]}], "keywords": [{"text": "NovaQuest Capital Management", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.94041}, {"text": "33-year-old Vivek Ramaswamy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.809217}, {"text": "late-stage pharmaceutical research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.799746}, {"text": "Roivant Sciences Ltd.", "sentiment": {"score": 0.392333, "label": "positive"}, "relevance": 0.786998}, {"text": "research programs", "sentiment": {"score": 0.425516, "label": "positive"}, "relevance": 0.771543}, {"text": "Late-stage clinical trials", "sentiment": {"score": -0.45336, "label": "negative"}, "relevance": 0.759726}, {"text": "latest private biotechnology", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.74145}, {"text": "individual research programs", "sentiment": {"score": 0.417088, "label": "positive"}, "relevance": 0.739472}, {"text": "Forty-nine biotechnology companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.738066}, {"text": "Vision Fund", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.735119}, {"text": "Roivant unit Axovant", "sentiment": {"score": -0.747543, "label": "negative"}, "relevance": 0.735041}, {"text": "Roivant unit Myovant", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.731762}, {"text": "proprietary research pipeline", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.72882}, {"text": "new price tag", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.726644}, {"text": "Moderna Therapeutics Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.726266}, {"text": "larger pharmaceutical players", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.724161}, {"text": "new investor NovaQuest", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.72346}, {"text": "management teams", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.722925}, {"text": "initial public offerings", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.721241}, {"text": "North Carolina-based firm", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.712368}, {"text": "private capital", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.710805}, {"text": "Takeda Pharmaceutical Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.710288}, {"text": "positive final-stage studies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.704659}, {"text": "ultrarare childhood disease", "sentiment": {"score": -0.364089, "label": "negative"}, "relevance": 0.692757}, {"text": "Ramaswamy\u2019s belief", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.691475}, {"text": "editors Drew Armstrong", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.688804}, {"text": "Earlier Setback", "sentiment": {"score": -0.33059, "label": "negative"}, "relevance": 0.670491}, {"text": "late-stage trial", "sentiment": {"score": -0.747543, "label": "negative"}, "relevance": 0.663015}, {"text": "earlier research", "sentiment": {"score": -0.45336, "label": "negative"}, "relevance": 0.658023}, {"text": "late-stage study", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.657601}, {"text": "drug research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.654029}, {"text": "company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.652939}, {"text": "private firms", "sentiment": {"score": 0.392333, "label": "positive"}, "relevance": 0.648991}, {"text": "new financing", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.647824}, {"text": "splashy bets", "sentiment": {"score": -0.220825, "label": "negative"}, "relevance": 0.647518}, {"text": "Roivant subsidiary", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.64549}, {"text": "new funding", "sentiment": {"score": 0.392333, "label": "positive"}, "relevance": 0.641887}, {"text": "new investors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.639659}, {"text": "earlier studies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.638049}, {"text": "biotechnology industry", "sentiment": {"score": 0.392333, "label": "positive"}, "relevance": 0.637533}, {"text": "Axovant setback", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.634898}, {"text": "SoftBank\u2019s Vision", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.634184}, {"text": "parent company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.633848}, {"text": "RTW Investments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.633738}, {"text": "hedge-fund analyst", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.633694}, {"text": "Previous backers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.633681}, {"text": "adequate incentives", "sentiment": {"score": 0.433945, "label": "positive"}, "relevance": 0.630757}, {"text": "private valuations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.629986}, {"text": "pharmaceutical wunderkind", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.629546}, {"text": "drug executives", "sentiment": {"score": 0.433945, "label": "positive"}, "relevance": 0.628758}]}, "extracted_metadata": {"sha1": "f3a75baf9292b1775714f4ba205e095f98cc324b", "filename": "1542123646600.zip-3b4df8aa5ba2e619c4d329dde5c3cad4.xml", "file_type": "json"}, "title": "SoftBank-Backed Biotech Roivant Climbs to $7 Billion Valuation -", "forum_title": "News Wire"}, {"id": "jzKJ-3iYdg-g5c3gRdJ1j-uOHZKahQgwmH_P9QS8lydntlJBxefU8DsG7Mpys7ev", "result_metadata": {"score": 31.951225}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.33, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0.334727, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": "Takeda to vote on $62bn Shire acquisition, looming debt a factor", "object": {"text": "on $62bn Shire acquisition", "keywords": [{"text": "Shire acquisition"}], "entities": [{"type": "Company", "text": "Shire"}]}, "action": {"verb": {"text": "vote", "tense": "future"}, "text": "to vote", "normalized": "to vote"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": "Takeda to vote on $62bn Shire acquisition, looming debt a factor", "object": {"text": "debt", "keywords": [{"text": "debt"}]}, "action": {"verb": {"text": "loom", "tense": "present"}, "text": "looming", "normalized": "loom"}}], "concepts": [], "categories": [{"score": 0.900668, "label": "/business and industrial/company/merger and acquisition"}], "relations": [{"type": "agentOf", "sentence": "Takeda to vote on $62bn Shire acquisition, looming debt a factor", "score": 0.437143, "arguments": [{"text": "Shire", "location": [24, 29], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "acquisition", "location": [30, 41], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}], "keywords": [{"text": "Shire acquisition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.99544}, {"text": "Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.793714}, {"text": "factor", "sentiment": {"score": -0.567553, "label": "negative"}, "relevance": 0.626116}, {"text": "debt", "sentiment": {"score": -0.567553, "label": "negative"}, "relevance": 0.597066}]}, "crawl_date": "2018-11-13T15:26:56Z", "url": "https://www.in-pharmatechnologist.com/Article/2018/11/13/Takeda-to-vote-on-62bn-Shire-acquisition-looming-debt-a-factor", "host": "in-pharmatechnologist.com", "text": "The acquisition will see Takeda become the only pharmaceutical company listed on both the Tokyo Stock Exchange in Japan and the New York Stock Exchange in the US.", "main_image_url": "https://cdn-a.william-reed.com/var/wrbm_gb_food_pharma/storage/images/publications/pharmaceutical-science/in-pharmatechnologist.com/article/2018/11/13/takeda-to-vote-on-62bn-shire-acquisition-looming-debt-a-factor/8834042-1-eng-GB/Takeda-to-vote-on-62bn-Shire-acquisition-looming-debt-a-factor.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-13T00:00:00Z", "enriched_text": {"entities": [{"count": 9, "sentiment": {"score": -0.287268, "label": "negative"}, "text": "Takeda", "relevance": 0.955365, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.280987, "label": "negative"}, "text": "Takeda Pharmaceutical", "relevance": 0.4328, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "\u200b Takeda", "relevance": 0.322965, "type": "Company"}, {"count": 3, "sentiment": {"score": -0.68802, "label": "negative"}, "text": "Shire", "relevance": 0.318305, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 2, "sentiment": {"score": 0.559044, "label": "positive"}, "text": "Shire", "relevance": 0.278133, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tokyo Stock Exchange", "relevance": 0.175253, "type": "Company", "disambiguation": {"subtype": [], "name": "Tokyo Stock Exchange", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo_Stock_Exchange"}}, {"count": 2, "sentiment": {"score": -0.375482, "label": "negative"}, "text": "US", "relevance": 0.161521, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 2, "sentiment": {"score": -0.280987, "label": "negative"}, "text": "new york", "relevance": 0.161162, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.153127, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": -0.243016, "label": "negative"}, "text": "Maggie Lynch", "relevance": 0.14653, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "William Reed Business Media Ltd", "relevance": 0.13037, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.68802, "label": "negative"}, "text": "bowel disease", "relevance": 0.128243, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Brazil", "relevance": 0.103382, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0.350643, "label": "positive"}, "text": "China", "relevance": 0.0952748, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "46%", "relevance": 0.0952748, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "54%", "relevance": 0.0952748, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "3%", "relevance": 0.0952748, "type": "Quantity"}], "sentiment": {"document": {"score": 0.645467, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}]}, "sentence": "Subscribe to our FREE newsletter Subscribe Takeda to vote on $62bn Shire acquisition, looming debt a factor By Maggie Lynch Related tags: acquistion , Debt , sharehoder , new york stock exchange Takeda Pharmaceutical will hold an investor vote next month on the $62bn acquisition of rare disease specialist, Shire.", "object": {"text": "on $62bn Shire acquisition", "keywords": [{"text": "Shire acquisition"}], "entities": [{"type": "Company", "text": "Shire"}]}, "action": {"verb": {"text": "vote", "tense": "future"}, "text": "to vote", "normalized": "to vote"}}, {"subject": {"text": "acquistion , Debt , sharehoder , new york stock exchange Takeda Pharmaceutical", "keywords": [{"text": "stock exchange Takeda"}, {"text": "acquistion"}, {"text": "Debt"}, {"text": "sharehoder"}], "entities": [{"type": "Location", "text": "new york", "disambiguation": {"subtype": ["City"]}}, {"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": "Subscribe to our FREE newsletter Subscribe Takeda to vote on $62bn Shire acquisition, looming debt a factor By Maggie Lynch Related tags: acquistion , Debt , sharehoder , new york stock exchange Takeda Pharmaceutical will hold an investor vote next month on the $62bn acquisition of rare disease specialist, Shire.", "object": {"text": "an investor vote", "keywords": [{"text": "investor vote"}]}, "action": {"verb": {"text": "hold", "tense": "future"}, "text": "will hold", "normalized": "will hold"}}, {"subject": {"text": "Debt burden", "keywords": [{"text": "Debt burden"}]}, "sentence": " Debt burden is a concern for Takeda, as the company is reliant on a $30.9bn (\u20ac27.5bn) bridge loan to finance the acquisition.", "object": {"text": "a concern for Takeda", "keywords": [{"text": "Takeda"}, {"text": "concern"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}], "entities": []}, "sentence": " Debt burden is a concern for Takeda, as the company is reliant on a $30.9bn (\u20ac27.5bn) bridge loan to finance the acquisition.", "object": {"text": "reliant on a $30.9bn (\u20ac27.5bn) bridge loan", "keywords": [{"text": "bridge loan"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}], "entities": []}, "sentence": " Debt burden is a concern for Takeda, as the company is reliant on a $30.9bn (\u20ac27.5bn) bridge loan to finance the acquisition.", "object": {"text": "the acquisition", "keywords": [{"text": "acquisition"}]}, "action": {"verb": {"text": "finance", "tense": "future"}, "text": "to finance", "normalized": "to finance"}}, {"subject": {"text": "The deal", "keywords": [{"text": "deal"}], "entities": []}, "sentence": " The deal needs support from two-thirds of its shareholders.", "object": {"text": "support from two-thirds of its shareholders", "keywords": [{"text": "two-thirds"}, {"text": "shareholders"}, {"text": "support"}]}, "action": {"verb": {"text": "need", "tense": "present"}, "text": "needs", "normalized": "need"}}, {"subject": {"text": "The vote", "keywords": [{"text": "vote"}]}, "sentence": " The vote is set to take place next month, according to Takeda, on December 5 at an extraordinary general meeting (EGM).", "object": {"text": "place", "keywords": [{"text": "place"}]}, "action": {"verb": {"text": "take", "tense": "future"}, "text": "is set to take", "normalized": "be set to take"}}, {"subject": {"text": "The vote", "keywords": [{"text": "vote"}]}, "sentence": " The vote is set to take place next month, according to Takeda, on December 5 at an extraordinary general meeting (EGM).", "object": {"text": "to Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "accord", "tense": "present"}, "text": "according", "normalized": "accord"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda had said previously that this EGM would be held in 2019, but the earlier date means a decision will arrive sooner rather than later.", "object": {"text": "that this EGM would be held in 2019, but the earlier date means a decision will arrive sooner rather than later", "keywords": [{"text": "earlier date"}, {"text": "EGM"}, {"text": "decision"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "had said", "normalized": "have say"}}, {"subject": {"text": "this EGM", "keywords": [{"text": "EGM"}]}, "sentence": " Takeda had said previously that this EGM would be held in 2019, but the earlier date means a decision will arrive sooner rather than later.", "object": {"text": "held in 2019"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "this EGM", "keywords": [{"text": "EGM"}]}, "sentence": " Takeda had said previously that this EGM would be held in 2019, but the earlier date means a decision will arrive sooner rather than later.", "action": {"verb": {"text": "hold", "tense": "future"}, "text": "would be held", "normalized": "would be hold"}}, {"subject": {"text": "the earlier date means a decision", "keywords": [{"text": "earlier date"}, {"text": "decision"}]}, "sentence": " Takeda had said previously that this EGM would be held in 2019, but the earlier date means a decision will arrive sooner rather than later.", "action": {"verb": {"text": "arrive", "tense": "future"}, "text": "will arrive", "normalized": "will arrive"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " In May of 2018, Takeda agreed to buy Shire \u200b with a bid of 46% cash and 54% stock.", "object": {"text": "to buy Shire \u200b with a bid of 46% cash and 54% stock", "keywords": [{"text": "Shire"}, {"text": "bid"}, {"text": "cash"}, {"text": "stock"}], "entities": [{"type": "Quantity", "text": "46"}, {"type": "Quantity", "text": "54"}]}, "action": {"verb": {"text": "agree", "tense": "future"}, "text": "agreed", "normalized": "agree"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " In May of 2018, Takeda agreed to buy Shire \u200b with a bid of 46% cash and 54% stock.", "object": {"text": "Shire \u200b", "keywords": [{"text": "Shire"}]}, "action": {"verb": {"text": "buy", "tense": "future"}, "text": "agreed to buy", "normalized": "agree to buy"}}, {"subject": {"text": "Shire shareholders", "keywords": [{"text": "Shire shareholders"}], "entities": [{"type": "Company", "text": "Shire"}]}, "sentence": " Therefore, Shire shareholders would own around half of the merged company.", "object": {"text": "around half of the merged company", "keywords": [{"text": "merged company"}]}, "action": {"verb": {"text": "own", "tense": "future"}, "text": "would own", "normalized": "would own"}}, {"subject": {"text": "The deal", "keywords": [{"text": "deal"}], "entities": []}, "sentence": " The deal reached this level after Shire initially rejected \u200b Takeda\u2019s proposal, believing it had undervalued the company.", "object": {"text": "this level", "keywords": [{"text": "level"}]}, "action": {"verb": {"text": "reach", "tense": "past"}, "text": "reached", "normalized": "reach"}}, {"subject": {"text": "Shire", "keywords": [{"text": "Shire"}], "entities": [{"type": "Person", "text": "Shire"}]}, "sentence": " The deal reached this level after Shire initially rejected \u200b Takeda\u2019s proposal, believing it had undervalued the company.", "object": {"text": "\u200b Takeda\u2019s proposal", "keywords": [{"text": "Takeda\u2019s proposal"}], "entities": [{"type": "Company", "text": "\u200b Takeda"}]}, "action": {"verb": {"text": "reject", "tense": "past"}, "text": "rejected", "normalized": "reject"}}, {"subject": {"text": "proposal", "keywords": [{"text": "proposal"}]}, "sentence": " The deal reached this level after Shire initially rejected \u200b Takeda\u2019s proposal, believing it had undervalued the company.", "object": {"text": "\u200b Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "\u200b Takeda"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "The deal", "keywords": [{"text": "deal"}], "entities": []}, "sentence": " The deal reached this level after Shire initially rejected \u200b Takeda\u2019s proposal, believing it had undervalued the company.", "object": {"text": "it had undervalued the company", "keywords": [{"text": "company"}], "entities": []}, "action": {"verb": {"text": "believe", "tense": "present"}, "text": "believing", "normalized": "believe"}}, {"subject": {"text": "The acquisition", "keywords": [{"text": "acquisition"}]}, "sentence": " The acquisition will see Takeda become the only pharmaceutical company listed on both the Tokyo Stock Exchange in Japan and the New York Stock Exchange in the US.", "object": {"text": "Takeda become the only pharmaceutical company listed on both the Tokyo Stock Exchange in Japan and the New York Stock Exchange in the US", "keywords": [{"text": "Tokyo Stock Exchange"}, {"text": "New York Stock"}, {"text": "pharmaceutical company"}, {"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Tokyo Stock Exchange", "disambiguation": {"subtype": ["Company"], "name": "Tokyo Stock Exchange", "dbpedia_resource": "http://dbpedia.org/resource/Tokyo_Stock_Exchange"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Location", "text": "new york", "disambiguation": {"subtype": ["City"]}}, {"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "see", "tense": "future"}, "text": "will see", "normalized": "will see"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Should the acquisition go through, Takeda expects recurring pre-tax cost synergies for the combined group to reach at least $1.4bn annually.", "object": {"text": "recurring pre-tax cost synergies for the combined group to reach at least $1.4bn annually", "keywords": [{"text": "pre-tax cost synergies"}, {"text": "group"}]}, "action": {"verb": {"text": "expect", "tense": "present"}, "text": "expects", "normalized": "expect"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Should the acquisition go through, Takeda expects recurring pre-tax cost synergies for the combined group to reach at least $1.4bn annually.", "object": {"text": "pre-tax cost synergies", "keywords": [{"text": "pre-tax cost synergies"}]}, "action": {"verb": {"text": "recur", "tense": "present"}, "text": "recurring", "normalized": "recur"}}, {"subject": {"text": "European regulators \u200b", "keywords": [{"text": "European regulators"}]}, "sentence": " European regulators \u200b have yet to approve this transaction.", "object": {"text": "yet to approve this transaction", "keywords": [{"text": "transaction"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "European regulators \u200b", "keywords": [{"text": "European regulators"}]}, "sentence": " European regulators \u200b have yet to approve this transaction.", "object": {"text": "this transaction", "keywords": [{"text": "transaction"}]}, "action": {"verb": {"text": "approve", "tense": "future"}, "text": "to approve", "normalized": "to approve"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Per the acquisition, Takeda has proposed divesting Shire\u2019s drug SHP647 \u200b in an aim to address any European concerns regarding overlap in inflammatory bowel disease drug development.", "object": {"text": "proposed divesting Shire\u2019s drug SHP647 \u200b", "keywords": [{"text": "divesting Shire"}, {"text": "drug SHP647"}], "entities": [{"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Per the acquisition, Takeda has proposed divesting Shire\u2019s drug SHP647 \u200b in an aim to address any European concerns regarding overlap in inflammatory bowel disease drug development.", "object": {"text": "divesting Shire\u2019s drug SHP647 \u200b", "keywords": [{"text": "Shire\u2019s drug"}, {"text": "SHP647"}], "entities": [{"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "propose", "tense": "past"}, "text": "proposed", "normalized": "propose"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Per the acquisition, Takeda has proposed divesting Shire\u2019s drug SHP647 \u200b in an aim to address any European concerns regarding overlap in inflammatory bowel disease drug development.", "object": {"text": "Shire\u2019s drug SHP647 \u200b", "keywords": [{"text": "Shire"}, {"text": "drug SHP647"}], "entities": [{"type": "Location", "text": "Shire", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "divest", "tense": "present"}, "text": "has proposed divesting", "normalized": "have propose divest"}}, {"subject": {"text": "any European concerns", "keywords": [{"text": "European concerns"}]}, "sentence": " Per the acquisition, Takeda has proposed divesting Shire\u2019s drug SHP647 \u200b in an aim to address any European concerns regarding overlap in inflammatory bowel disease drug development.", "object": {"text": "overlap in inflammatory bowel disease drug development", "keywords": [{"text": "inflammatory bowel disease"}], "entities": [{"type": "HealthCondition", "text": "bowel disease"}]}, "action": {"verb": {"text": "regard", "tense": "present"}, "text": "regarding", "normalized": "regard"}}, {"subject": {"text": "Regulators in the US, Japan, China, and Brazil", "keywords": [{"text": "Regulators"}, {"text": "Brazil"}, {"text": "Japan"}, {"text": "China"}], "entities": [{"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Brazil", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Regulators in the US, Japan, China, and Brazil have already approved this acquisition.", "object": {"text": "already approved this acquisition", "keywords": [{"text": "acquisition"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Regulators in the US, Japan, China, and Brazil", "keywords": [{"text": "Regulators"}, {"text": "Brazil"}, {"text": "Japan"}, {"text": "China"}], "entities": [{"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Brazil", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Regulators in the US, Japan, China, and Brazil have already approved this acquisition.", "object": {"text": "this acquisition", "keywords": [{"text": "acquisition"}]}, "action": {"verb": {"text": "approve", "tense": "past"}, "text": "approved", "normalized": "approve"}}, {"subject": {"text": "London-listed Shire\u2019s shares", "keywords": [{"text": "London-listed Shire"}, {"text": "shares"}]}, "sentence": " London-listed Shire\u2019s shares rose 3% recently, hitting the highest share level since Takeda first announced its interest in acquiring the company.", "object": {"text": "3%", "entities": [{"type": "Quantity", "text": "3"}]}, "action": {"verb": {"text": "rise", "tense": "past"}, "text": "rose", "normalized": "rise"}}, {"subject": {"text": "London-listed Shire\u2019s shares", "keywords": [{"text": "London-listed Shire"}, {"text": "shares"}]}, "sentence": " London-listed Shire\u2019s shares rose 3% recently, hitting the highest share level since Takeda first announced its interest in acquiring the company.", "object": {"text": "the highest share level", "keywords": [{"text": "highest share level"}]}, "action": {"verb": {"text": "hit", "tense": "present"}, "text": "hitting", "normalized": "hit"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " London-listed Shire\u2019s shares rose 3% recently, hitting the highest share level since Takeda first announced its interest in acquiring the company.", "object": {"text": "its interest"}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " London-listed Shire\u2019s shares rose 3% recently, hitting the highest share level since Takeda first announced its interest in acquiring the company.", "object": {"text": "the company", "keywords": [{"text": "company"}], "entities": []}, "action": {"verb": {"text": "acquire", "tense": "present"}, "text": "acquiring", "normalized": "acquire"}}, {"subject": {"text": "all contents of this web site", "keywords": [{"text": "web site"}, {"text": "contents"}], "entities": []}, "sentence": " Copyright - Unless otherwise stated all contents of this web site are \u00a9 2018 - William Reed Business Media Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions Subscribe to our FREE newsletter Subscribe", "object": {"text": "\u00a9 2018 - William Reed Business Media Ltd - All Rights Reserved", "keywords": [{"text": "William Reed Business"}, {"text": "Media"}, {"text": "Rights"}], "entities": [{"type": "Company", "text": "William Reed Business Media Ltd"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Full details for the use of materials on this site", "keywords": [{"text": "details"}, {"text": "materials"}, {"text": "site"}], "entities": []}, "sentence": " Copyright - Unless otherwise stated all contents of this web site are \u00a9 2018 - William Reed Business Media Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions Subscribe to our FREE newsletter Subscribe", "action": {"verb": {"text": "find", "tense": "future"}, "text": "can be found", "normalized": "can be find"}}], "concepts": [{"text": "Stock", "relevance": 0.986305, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Stock market", "relevance": 0.870781, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "Mergers and acquisitions", "relevance": 0.769157, "dbpedia_resource": "http://dbpedia.org/resource/Mergers_and_acquisitions"}, {"text": "Tokyo Stock Exchange", "relevance": 0.722041, "dbpedia_resource": "http://dbpedia.org/resource/Tokyo_Stock_Exchange"}, {"text": "New York Stock Exchange", "relevance": 0.694121, "dbpedia_resource": "http://dbpedia.org/resource/New_York_Stock_Exchange"}, {"text": "Inflammatory bowel disease", "relevance": 0.662101, "dbpedia_resource": "http://dbpedia.org/resource/Inflammatory_bowel_disease"}, {"text": "Pharmacology", "relevance": 0.632165, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Share", "relevance": 0.623796, "dbpedia_resource": "http://dbpedia.org/resource/Share_(finance)"}, {"text": "Security", "relevance": 0.592316, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Copyright", "relevance": 0.588204, "dbpedia_resource": "http://dbpedia.org/resource/Copyright"}, {"text": "Stock exchange", "relevance": 0.58605, "dbpedia_resource": "http://dbpedia.org/resource/Stock_exchange"}, {"text": "Debt", "relevance": 0.582294, "dbpedia_resource": "http://dbpedia.org/resource/Debt"}, {"text": "Inflammation", "relevance": 0.575607, "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}, {"text": "Corporate finance", "relevance": 0.553209, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_finance"}, {"text": "All rights reserved", "relevance": 0.529005, "dbpedia_resource": "http://dbpedia.org/resource/All_rights_reserved"}, {"text": "Japan", "relevance": 0.515391, "dbpedia_resource": "http://dbpedia.org/resource/Japan"}, {"text": "Tokyo", "relevance": 0.502369, "dbpedia_resource": "http://dbpedia.org/resource/Tokyo"}, {"text": "Ulcerative colitis", "relevance": 0.491103, "dbpedia_resource": "http://dbpedia.org/resource/Ulcerative_colitis"}, {"text": "Shareholder", "relevance": 0.462613, "dbpedia_resource": "http://dbpedia.org/resource/Shareholder"}, {"text": "European Union", "relevance": 0.454505, "dbpedia_resource": "http://dbpedia.org/resource/European_Union"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.45034, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Economy of Japan", "relevance": 0.416477, "dbpedia_resource": "http://dbpedia.org/resource/Economy_of_Japan"}, {"text": "Reed Business Information", "relevance": 0.407252, "dbpedia_resource": "http://dbpedia.org/resource/Reed_Business_Information"}], "categories": [{"score": 0.728868, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.463364, "label": "/finance/financial news"}, {"score": 0.301098, "label": "/finance/investing/day trading"}], "relations": [{"type": "affectedBy", "sentence": "Subscribe to our FREE newsletter Subscribe Takeda to vote on $62bn Shire acquisition, looming debt a factor By Maggie Lynch Related tags: acquistion , Debt , sharehoder , new york stock exchange Takeda Pharmaceutical will hold an investor vote next month on the $62bn acquisition of rare disease specialist, Shire.", "score": 0.474191, "arguments": [{"text": "Subscribe Takeda", "location": [33, 49], "entities": [{"type": "Organization", "text": "Subscribe Takeda"}]}, {"text": "acquisition", "location": [73, 84], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "managerOf", "sentence": "Therefore, Shire shareholders would own around half of the merged company.", "score": 0.462371, "arguments": [{"text": "Shire", "location": [855, 860], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "shareholders", "location": [861, 873], "entities": [{"type": "Organization", "text": "shareholders", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "The deal reached this level after Shire initially rejected   Takeda's proposal, believing it had undervalued the company.", "score": 0.8993, "arguments": [{"text": "Shire", "location": [953, 958], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "rejected", "location": [969, 977], "entities": [{"type": "EventCommunication", "text": "rejected"}]}]}, {"type": "affectedBy", "sentence": "The deal reached this level after Shire initially rejected   Takeda's proposal, believing it had undervalued the company.", "score": 0.392631, "arguments": [{"text": "Takeda", "location": [980, 986], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical"}]}, {"text": "rejected", "location": [969, 977], "entities": [{"type": "EventCommunication", "text": "rejected"}]}]}, {"type": "agentOf", "sentence": "The deal reached this level after Shire initially rejected   Takeda's proposal, believing it had undervalued the company.", "score": 0.99367, "arguments": [{"text": "Takeda", "location": [980, 986], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical"}]}, {"text": "proposal", "location": [989, 997], "entities": [{"type": "EventCommunication", "text": "proposal"}]}]}, {"type": "employedBy", "sentence": "European regulators   have yet to approve this transaction.", "score": 0.600623, "arguments": [{"text": "regulators", "location": [1354, 1364], "entities": [{"type": "Person", "text": "regulators"}]}, {"text": "European", "location": [1345, 1353], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Per the acquisition, Takeda has proposed divesting Shire's drug SHP647   in an aim to address any European concerns regarding overlap in inflammatory bowel disease drug development.", "score": 0.560102, "arguments": [{"text": "Takeda", "location": [1426, 1432], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical"}]}, {"text": "SHP647", "location": [1469, 1475], "entities": [{"type": "Facility", "text": "SHP647"}]}]}, {"type": "residesIn", "sentence": "Per the acquisition, Takeda has proposed divesting Shire's drug SHP647   in an aim to address any European concerns regarding overlap in inflammatory bowel disease drug development.", "score": 0.289976, "arguments": [{"text": "Shire", "location": [1456, 1461], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "SHP647", "location": [1469, 1475], "entities": [{"type": "Facility", "text": "SHP647"}]}]}, {"type": "locatedAt", "sentence": "Per the acquisition, Takeda has proposed divesting Shire's drug SHP647   in an aim to address any European concerns regarding overlap in inflammatory bowel disease drug development.", "score": 0.345071, "arguments": [{"text": "drug", "location": [1464, 1468], "entities": [{"type": "Substance", "text": "drug"}]}, {"text": "SHP647", "location": [1469, 1475], "entities": [{"type": "Facility", "text": "SHP647"}]}]}, {"type": "agentOf", "sentence": "London-listed Shire's shares rose 3% recently, hitting the highest share level since Takeda first announced its interest in acquiring the company.", "score": 0.827937, "arguments": [{"text": "Takeda", "location": [1759, 1765], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical"}]}, {"text": "announced", "location": [1772, 1781], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "managerOf", "sentence": "Copyright - Unless otherwise stated all contents of this web site are \u00a9 2018 - William Reed Business Media Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions Subscribe to our FREE newsletter Subscribe", "score": 0.257652, "arguments": [{"text": "William Reed", "location": [1900, 1912], "entities": [{"type": "Person", "text": "William Reed"}]}, {"text": "Business Media Ltd - All Rights Reserved", "location": [1913, 1953], "entities": [{"type": "Organization", "text": "Business Media Ltd - All Rights Reserved"}]}]}, {"type": "agentOf", "sentence": "Subscribe to our FREE newsletter Subscribe Takeda to vote on $62bn Shire acquisition, looming debt a factor By Maggie Lynch Related tags: acquistion , Debt , sharehoder , new york stock exchange Takeda Pharmaceutical will hold an investor vote next month on the $62bn acquisition of rare disease specialist, Shire.", "score": 0.487554, "arguments": [{"text": "Shire", "location": [67, 72], "entities": [{"type": "Person", "text": "Shire"}]}, {"text": "acquisition", "location": [73, 84], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "affectedBy", "sentence": "Subscribe to our FREE newsletter Subscribe Takeda to vote on $62bn Shire acquisition, looming debt a factor By Maggie Lynch Related tags: acquistion , Debt , sharehoder , new york stock exchange Takeda Pharmaceutical will hold an investor vote next month on the $62bn acquisition of rare disease specialist, Shire.", "score": 0.535131, "arguments": [{"text": "investor", "location": [230, 238], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical"}]}, {"text": "vote", "location": [239, 243], "entities": [{"type": "EventElection", "text": "vote"}]}]}, {"type": "timeOf", "sentence": "Subscribe to our FREE newsletter Subscribe Takeda to vote on $62bn Shire acquisition, looming debt a factor By Maggie Lynch Related tags: acquistion , Debt , sharehoder , new york stock exchange Takeda Pharmaceutical will hold an investor vote next month on the $62bn acquisition of rare disease specialist, Shire.", "score": 0.848785, "arguments": [{"text": "next month", "location": [244, 254], "entities": [{"type": "Date", "text": "next month"}]}, {"text": "vote", "location": [239, 243], "entities": [{"type": "EventElection", "text": "vote"}]}]}, {"type": "partOf", "sentence": "The deal needs support from two-thirds of its shareholders.", "score": 0.928525, "arguments": [{"text": "shareholders", "location": [487, 499], "entities": [{"type": "Organization", "text": "shareholders", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "its", "location": [483, 486], "entities": [{"type": "Organization", "text": "Subscribe Takeda"}]}]}, {"type": "timeOf", "sentence": "The vote is set to take place next month, according to Takeda, on December 5 at an extraordinary general meeting (EGM).", "score": 0.771254, "arguments": [{"text": "next month", "location": [531, 541], "entities": [{"type": "Date", "text": "next month"}]}, {"text": "vote", "location": [505, 509], "entities": [{"type": "EventElection", "text": "vote"}]}]}, {"type": "agentOf", "sentence": "Takeda had said previously that this EGM would be held in 2019, but the earlier date means a decision will arrive sooner rather than later.", "score": 0.982225, "arguments": [{"text": "Takeda", "location": [621, 627], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical"}]}, {"text": "said", "location": [632, 636], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "timeOf", "sentence": "In May of 2018, Takeda agreed to buy Shire   with a bid of 46% cash and 54% stock.", "score": 0.70313, "arguments": [{"text": "May of 2018", "location": [764, 775], "entities": [{"type": "Date", "text": "May of 2018"}]}, {"text": "agreed", "location": [784, 790], "entities": [{"type": "EventCommunication", "text": "agreed"}]}]}, {"type": "agentOf", "sentence": "In May of 2018, Takeda agreed to buy Shire   with a bid of 46% cash and 54% stock.", "score": 0.997436, "arguments": [{"text": "Takeda", "location": [777, 783], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical"}]}, {"text": "agreed", "location": [784, 790], "entities": [{"type": "EventCommunication", "text": "agreed"}]}]}], "keywords": [{"text": "Takeda", "sentiment": {"score": -0.00823426, "label": "negative"}, "relevance": 0.904493}, {"text": "newsletter Subscribe Takeda", "sentiment": {"score": 0.559044, "label": "positive"}, "relevance": 0.817879}, {"text": "stock exchange Takeda", "sentiment": {"score": -0.280987, "label": "negative"}, "relevance": 0.783063}, {"text": "FREE newsletter Subscribe", "sentiment": {"score": 0.63149, "label": "positive"}, "relevance": 0.69249}, {"text": "new york stock", "sentiment": {"score": -0.280987, "label": "negative"}, "relevance": 0.664788}, {"text": "york stock exchange", "sentiment": {"score": -0.280987, "label": "negative"}, "relevance": 0.659926}, {"text": "Shire acquisition", "sentiment": {"score": 0.559044, "label": "positive"}, "relevance": 0.563258}, {"text": "Maggie Lynch Related", "sentiment": {"score": -0.243016, "label": "negative"}, "relevance": 0.511328}, {"text": "rare disease specialist", "sentiment": {"score": -0.280987, "label": "negative"}, "relevance": 0.505692}, {"text": "pre-tax cost synergies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.495896}, {"text": "extraordinary general meeting", "sentiment": {"score": 0.437898, "label": "positive"}, "relevance": 0.490765}, {"text": "Shire shareholders", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.488904}, {"text": "Tokyo Stock Exchange", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.478284}, {"text": "London-listed Shire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.477967}, {"text": "inflammatory bowel disease", "sentiment": {"score": -0.68802, "label": "negative"}, "relevance": 0.473481}, {"text": "highest share level", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.472351}, {"text": "William Reed Business", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.470562}, {"text": "Shire\u2019s drug", "sentiment": {"score": -0.68802, "label": "negative"}, "relevance": 0.461448}, {"text": "investor vote", "sentiment": {"score": -0.280987, "label": "negative"}, "relevance": 0.428751}, {"text": "Debt burden", "sentiment": {"score": -0.732828, "label": "negative"}, "relevance": 0.425704}, {"text": "Conditions Subscribe", "sentiment": {"score": 0.703937, "label": "positive"}, "relevance": 0.421576}, {"text": "merged company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.407889}, {"text": "bridge loan", "sentiment": {"score": -0.373632, "label": "negative"}, "relevance": 0.407528}, {"text": "earlier date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.402671}, {"text": "European regulators", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.402653}, {"text": "pharmaceutical company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.40062}, {"text": "web site", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.392551}, {"text": "drug development", "sentiment": {"score": -0.68802, "label": "negative"}, "relevance": 0.391355}, {"text": "European concerns", "sentiment": {"score": -0.68802, "label": "negative"}, "relevance": 0.389295}, {"text": "EGM", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.372076}, {"text": "deal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.335903}, {"text": "acquistion", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.333975}, {"text": "Japan", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.330564}, {"text": "two-thirds", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.327998}, {"text": "overlap", "sentiment": {"score": -0.68802, "label": "negative"}, "relevance": 0.321359}, {"text": "sharehoder", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.318531}, {"text": "factor", "sentiment": {"score": -0.243016, "label": "negative"}, "relevance": 0.318322}, {"text": "support", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.317276}, {"text": "place", "sentiment": {"score": 0.479668, "label": "positive"}, "relevance": 0.316914}, {"text": "bid", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.316501}, {"text": "tags", "sentiment": {"score": -0.243016, "label": "negative"}, "relevance": 0.315857}, {"text": "proposal", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.315715}, {"text": "shares", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.315565}, {"text": "group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.315538}, {"text": "transaction", "sentiment": {"score": 0.572829, "label": "positive"}, "relevance": 0.315403}, {"text": "contents", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.315319}, {"text": "Media", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.315263}, {"text": "Rights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.315244}, {"text": "details", "sentiment": {"score": 0.703937, "label": "positive"}, "relevance": 0.315225}, {"text": "materials", "sentiment": {"score": 0.703937, "label": "positive"}, "relevance": 0.315202}]}, "extracted_metadata": {"sha1": "ccb1338bf26749d374a6942f7f37392913152ae6", "filename": "1542122816275.zip-ecfb5c18b1354dfa4228b8645135791d.xml", "file_type": "json"}, "title": "Takeda to vote on $62bn Shire acquisition, looming debt a factor"}, {"id": "Pk_Gcs6_OFAsCrO4dTwgnqejTqxnTQka-qQbuBTAm0ngMQHqGRBvokFUscrtj42x", "result_metadata": {"score": 31.87366}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Barclays", "relevance": 0.972986, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "United Kingdom", "relevance": 0.700474, "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.5607, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.759305, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "BARCLAYS PLC UK", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.970653}, {"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.621373}, {"text": "Regulatory Announcement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533011}]}, "crawl_date": "2018-11-13T16:58:05Z", "url": "https://www.businesswire.com/news/home/20181113005677/en/BARCLAYS-PLC-UK-Regulatory-Announcement-Form-8.3", "host": "businesswire.com", "text": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC. are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "main_image_url": "http://www.businesswire.com/images/bwlogo_square.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-13T12:48:00-06:00", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.744131, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.71099, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.576908, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Class of Product Nature", "relevance": 0.572145, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS", "relevance": 0.551523, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.542889, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Contacts BARCLAYS PLC", "relevance": 0.526654, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.512807, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.469844, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.453036, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,255,100 1.29%", "relevance": 0.453036, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.453036, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.453036, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,036,064 1.39%", "relevance": 0.453036, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,845,486 1.49%", "relevance": 0.453036, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,497,625 1.57%", "relevance": 0.453036, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,403,150 4.20%", "relevance": 0.453036, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,694,325 4.24%", "relevance": 0.453036, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.453036, "type": "Quantity"}], "sentiment": {"document": {"score": 0.649075, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "33,403,150 4.20% 33,694,325 4.24% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "33,403,150 4.20"}, {"type": "Quantity", "text": "33,694,325 4.24"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,036,064 1.39% 12,497,625 1.57% (2) Cash-settled derivatives: 11,845,486 1.49% 10,255,100 1.29% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% TOTAL: 33,403,150 4.20% 33,694,325 4.24% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 13 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Receipt", "keywords": [{"text": "Receipt"}]}, "sentence": " Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 659263 Time of Receipt (offset from UTC): 20181113T121206+0000 Contacts BARCLAYS PLC", "object": {"text": "from UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}], "concepts": [{"text": "Option", "relevance": 0.977103, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.738773, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.695562, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.619561, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.505342, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.41033, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Options", "relevance": 0.403988, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Moneyness", "relevance": 0.378444, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Security", "relevance": 0.347536, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "United States dollar", "relevance": 0.331521, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}, {"text": "Contract", "relevance": 0.328972, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Bond", "relevance": 0.324281, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "December", "relevance": 0.313885, "dbpedia_resource": "http://dbpedia.org/resource/December"}, {"text": "Unit type", "relevance": 0.302197, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Barclays", "relevance": 0.29509, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}], "categories": [{"score": 0.576702, "label": "/real estate/buying and selling homes"}, {"score": 0.472151, "label": "/finance/financial news"}, {"score": 0.450726, "label": "/finance/investing"}], "relations": [{"type": "populationOf", "sentence": "LONDON- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \"Code\") 1.", "score": 0.465196, "arguments": [{"text": "8.3", "location": [13, 16], "entities": [{"type": "Cardinal", "text": "8.3"}]}, {"text": "LONDON", "location": [0, 6], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC.", "score": 0.419441, "arguments": [{"text": "person", "location": [7769, 7775], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [7801, 7813], "entities": [{"type": "Organization", "text": "BARCLAYS PLC Category Code", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "basedIn", "sentence": "Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 659263 Time of Receipt (offset from UTC): 20181113T121206+0000 Contacts BARCLAYS PLC", "score": 0.626381, "arguments": [{"text": "UTC", "location": [10144, 10147], "entities": [{"type": "Organization", "text": "UTC"}]}, {"text": "Receipt", "location": [10123, 10130], "entities": [{"type": "GeopoliticalEntity", "text": "Receipt"}]}]}, {"type": "hasAttribute", "sentence": "sale Number of Price per unit security securities ADR Purchase 3,892 19.7795 USD ADR Purchase 6,370 19.8575 USD ADR Purchase 13,817 19.7356 USD ADR Purchase 382,720 19.7857 USD ADR Sale 6,370 19.8575 USD ADR Sale 10,000 19.8017 USD ADR Sale 13,817 19.7356 USD ADR Sale 144,912 19.7795 USD ADR Sale 241,700 19.7894 USD ADR Sale 243,646 19.7893 USD Ordinary NPV Purchase 100 4,515.5000 JPY Ordinary NPV Purchase 400 4,550.5500 JPY Ordinary NPV Purchase 500 4,514.8000 JPY Ordinary NPV Purchase 600 4,518.5000 JPY Ordinary NPV Purchase 700 4,542.6714 JPY Ordinary NPV Purchase 800 4,564.2500 JPY Ordinary NPV Purchase 1,300 4,515.7692 JPY Ordinary NPV Purchase 1,800 4,569.1666 JPY Ordinary NPV Purchase 1,900 4,545.8421 JPY Ordinary NPV Purchase 2,300 4,509.5652 JPY Ordinary NPV Purchase 2,400 4,535.7916 JPY Ordinary NPV Purchase 2,900 4,501.6552 JPY Ordinary NPV Purchase 3,700 4,548.1027 JPY Ordinary NPV Purchase 4,000 4,571.9000 JPY Ordinary NPV Purchase 4,100 4,526.8292 JPY Ordinary NPV Purchase", "score": 0.658918, "arguments": [{"text": "USD ADR Sale", "location": [2706, 2718], "entities": [{"type": "Organization", "text": "USD ADR Sale"}]}, {"text": "10,000 19.8017 USD", "location": [2719, 2737], "entities": [{"type": "Money", "text": "10,000 19.8017 USD", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "sale Number of Price per unit security securities ADR Purchase 3,892 19.7795 USD ADR Purchase 6,370 19.8575 USD ADR Purchase 13,817 19.7356 USD ADR Purchase 382,720 19.7857 USD ADR Sale 6,370 19.8575 USD ADR Sale 10,000 19.8017 USD ADR Sale 13,817 19.7356 USD ADR Sale 144,912 19.7795 USD ADR Sale 241,700 19.7894 USD ADR Sale 243,646 19.7893 USD Ordinary NPV Purchase 100 4,515.5000 JPY Ordinary NPV Purchase 400 4,550.5500 JPY Ordinary NPV Purchase 500 4,514.8000 JPY Ordinary NPV Purchase 600 4,518.5000 JPY Ordinary NPV Purchase 700 4,542.6714 JPY Ordinary NPV Purchase 800 4,564.2500 JPY Ordinary NPV Purchase 1,300 4,515.7692 JPY Ordinary NPV Purchase 1,800 4,569.1666 JPY Ordinary NPV Purchase 1,900 4,545.8421 JPY Ordinary NPV Purchase 2,300 4,509.5652 JPY Ordinary NPV Purchase 2,400 4,535.7916 JPY Ordinary NPV Purchase 2,900 4,501.6552 JPY Ordinary NPV Purchase 3,700 4,548.1027 JPY Ordinary NPV Purchase 4,000 4,571.9000 JPY Ordinary NPV Purchase 4,100 4,526.8292 JPY Ordinary NPV Purchase", "score": 0.693357, "arguments": [{"text": "ADR Sale", "location": [2738, 2746], "entities": [{"type": "Organization", "text": "ADR Sale"}]}, {"text": "10,000 19.8017 USD", "location": [2719, 2737], "entities": [{"type": "Money", "text": "10,000 19.8017 USD", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "employedBy", "sentence": "4,515.9571 JPY Ordinary NPV Sale 11,300 4,557.5575 JPY Ordinary NPV Sale 27,300 4,548.9890 JPY Ordinary NPV Sale 41,300 4,559.0000 JPY Ordinary NPV Sale 41,400 4,540.0458 JPY Ordinary NPV Sale 44,800 4,519.2366 JPY Ordinary NPV Sale 46,300 4,541.5550 JPY Ordinary NPV Sale 60,000 4,533.8600 JPY Ordinary NPV Sale 154,300 4,525.8476 JPY Ordinary NPV Sale 344,000 4,531.1872 JPY Ordinary NPV Sale 370,000 4,531.8018 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV CFD Long 38,600 4,559.0000 JPY Ordinary NPV SWAP Long 38,600 4,559.0000 JPY Ordinary NPV SWAP Short 900 4,546.3111 JPY Ordinary NPV CFD Short 15,500 4,500.4500 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing,", "score": 0.500498, "arguments": [{"text": "Cash", "location": [4959, 4963], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Product Nature", "location": [5005, 5019], "entities": [{"type": "Organization", "text": "Product Nature", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "4,515.9571 JPY Ordinary NPV Sale 11,300 4,557.5575 JPY Ordinary NPV Sale 27,300 4,548.9890 JPY Ordinary NPV Sale 41,300 4,559.0000 JPY Ordinary NPV Sale 41,400 4,540.0458 JPY Ordinary NPV Sale 44,800 4,519.2366 JPY Ordinary NPV Sale 46,300 4,541.5550 JPY Ordinary NPV Sale 60,000 4,533.8600 JPY Ordinary NPV Sale 154,300 4,525.8476 JPY Ordinary NPV Sale 344,000 4,531.1872 JPY Ordinary NPV Sale 370,000 4,531.8018 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV CFD Long 38,600 4,559.0000 JPY Ordinary NPV SWAP Long 38,600 4,559.0000 JPY Ordinary NPV SWAP Short 900 4,546.3111 JPY Ordinary NPV CFD Short 15,500 4,500.4500 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing,", "score": 0.610211, "arguments": [{"text": "i", "location": [5347, 5348], "entities": [{"type": "Person", "text": "JPY Ordinary NPV Purchase"}]}, {"text": "Writing", "location": [5350, 5357], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [6321, 6327], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [6338, 6345], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 13 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [7247, 7253], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [7261, 7265], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the \"Code\") 1.", "score": 0.522588, "arguments": [{"text": "Rule 8", "location": [7693, 7699], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [7707, 7720], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [7328, 7352], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [7320, 7325], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [9839, 9863], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [9831, 9836], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [7487, 7492], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [7506, 7533], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [9998, 10003], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [10017, 10044], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}], "keywords": [{"text": "JPY Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.99175}, {"text": "Ordinary NPV Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.764836}, {"text": "Ordinary NPV Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.719861}, {"text": "Ordinary NPV Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.433299}, {"text": "USD Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.431423}, {"text": "Ordinary NPV CFD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.429329}, {"text": "Ordinary NPV SWAP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.428941}, {"text": "securities Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.42563}, {"text": "relevant securities", "sentiment": {"score": 0.229926, "label": "positive"}, "relevance": 0.423611}, {"text": "NPV Call Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.379955}, {"text": "NPV Put Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.364937}, {"text": "NPV CFD Short", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.354986}, {"text": "NPV SWAP Short", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.354665}, {"text": "NPV SWAP Long", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.354489}, {"text": "USD ADR Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.342777}, {"text": "Options Written", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.335085}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.32865}, {"text": "USD ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.284168}, {"text": "supplemental form", "sentiment": {"score": 0.425721, "label": "positive"}, "relevance": 0.27158}, {"text": "open positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.265936}, {"text": "short positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.265429}, {"text": "Product description e.g.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.264031}, {"text": "relevant security Product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.263213}, {"text": "security Product description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.26253}, {"text": "class", "sentiment": {"score": -0.251285, "label": "negative"}, "relevance": 0.262066}, {"text": "Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.261489}, {"text": "unit security securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.259354}, {"text": "Options Purchased", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.258996}, {"text": "securities ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.249151}, {"text": "number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.245872}, {"text": "person", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.240418}, {"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.240156}, {"text": "new securities", "sentiment": {"score": 0.582177, "label": "positive"}, "relevance": 0.240083}, {"text": "Barclays PLC.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.239531}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.239305}, {"text": "Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.239276}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.238952}, {"text": "relevant Purchase/sale Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.23877}, {"text": "disclosure", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.238544}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.238051}, {"text": "monetary amounts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.237685}, {"text": "details", "sentiment": {"score": 0.0877267, "label": "positive"}, "relevance": 0.237631}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.237361}, {"text": "Short Positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.237059}, {"text": "relevant description reference", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.236839}, {"text": "relevant security Nature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.236177}, {"text": "stock-settled derivative positions", "sentiment": {"score": -0.27481, "label": "negative"}, "relevance": 0.236055}, {"text": "PUBLIC OPENING POSITION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235956}, {"text": "securities Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235845}, {"text": "cash-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.235117}]}, "extracted_metadata": {"sha1": "4bab2b687516be0011d21f767afa22d617d134e7", "filename": "1542128285088.zip-8885d13e0d299f962fa43a75a0e2ab58.xml", "file_type": "json"}, "title": "BARCLAYS PLC UK Regulatory Announcement: Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD", "forum_title": "All News | Business Wire"}, {"id": "qbEIvWtUgtqzGU4nBNbl2DBtHexHuM903578k_Pc1IkOKc3knRV8Z5b-T7pVUbRp", "result_metadata": {"score": 31.87366}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Barclays", "relevance": 0.972986, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "United Kingdom", "relevance": 0.700474, "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.5607, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.759305, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "BARCLAYS PLC UK", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.970653}, {"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.621373}, {"text": "Regulatory Announcement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533011}]}, "crawl_date": "2018-11-14T14:34:42Z", "url": "https://www.businesswire.com/news/home/20181114005521/en/BARCLAYS-PLC-UK-Regulatory-Announcement-Form-8.3", "host": "businesswire.com", "text": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC. are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "main_image_url": "http://www.businesswire.com/images/bwlogo_square.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-14T13:45:00-06:00", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.737473, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.705146, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.572711, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Class of Product Nature", "relevance": 0.561611, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS", "relevance": 0.54672, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.542654, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Contacts BARCLAYS PLC", "relevance": 0.519278, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.512164, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.46727, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.451315, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,255,100 1.29%", "relevance": 0.451315, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.451315, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.451315, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,035,954 1.39%", "relevance": 0.451315, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,851,586 1.49%", "relevance": 0.451315, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,251,115 1.54%", "relevance": 0.451315, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,409,140 4.20%", "relevance": 0.451315, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,447,815 4.21%", "relevance": 0.451315, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.451315, "type": "Quantity"}], "sentiment": {"document": {"score": 0.643736, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "33,409,140 4.20% 33,447,815 4.21% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "33,409,140 4.20"}, {"type": "Quantity", "text": "33,447,815 4.21"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,035,954 1.39% 12,251,115 1.54% (2) Cash-settled derivatives: 11,851,586 1.49% 10,255,100 1.29% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% TOTAL: 33,409,140 4.20% 33,447,815 4.21% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 14 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Receipt", "keywords": [{"text": "Receipt"}]}, "sentence": " Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 659320 Time of Receipt (offset from UTC): 20181114T130924+0000 Contacts BARCLAYS PLC", "object": {"text": "from UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}], "concepts": [{"text": "Option", "relevance": 0.95809, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.750129, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.683489, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.59586, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.57434, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.416035, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Derivative", "relevance": 0.381321, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Options", "relevance": 0.37646, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Moneyness", "relevance": 0.373478, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Security", "relevance": 0.342245, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "December", "relevance": 0.322383, "dbpedia_resource": "http://dbpedia.org/resource/December"}, {"text": "Contract", "relevance": 0.319969, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Bond", "relevance": 0.31828, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}], "categories": [{"score": 0.568829, "label": "/real estate/buying and selling homes"}, {"score": 0.468607, "label": "/finance/financial news"}, {"score": 0.462237, "label": "/finance/investing"}], "relations": [{"type": "populationOf", "sentence": "LONDON- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \"Code\") 1.", "score": 0.465196, "arguments": [{"text": "8.3", "location": [13, 16], "entities": [{"type": "Cardinal", "text": "8.3"}]}, {"text": "LONDON", "location": [0, 6], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC.", "score": 0.419441, "arguments": [{"text": "person", "location": [8492, 8498], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [8524, 8536], "entities": [{"type": "Organization", "text": "BARCLAYS PLC Category Code", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "basedIn", "sentence": "Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 659320 Time of Receipt (offset from UTC): 20181114T130924+0000 Contacts BARCLAYS PLC", "score": 0.488667, "arguments": [{"text": "UTC", "location": [10867, 10870], "entities": [{"type": "Organization", "text": "UTC"}]}, {"text": "Receipt", "location": [10846, 10853], "entities": [{"type": "GeopoliticalEntity", "text": "Receipt"}]}]}, {"type": "hasAttribute", "sentence": "8,700 4,520.6896 JPY Ordinary NPV Purchase 9,800 4,514.0816 JPY Ordinary NPV Purchase 13,500 4,529.3481 JPY Ordinary NPV Purchase 17,600 4,533.4090 JPY Ordinary NPV Purchase 35,900 4,522.4066 JPY Ordinary NPV Purchase 79,200 4,514.8952 JPY Ordinary NPV Purchase 333,300 4,515.2394 JPY Ordinary NPV Purchase 391,800 4,518.8351 JPY Ordinary NPV Purchase 400,800 4,518.3957 JPY Ordinary NPV Sale 76 4,509.5526 JPY Ordinary NPV Sale 76 4,510.5526 JPY Ordinary NPV Sale 77 4,496.5584 JPY Ordinary NPV Sale 100 4,536.0000 JPY Ordinary NPV Sale 100 4,531.9000 JPY Ordinary NPV Sale 191 4,507.7486 JPY Ordinary NPV Sale 200 4,512.8500 JPY Ordinary NPV Sale 230 4,507.5522 JPY Ordinary NPV Sale 400 4,510.2500 JPY Ordinary NPV Sale 422 4,511.9795 JPY Ordinary NPV Sale 499 4,502.5490 JPY Ordinary NPV Sale 600 4,539.0000 JPY Ordinary NPV Sale 1,100 4,522.8181 JPY Ordinary NPV Sale 1,187 4,502.6141 JPY Ordinary NPV Sale 1,300 4,503.5384 JPY Ordinary NPV Sale 1,342 4,505.7637 JPY Ordinary NPV Sale 1,500", "score": 0.771565, "arguments": [{"text": "JPY Ordinary NPV Sale", "location": [3917, 3938], "entities": [{"type": "Person", "text": "JPY Ordinary NPV Purchase"}]}, {"text": "76", "location": [3939, 3941], "entities": [{"type": "Age", "text": "76"}]}]}, {"type": "hasAttribute", "sentence": "8,700 4,520.6896 JPY Ordinary NPV Purchase 9,800 4,514.0816 JPY Ordinary NPV Purchase 13,500 4,529.3481 JPY Ordinary NPV Purchase 17,600 4,533.4090 JPY Ordinary NPV Purchase 35,900 4,522.4066 JPY Ordinary NPV Purchase 79,200 4,514.8952 JPY Ordinary NPV Purchase 333,300 4,515.2394 JPY Ordinary NPV Purchase 391,800 4,518.8351 JPY Ordinary NPV Purchase 400,800 4,518.3957 JPY Ordinary NPV Sale 76 4,509.5526 JPY Ordinary NPV Sale 76 4,510.5526 JPY Ordinary NPV Sale 77 4,496.5584 JPY Ordinary NPV Sale 100 4,536.0000 JPY Ordinary NPV Sale 100 4,531.9000 JPY Ordinary NPV Sale 191 4,507.7486 JPY Ordinary NPV Sale 200 4,512.8500 JPY Ordinary NPV Sale 230 4,507.5522 JPY Ordinary NPV Sale 400 4,510.2500 JPY Ordinary NPV Sale 422 4,511.9795 JPY Ordinary NPV Sale 499 4,502.5490 JPY Ordinary NPV Sale 600 4,539.0000 JPY Ordinary NPV Sale 1,100 4,522.8181 JPY Ordinary NPV Sale 1,187 4,502.6141 JPY Ordinary NPV Sale 1,300 4,503.5384 JPY Ordinary NPV Sale 1,342 4,505.7637 JPY Ordinary NPV Sale 1,500", "score": 0.824046, "arguments": [{"text": "JPY Ordinary NPV Sale", "location": [3953, 3974], "entities": [{"type": "Person", "text": "JPY Ordinary NPV Purchase"}]}, {"text": "76", "location": [3975, 3977], "entities": [{"type": "Age", "text": "76"}]}]}, {"type": "hasAttribute", "sentence": "settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV SWAP Long 76 4,509.5490 JPY Ordinary NPV SWAP Long 76 4,510.5489 JPY Ordinary NPV SWAP Long 77 4,496.5503 JPY Ordinary NPV SWAP Long 191 4,507.7491 JPY Ordinary NPV SWAP Long 230 4,507.5492 JPY Ordinary NPV SWAP Long 300 4,523.6666 JPY Ordinary NPV SWAP Long 422 4,511.9781 JPY Ordinary NPV SWAP Long 499 4,502.5497 JPY Ordinary NPV SWAP Long 1,187 4,502.6142 JPY Ordinary NPV SWAP Long 1,342 4,505.7636 JPY Ordinary NPV CFD Long 3,700 4,512.5489 JPY Ordinary NPV SWAP Short 2,000 4,520.0000 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling,", "score": 0.925802, "arguments": [{"text": "JPY Ordinary NPV SWAP Long", "location": [5535, 5561], "entities": [{"type": "Person", "text": "JPY Ordinary NPV SWAP Long"}]}, {"text": "76", "location": [5562, 5564], "entities": [{"type": "Age", "text": "76"}]}]}, {"type": "agentOf", "sentence": "settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV SWAP Long 76 4,509.5490 JPY Ordinary NPV SWAP Long 76 4,510.5489 JPY Ordinary NPV SWAP Long 77 4,496.5503 JPY Ordinary NPV SWAP Long 191 4,507.7491 JPY Ordinary NPV SWAP Long 230 4,507.5492 JPY Ordinary NPV SWAP Long 300 4,523.6666 JPY Ordinary NPV SWAP Long 422 4,511.9781 JPY Ordinary NPV SWAP Long 499 4,502.5497 JPY Ordinary NPV SWAP Long 1,187 4,502.6142 JPY Ordinary NPV SWAP Long 1,342 4,505.7636 JPY Ordinary NPV CFD Long 3,700 4,512.5489 JPY Ordinary NPV SWAP Short 2,000 4,520.0000 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling,", "score": 0.661901, "arguments": [{"text": "i", "location": [6070, 6071], "entities": [{"type": "Person", "text": "JPY Ordinary NPV SWAP Long"}]}, {"text": "Writing", "location": [6073, 6080], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [7044, 7050], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [7061, 7068], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 14 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [7970, 7976], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [7984, 7988], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the \"Code\") 1.", "score": 0.522588, "arguments": [{"text": "Rule 8", "location": [8416, 8422], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [8430, 8443], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [8051, 8075], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [8043, 8048], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [10562, 10586], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [10554, 10559], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [8210, 8215], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [8229, 8256], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [10721, 10726], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [10740, 10767], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}], "keywords": [{"text": "JPY Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.995202}, {"text": "Ordinary NPV Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.687458}, {"text": "Ordinary NPV Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.618804}, {"text": "Ordinary NPV SWAP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.456862}, {"text": "NPV SWAP Long", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.422762}, {"text": "Ordinary NPV Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.38507}, {"text": "USD Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.379878}, {"text": "securities Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.377391}, {"text": "Ordinary NPV CFD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.374233}, {"text": "relevant securities", "sentiment": {"score": 0.229926, "label": "positive"}, "relevance": 0.353647}, {"text": "NPV Call Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.334367}, {"text": "NPV Put Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.324386}, {"text": "NPV SWAP Short", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.321703}, {"text": "Options Written", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.29346}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.288393}, {"text": "supplemental form", "sentiment": {"score": 0.425721, "label": "positive"}, "relevance": 0.249079}, {"text": "short positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.245154}, {"text": "open positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.244832}, {"text": "class", "sentiment": {"score": -0.251285, "label": "negative"}, "relevance": 0.244169}, {"text": "Product description e.g.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.243451}, {"text": "relevant security Product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.242249}, {"text": "security Product description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.242224}, {"text": "Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.241818}, {"text": "USD ADR Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.241395}, {"text": "Options Purchased", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.240252}, {"text": "unit security securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.239284}, {"text": "number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.232571}, {"text": "securities ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.229099}, {"text": "person", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.22859}, {"text": "Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.227902}, {"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.227434}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.226854}, {"text": "Barclays PLC.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.226806}, {"text": "details", "sentiment": {"score": 0.0877267, "label": "positive"}, "relevance": 0.226692}, {"text": "disclosure", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.226629}, {"text": "USD ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.226581}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.226559}, {"text": "new securities", "sentiment": {"score": 0.582177, "label": "positive"}, "relevance": 0.226455}, {"text": "monetary amounts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.225847}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.225807}, {"text": "relevant Purchase/sale Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.225665}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.225298}, {"text": "relevant description reference", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.224469}, {"text": "PUBLIC OPENING POSITION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.224448}, {"text": "Short Positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.224103}, {"text": "cash-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.22388}, {"text": "relevant security Nature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.223689}, {"text": "stock-settled derivative positions", "sentiment": {"score": -0.27481, "label": "negative"}, "relevance": 0.223601}, {"text": "securities Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.223163}, {"text": "stock-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.223129}]}, "extracted_metadata": {"sha1": "b7728ca5a212843a9f06564386f6055aca50a13c", "filename": "1542206082765.zip-71b219f17525d21fafad125e92a0a7ee.xml", "file_type": "json"}, "title": "BARCLAYS PLC UK Regulatory Announcement: Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD", "forum_title": "All News | Business Wire"}, {"id": "bTE-PWx4-m-_qo52djhF2CV6hJLpEBZIiJ6VB4_Vl4A9uNhDseh08si1Itg0idln", "result_metadata": {"score": 31.873367}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Barclays", "relevance": 0.972986, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "United Kingdom", "relevance": 0.700474, "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.5607, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.6964, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.412502, "label": "/law, govt and politics/government"}], "relations": [], "keywords": [{"text": "BARCLAYS PLC UK", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.901143}, {"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.587635}, {"text": "Regulatory Announcement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.506342}, {"text": "AMENDMENT", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.302334}]}, "crawl_date": "2018-11-14T12:03:48Z", "url": "https://www.businesswire.com/news/home/20181114005442/en/BARCLAYS-PLC-UK-Regulatory-Announcement-Form-8.3", "host": "businesswire.com", "text": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC. are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "main_image_url": "http://www.businesswire.com/images/bwlogo_square.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-14T11:58:00-06:00", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ADR Purchase", "relevance": 0.832032, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.725127, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.692392, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.576044, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Class of Product Nature", "relevance": 0.570814, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS", "relevance": 0.551296, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.542878, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Contacts BARCLAYS PLC", "relevance": 0.526306, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.478421, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.46956, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.452794, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,255,100 1.29%", "relevance": 0.452794, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.452794, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.452794, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,670,800 1.47%", "relevance": 0.452794, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,795,186 1.48%", "relevance": 0.452794, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,195,715 1.53%", "relevance": 0.452794, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,392,415 4.20%", "relevance": 0.452794, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "33,987,586 4.28%", "relevance": 0.452794, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.452794, "type": "Quantity"}], "sentiment": {"document": {"score": 0.624857, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "33,987,586 4.28% 33,392,415 4.20% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "33,392,415 4.20"}, {"type": "Quantity", "text": "33,987,586 4.28"}]}, "sentence": " Class of relevant security: Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,670,800 1.47% 12,195,715 1.53% (2) Cash-settled derivatives: 11,795,186 1.48% 10,255,100 1.29% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% TOTAL: 33,987,586 4.28% 33,392,415 4.20% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 14 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Receipt", "keywords": [{"text": "Receipt"}]}, "sentence": " Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 659314 Time of Receipt (offset from UTC): 20181114T113752+0000 Contacts BARCLAYS PLC", "object": {"text": "from UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}], "concepts": [{"text": "Option", "relevance": 0.97635, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.738362, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.694339, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.618112, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.504652, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option style", "relevance": 0.409956, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Options", "relevance": 0.402719, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Moneyness", "relevance": 0.378169, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Security", "relevance": 0.346944, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "United States dollar", "relevance": 0.33115, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}, {"text": "Contract", "relevance": 0.328306, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Bond", "relevance": 0.3237, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Unit type", "relevance": 0.301728, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Barclays", "relevance": 0.294672, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}], "categories": [{"score": 0.586976, "label": "/real estate/buying and selling homes"}, {"score": 0.465444, "label": "/finance/financial news"}, {"score": 0.446942, "label": "/finance/investing"}], "relations": [{"type": "agentOf", "sentence": "Sale 2,800 4,576.7500 JPY Ordinary NPV Sale 2,800 4,572.1428 JPY Ordinary NPV Sale 2,900 4,570.3103 JPY Ordinary NPV Sale 5,400 4,560.9166 JPY Ordinary NPV Sale 7,700 4,558.8831 JPY Ordinary NPV Sale 10,000 4,540.0000 JPY Ordinary NPV Sale 11,300 4,552.2477 JPY Ordinary NPV Sale 12,800 4,570.9921 JPY Ordinary NPV Sale 44,900 4,555.1358 JPY Ordinary NPV Sale 82,500 4,561.5369 JPY Ordinary NPV Sale 181,500 4,566.0743 JPY Ordinary NPV Sale 223,000 4,557.8067 JPY Ordinary NPV Sale 227,700 4,557.4848 JPY (b) Cash-settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV SWAP Long 200 4,583.1150 JPY Ordinary NPV CFD Long 19,400 4,589.5410 JPY (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing,", "score": 0.682599, "arguments": [{"text": "i", "location": [5368, 5369], "entities": [{"type": "Person", "text": "JPY Ordinary NPV CFD"}]}, {"text": "Writing", "location": [5371, 5378], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [6342, 6348], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [6359, 6366], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 14 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [7268, 7274], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [7282, 7286], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the \"Code\") 1.", "score": 0.522588, "arguments": [{"text": "Rule 8", "location": [7714, 7720], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [7728, 7741], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [7349, 7373], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [7341, 7346], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [9860, 9884], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [9852, 9857], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [7508, 7513], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [7527, 7554], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [10019, 10024], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [10038, 10065], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC.", "score": 0.419441, "arguments": [{"text": "person", "location": [7790, 7796], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [7822, 7834], "entities": [{"type": "Organization", "text": "Contacts BARCLAYS PLC", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Sep 2019 Ordinary NPV Call Options Written -70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Purchased -39,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 70,000 4598.0000 European 14 Jun 2019 Ordinary NPV Put Options Written 75,900 4286.5200 European 6 Sep 2019 Ordinary NPV Put Options Written 78,000 5781.0000 European 14 Dec 2018 Ordinary NPV Put Options Written 104,700 5065.8300 European 17 Apr 2019 Ordinary NPV Put Options Written 114,000 4750.0200 European 14 May 2019 Ordinary NPV Call Options Purchased 10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Call Options Written -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Purchased -10,000,000 4620.0372 European 6 Nov 2018 Ordinary NPV Put Options Written 10,000,000 4620.0372 European 6 Nov 2018 3.", "score": 0.30982, "arguments": [{"text": "6", "location": [9354, 9355], "entities": [{"type": "Person", "text": "6"}]}, {"text": "European", "location": [9345, 9353], "entities": [{"type": "GeopoliticalEntity", "text": "European", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "basedIn", "sentence": "Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 659314 Time of Receipt (offset from UTC): 20181114T113752+0000 Contacts BARCLAYS PLC", "score": 0.488667, "arguments": [{"text": "UTC", "location": [10165, 10168], "entities": [{"type": "Organization", "text": "UTC"}]}, {"text": "Receipt", "location": [10144, 10151], "entities": [{"type": "GeopoliticalEntity", "text": "Receipt"}]}]}], "keywords": [{"text": "JPY Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.983451}, {"text": "Ordinary NPV Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.70273}, {"text": "Ordinary NPV Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.689185}, {"text": "Ordinary NPV Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.404684}, {"text": "USD Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.40139}, {"text": "securities Ordinary NPV", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.39766}, {"text": "Ordinary NPV CFD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.39347}, {"text": "relevant securities", "sentiment": {"score": 0.229926, "label": "positive"}, "relevance": 0.393211}, {"text": "NPV Call Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.357301}, {"text": "NPV Put Options", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.344274}, {"text": "Options Written", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.317547}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.311675}, {"text": "USD ADR Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.288564}, {"text": "USD ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.271523}, {"text": "supplemental form", "sentiment": {"score": 0.425721, "label": "positive"}, "relevance": 0.262216}, {"text": "short positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.257764}, {"text": "open positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.257238}, {"text": "unit security securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.256932}, {"text": "Product description e.g.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.255548}, {"text": "relevant security Product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.254668}, {"text": "class", "sentiment": {"score": -0.251285, "label": "negative"}, "relevance": 0.254279}, {"text": "security Product description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.25419}, {"text": "Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.253393}, {"text": "Options Purchased", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.251234}, {"text": "securities ADR Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.241105}, {"text": "number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.240117}, {"text": "disclosure", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.235989}, {"text": "person", "sentiment": {"score": 0.210866, "label": "positive"}, "relevance": 0.235361}, {"text": "new securities", "sentiment": {"score": 0.582177, "label": "positive"}, "relevance": 0.234649}, {"text": "Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.234368}, {"text": "KEY INFORMATION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.234127}, {"text": "TAKEDA PHARMACEUTICAL", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.233913}, {"text": "relevant Purchase/sale Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.233449}, {"text": "Barclays PLC.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.233348}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.232961}, {"text": "details", "sentiment": {"score": 0.0877268, "label": "positive"}, "relevance": 0.232916}, {"text": "monetary amounts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.232761}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.232387}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.232105}, {"text": "derivative transactions", "sentiment": {"score": -0.412596, "label": "negative"}, "relevance": 0.232104}, {"text": "relevant description reference", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.231787}, {"text": "Short Positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.231635}, {"text": "relevant security Nature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.231187}, {"text": "PUBLIC OPENING POSITION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.231179}, {"text": "stock-settled derivative positions", "sentiment": {"score": -0.27481, "label": "negative"}, "relevance": 0.231105}, {"text": "securities Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.230908}, {"text": "cash-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.230479}, {"text": "stock-settled derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.229603}, {"text": "e.g. call option", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.229449}, {"text": "Panel\u2019s Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.228924}]}, "extracted_metadata": {"sha1": "f6282f69ddc20d02e53eb9b99d3ff3ff985b2aac", "filename": "1542197028088.zip-182342add326306a7eeb87a2ff604ac5.xml", "file_type": "json"}, "title": "BARCLAYS PLC UK Regulatory Announcement: Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD - AMENDMENT", "forum_title": "All News | Business Wire"}]}